

Proposed Updates to The ASAM Criteria, Fourth Edition, Adolescent Volume

Request for public comments, October - November 2024

Editorial Team: R. Corey Waller, MD, MS, FACEP, DFASAM (Editor-in-Chief); Sandra Gomez-Luna, MD, FAPA, DFASAM (Lead Adolescent Editor); Lisa R. Fortuna, MD, MPH, MDiv; Scott E. Hadland, MD, MPH, FASAM; Peter Metz, MD, DLFAACAP, LFAPA (Editorial Advisor)

Background

The ASAM Criteria, first published in 1991, provides national standards for conducting a multidimensional assessment and determining the appropriate level of addiction treatment for a given patient. In addition, these standards offer a model for organizing the addiction treatment system, including the types and intensities of treatment that should be available across the care continuum. ASAM is currently working to develop the Adolescent and Transition Age Youth Volume of the Fourth Edition of *The ASAM Criteria* under the guidance of a new adolescent editorial team, led by Dr. Sandra Gomez-Luna, MD, FAPA, FASAM and Dr. R. Corey Waller, MD, MS, FACEP, DFASAM, and using a [rigorous methodology](#) for evidence review and formal consensus.

In the Third Edition of *The ASAM Criteria*, standards and decision rules for adolescents were interwoven with standards for adults, making them more difficult to interpret. In addition, research on the treatment of adolescents has evolved significantly since these standards were last updated in 2013. Evolving research also illustrates the unique developmental needs of transition age-youth. From approximately age 16 to age 25, youth have social roles and responsibilities, and family, peer, and community supports are changing. This is also a period of significant neurodevelopment as executive functioning fully matures. As such, the next volume of the Fourth Edition of *The ASAM Criteria* will focus on the needs of adolescents and transition age youth.

ASAM's goals are to:

- Develop a comprehensive set of standards for adolescents (defined here as youth under 18 years of age) and transition-age youth (defined here as ages 16-25) that reflects the state of the science and best clinical practice and the unique developmental needs of these populations.
- Promote integrated care for co-occurring mental health conditions.
- Promote holistic and individualized care, which is patient centered and has a family-systems orientation.
- Support delivery of a chronic care model of treatment for addiction and co-occurring conditions, when appropriate.
- Promote early intervention and prevention to prevent risky substance use from causing harm and progressing to SUD.

1 Request for Input

2 This document outlines the draft ASAM Criteria standards for Adolescent levels of care, including
3 the standards for:

- 4 • Assessment and Treatment Planning
- 5 • The ASAM Criteria Youth Continuum of Care
- 6 • Service Characteristics for each Level of Care

7 We are requesting feedback on the appropriateness of these standards for the care of adolescents
8 and transition age youth as well as the feasibility of implementing them in diverse healthcare
9 systems. The full text will be professionally copyedited prior to publication.

10 The full narrative text will not be released for public comment. See the draft Table of Contents in
11 Appendix A for an outline of the topics that will be covered.

12 The Adult Volume of The ASAM Criteria, Fourth Edition was released in December 2023. For more
13 information on the framework from that volume, see our [website](#).

14 Planned future separate volumes include:

- 15 • Correctional Settings and Reentry
- 16 • Behavioral Addictions.

17 The comment period will close at **11:59PM ET on November 15, 2024**. We will be collecting
18 comments through an electronic survey. For each comment you will be asked to input the page and
19 line number (not a range, just a single number) in the appropriate boxes. Always submit your
20 response before exiting. If you have additional comments at a later time, you can reenter the survey
21 and submit a new response.

22 Please submit your comments [here](#). For a preview of the survey, please click [here](#).

23 Please note that your comments may be made public.

24 If you have questions, please email ASAMCriteria@asam.org.

25

26

1 **Table of Contents**

2 **Background 1**

3 **Request for Input 2**

4 **Table of Contents 3**

5 **Summary of Major Changes 5**

6 **Core ASAM Criteria Standards 6**

7 **Assessment and Treatment Planning 7**

8 *The Six Dimensions..... 7*

9 *Subdimensions 8*

10 *Assessment Standards 9*

11 *Adolescent Treatment Planning Standards 34*

12 **The ASAM Continuum of Care – Adolescent 37**

13 *Integrating mental health and SUD treatment 38*

14 *Addressing challenges with adolescent access to medically managed care 39*

15 *Access to addiction and psychiatric medication 39*

16 *Incorporating intensive home and community-based services..... 40*

17 *Medical monitoring in intensive levels of care 40*

18 *Accommodation for missed school 40*

19 *Incorporating early intervention and prevention 41*

20 **Level of Care Service Characteristic Standards 42**

21 *Overview of Service Characteristic Standards..... 42*

22 *Universal Standards 45*

23 *Secondary Prevention and Early Intervention Standards 71*

24 *Co-occurring Enhanced (COE) Standards 73*

25 *Level 1.0Y Standards 75*

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

1 *Level 1.5Y Standards* 79

2 *Level 2.1Y Standards* 81

3 *Level 2.5Y Standards* 86

4 *Level 3.5Y Standards* 92

5 *Universal MM Standards* 100

6 *Level 1.7Y Standards* 107

7 *Level 2.7Y Standards* 111

8 *Level 3.7Y Standards* 116

9 *Level 4Y Standards* 121

10 *Level 4Y General Hospital* 122

11 *Level 4Y Addiction Specialty Unit* 127

12 *Level 4Y Psychiatric* 131

13 **Appendix A. Adolescent and Transition Aged Youth Volume Draft Outline..... 134**

14 **Appendix B. ASAM Criteria/CALOCUS-CASII Levels of Care Crosswalk..... 135**

15 **Appendix C. ASAM Criteria/CALOCUS-CASII Assessment Dimensions Crosswalk .. 136**

16 **Appendix D. Recommended Staff Competencies 139**

17

18

19

20

1 Summary of Major Changes

2 The adolescent editorial team is proposing major changes in the Adolescent and Transition-Aged
3 Volume of The ASAM Criteria, Fourth Edition to facilitate dissemination and implementation and to
4 address known gaps in the quality of adolescent addiction treatment. The core principles remain
5 the same, though have been updated to reflect the needs of adolescent and transition-aged youth:

- 6 • Admission into treatment is based on patient needs rather than arbitrary prerequisites.
- 7 • Patients receive a multidimensional assessment that addresses the broad biological,
8 psychological, social, cultural, and developmental factors that contribute to SUDs,
9 addiction, and recovery.
- 10 • Treatment plans are individualized based on patient
11 and family needs and preferences.
- 12 • Care is interdisciplinary, evidence-based, patient-
13 centered, and delivered from a place of empathy.
- 14 • Co-occurring mental health conditions are an
15 expectation among patients with SUD.
- 16 • Patients move along the clinical continuum of care
17 based on their progress and outcomes with a focus on
18 transition to the least restrictive level of care as quickly as possible while maintaining safety
19 and effectiveness.
- 20 • Clinicians should seek to obtain assent/consent from adolescent patients using a shared
21 decision-making framework to support participation in treatment.
- 22 • Early intervention is critical for prevention of disease progression and warrants specialty
23 care.
- 24 • Adolescent treatment should be family-driven and youth-guided.
- 25 • Treatment interventions may take place within the patient’s home, school, and community
26 as appropriate – with a team-based approach to care coordination.
- 27 • Interventions should be developmentally appropriate; adolescent patients and transition-
28 age youth should be treated in peer-specific groups, separate from adults.

Family is defined as the patient’s primary support system. Family is not limited to biological family and includes other caregivers including those with which the patient is living and/or has deep emotional attachments.

29 These central principles of *The ASAM Criteria* reflect the biopsychosocial nature of addiction. The
30 standards in *The ASAM Criteria* promote a holistic view of patients, acknowledging the role that
31 physical and mental health, stage of development, life circumstances (eg, education, employment,
32 social support, housing, trauma history, criminal legal involvement, etc.), and individual needs,
33 strengths, and goals play in the development and maintenance of SUD and addiction. All these
34 factors are assessed to develop an individualized treatment plan. *The ASAM Criteria* emphasizes
35 the importance of treatment plans tailored to the needs of individual patients and families and
36 regular reassessment and modification of treatment plans that reflect both response to treatment
37 and the evolving needs of the patient and family as life circumstances change.

38 To reflect the evolving needs of the field, the Adolescent Editorial Team is proposing updates to *The*
39 *ASAM Criteria* to:

- 1 • Update the continuum of care, including the expectation for:
 - 2 ○ Fully integrated mental health and SUD treatment
 - 3 ○ Availability of intensive home and community-based services
 - 4 ○ Medical monitoring in intensive levels of care
- 5 • Support access to specialty early intervention and prevention services for youth who are
- 6 using substances and at high risk for SUD
- 7 • Update the ASAM Criteria Assessment and Treatment Planning standards
- 8 • Increase access to addiction and psychiatric medication
- 9 • Address challenges with adolescent access to medically managed care
- 10 • Consider adolescent patients' educational needs during treatment


11 The following sections provide a comprehensive overview of the proposed changes and present the
12 draft standards.

13 Core ASAM Criteria Standards

14 The ASAM Criteria includes standards and decision rules including:

- 15 1. Multidimensional assessment standards for:
 - 16 a. Level of Care Assessment
 - 17 b. Treatment Planning Assessment
 - 18 c. Reassessment and Treatment Plan Review
- 19 2. Treatment planning standards
- 20 3. Dimensional Admission Criteria
- 21 4. Transition and Continued Service Criteria
- 22 5. Continuum of care standards including the levels of care that should be available and
- 23 service characteristic standards at each level of care

24 Figure 1. Patient's Journey Through the Continuum of Care



25

1 When a patient enters treatment a Level of Care Assessment is administered and the Dimensional
2 Admission Criteria are used to make recommendations for the least intensive/restrictive level of
3 care where the patient can be safely and effectively treated (see Figure 1). Once the patient has
4 been admitted to a level of care in the care continuum a Treatment Planning Assessment is
5 administered and used to develop an individualized treatment plan. Patients are regularly
6 reassessed and treatment plans are updated based on patient progress and challenges. The
7 Transition and Continued Service Criteria are used to determine when a patient should transition to
8 a more or less intensive level of care or continue in the same level of care.

9 Note that the Dimensional Admission Criteria and Transition and Continued Service Criteria are not
10 released for public comment. These decision rules undergo validation testing in parallel with the
11 public comment period.

12 Assessment and Treatment Planning

13 A core principle of *The ASAM Criteria* is the use of a multidimensional assessment to drive level of
14 care recommendations and the development of an individualized treatment plan. A full
15 biopsychosocial assessment is not necessary for making a level of care recommendation, but it is
16 the foundation for a comprehensive treatment plan.

17 In these standards, we discuss three types of assessments:

- 18 1. Level of Care Assessment, in which clinicians gather specific information to
19 recommend an appropriate level of care and support initiation of treatment for
20 immediate needs;
- 21 2. Treatment Planning Assessment, in which clinicians conduct a comprehensive
22 biopsychosocial assessment to gather more detailed information for longer-term
23 treatment planning; and
- 24 3. Treatment Plan Reviews, in which clinicians conduct repeated assessments to support
25 treatment plan updates and measurement-based care and inform level of care
26 transitions.


27 The Six Dimensions

28 The 4th Edition of *The ASAM Criteria: Adult Volume* updated the six assessment dimensions (Figure
29 2) and introduced the concept of subdimensions. Major changes include:

- 30 • Updating the names of the dimensions for conciseness and to reflect current terminology.
- 31 • Explicit consideration of addiction medication needs in Dimension 1.
- 32 • The Third Edition's Dimension 4: Readiness to Change does not contribute independently to
33 the recommended level of care; rather, readiness and motivation for change impact clinical
34 judgments related to risks in other dimensions and influences the services that should be
35 delivered at any level of care.

- 1 • With the removal of the readiness to change as a distinct dimension, the previous
2 Dimensions 5 and 6 have now shifted to Dimension 4 (Substance Use Related Risks) and
3 Dimension 5 (Recovery Environment interactions).
- 4 • A new Dimension 6 was added, Person-centered considerations, which considers barriers
5 to care, patient and family preferences, and need for motivational enhancement services.

6 Figure 2. Changes to *The ASAM Criteria* Dimensions in the Fourth Edition



7

8 Subdimensions

9 The Fourth Edition describes subdimensions that should be assessed within each dimension.
10 These subdimensions are the foundation for *The ASAM Criteria* Dimensional Admission Criteria. In
11 the updated framework, clinicians assign risk ratings (based on the clinical severity described in
12 the Dimensional Admission Criteria). The subdimensions in **bolded blue** are considered when
13 determining an appropriate level of care recommendation. All subdimensions are considered
14 during treatment planning.

15 Dimensions and Subdimensions – Adolescent

16 The editors propose the following subdimensions for the Adolescent Volume of *The ASAM Criteria*.
17 The changes in relation to the adult volume are indicated below.

18 Dimension 1 – Intoxication, Withdrawal, and Addiction Medications

- 19 • Intoxication and Associated Risks
- 20 • Withdrawal and Associated Risks
- 21 • Addiction Medication Needs

22 Dimension 2 – Biomedical Conditions

- 23 • Physical Health Concerns
- 24 • Pregnancy-related Concerns
- 25 • Sleep Concerns

1 Dimension 3 – Psychiatric and Cognitive Conditions

- 2 • Active Psychiatric Concerns
- 3 • **Intellectual and Developmental Concerns** [replaces the persistent disability
- 4 subdimension]
- 5 • Trauma Exposure and Related Needs [updated to include exposure]
- 6 • Psychiatric and Cognitive History

7 Dimension 4 – Substance Use Related Risks

- 8 • Likelihood of Risky Substance Use
- 9 • Likelihood of Risky SUD-related Behaviors

10 Dimension 5 – Recovery Environment Interactions

- 11 • Ability to Function Effectively in Current Environment
- 12 • Safety in Current Environment
- 13 • Support in Current Environment
- 14 • Cultural Perceptions of Substance Use and Addiction
- 15 • Educational Needs [added to address adolescent specific needs]

16 Dimension 6 – Person-Centered Considerations

- 17 • Patient Needs and Preferences [updated to include needs]
- 18 • Family and Support System Preferences [added to reflect the importance of family in
- 19 adolescent care]
- 20 • Barriers to Care
- 21 • Need for Motivational Enhancement

22

23 Assessment Standards

24 General Adolescent Assessment Policies and Procedures

- 25 • Clinicians should seek to obtain consent (and/or assent based on local regulations) from
- 26 adolescents for assessment and treatment, and engage them as central participants in
- 27 shared decision-making.
 - 28 ○ If the program is legally required to disclose any information regarding a minor
 - 29 patient’s health status (eg, infectious disease, pregnancy status), the patient should
 - 30 be informed at the onset of the assessment.
- 31 • A Level of Care Assessment should be conducted prior to admission to recommend the
- 32 least intensive and restrictive level of care where the patient can be safely and effectively
- 33 treated.
- 34 • Treatment programs should have the ability to assess vital signs and refer for timely medical
- 35 assessment as needed.

- 1 • After the patient is admitted to a level of care, a comprehensive multidimensional
2 Treatment Planning Assessment should be conducted.
 - 3 ○ If the patient requires immediate treatment for acute biomedical or psychiatric
4 symptoms, the Treatment Planning Assessment should occur once the patient is
5 stabilized, coherent, and able to participate comfortably.
- 6 • Reassessment and Treatment Plan Reviews should be conducted:
 - 7 ○ Periodically, within the timeframes specified in the level of care specific standards.
 - 8 ○ In response to significant events or changes in the patient's condition or patient or
9 family circumstances that may influence the treatment plan or the patient's
10 recovery process.
- 11 • Reassessment should focus on:
 - 12 ○ Progress towards addressing the patient's Dimensional Drivers (dimensional factors
13 that underly the recommendation for a certain level of care).
 - 14 ○ Progress towards the goals in the patient's individualized treatment plan
 - 15 ○ Any changes to the patient's signs, symptoms, or level of function across
16 dimensions and subdimensions
- 17 • Reassessments should incorporate both patient and family-reported information and
18 clinician observation.
 - 19 ○ Clinicians should seek to engage with both parents, if applicable and separate from
20 the patient, when collecting the patient's history.

21 *Considerations for Transition Age Youth*

22 For patients who are 16 years and older:

- 23 • The Treatment Planning Assessment should assess the patient's developmental stage
24 including the skills necessary to support a successful transition to the adult care system.
25 The assessment should clearly document:
 - 26 ○ acquired healthcare management skills (eg, scheduling healthcare appointments,
27 knowing what your medications are [including dosing], calling the pharmacy to
28 arrange prescription pick-ups), and
 - 29 ○ health care management skills the patient needs to continue to develop.
- 30 • The patient's treatment plan should incorporate services to help patients build the skills
31 necessary to support a successful transition to the adult care system.

32

33 **Dimension 1: Intoxication, Withdrawal, and Addiction Medications**

34 *D1 Level of Care Assessment*

35 **General Considerations**

- 36 • When assessing Dimension 1, the clinician should determine whether the patient is at risk
37 for or is currently experiencing intoxication or withdrawal, including taking a history of
38 recent substance use.

- 1 • If intoxication or withdrawal is apparent at the time of the assessment, a clinician should
2 examine the patient for significant disturbances in vital signs, including blood pressure,
3 heart rate, oxygen saturation, and temperature.
- 4 • The clinician should also note whether the patient is oriented to person, place, time, and
5 situation and displays or reports any problems with balance, gait, sensation, and/or
6 behavioral disturbances (e.g., agitation, disinhibition).
- 7 • When the history and exam are inconclusive as to substance(s) used, toxicology screens
8 (that include drugs commonly used by population locally) can be considered.

9

10 Family Assessment Considerations

- 11 • If the patient is at risk for or is currently experiencing intoxication or withdrawal the clinician
12 should seek to collect collateral information from family members (if available), including:
 - 13 ○ Is there any indication that the patient's recent substance use may be more
14 concerning than reported by the patient (ie, higher quantity consumed)?
 - 15 ○ Does the patient have a history of overdose and/or severe or complicated
16 withdrawal?
 - 17 ○ Does the patient have biomedical or psychiatric comorbidities that might
18 complicate treatment of intoxication or withdrawal?
 - 19 ○ Has the patient previously received intoxication or withdrawal management
20 services? If so, what was the outcome? Did the patient experience any adverse
21 events?
 - 22 ○ Does the family indicate that they are able to monitor the patient's symptoms and
23 help the patient adhere to the treatment plan, including medications and follow up
24 appointments?

25 Intoxication and Associated Risks [LOC Assessment]

- 26 • Is the patient intoxicated?
 - 27 • If YES:
 - 28 ○ Are they medically stable? [if NO, transfer to the emergency department]
 - 29 ○ What is the peak anticipated severity of intoxication signs and symptoms (ie,
30 based on substances ingested, potency, quantity, time frame)?*
 - 31 ○ Is medical management required?
 - 32 ■ If YES:
 - 33 • Is afterhours medical management required?
 - 34 • What level of nurse monitoring does the patient need (ie,
35 extended nurse monitoring during the day, afterhours nurse
36 monitoring)?
 - 37 • Is the patient expected to need IV fluids, IV medications, or
38 services that are only available in an acute care hospital (eg,
39 frequent lab testing, mechanical ventilation, etc.)
 - 40 ○ Are they behaviorally stable? Is behavioral intervention required?
 - 41 ○ Are they displaying altered mental status? If so, what level of observation is
42 needed?

1 ---

2 This determination should be made following program policies, procedures, and protocols approved by a physician or by
3 a qualified medical professional.

4 *Family Assessment – Intoxication and Associated Risks*

- 5 • Can the family or other collateral sources provide additional information about the
6 patient’s recent substance use and/or medical history to help inform assessment of
7 intoxication-related risks and treatment needs?

8

9 **Withdrawal and Associated Risks [LOC Assessment]**

- 10 • Is the patient currently in withdrawal or expected to enter withdrawal soon?
 - 11 • If YES:
 - 12 ○ Are they medically stable? [if NO, transfer to the emergency department]
 - 13 ○ What is the peak anticipated severity of withdrawal signs and symptoms (ie,
14 based on substances ingested, potency, quantity, time frame)?*
 - 15 ○ Is medical management required?
 - 16 ▪ If YES: Is afterhours medical management required?
 - 17 ▪ What level of nurse monitoring does the patient need (ie, extended nurse
18 monitoring during the day, afterhours nurse monitoring)?
 - 19 ▪ Is the patient expected to need IV fluids, IV medications, or services that
20 are only available in an acute care hospital (eg, frequent lab testing,
21 mechanical ventilation, etc.)?
 - 22 ○ Are they behaviorally stable? Is behavioral intervention required?
 - 23 ○ Are biomedical or psychiatric comorbidities expected to complicate withdrawal
24 management?
 - 25 ○ Does the patient have sufficient home support to enable effective outpatient
26 withdrawal management, if medically indicated?

27 ---

28 This determination should be made following program policies, procedures, and protocols approved by a physician or by
29 a qualified medical professional.

30

31 *Family Assessment – Withdrawal and Associated Risks*

- 32 • Can the family provide additional information about the patient’s potential withdrawal
33 related risks, based on their observations of recent use and/or the patient’s medical
34 history?

35

36 **Addiction Medication Needs [LOC Assessment]**

- 37 • Does the patient need to be assessed by a medical professional for **addiction**
38 **medications, including MOUD**? If yes,

- 1 • Is the patient expected to need to initiate or titrate addiction medications, including
- 2 MOUD?
- 3 ○ If YES:
- 4 ▪ Are complications/challenges anticipated (eg, due to prior history of
- 5 difficulty with MOUD initiation; anticipated issues with medication
- 6 adherence)?
- 7 ▪ Do biomedical or psychiatric comorbidities— such as pregnancy or
- 8 chronic pain—necessitate closer medical monitoring of initiation or
- 9 titration of addiction medications?

10 *Family Assessment – Addiction Medication Needs*

- 11 • Can the family provide additional information about the patient’s addiction medication
- 12 needs, based on their observations and/or the patient’s medical history? For example:
- 13 ○ Has the patient had difficulty achieving recovery with clinically managed care alone
- 14 (eg, without medical management, including addiction medications)?
- 15 ○ If the patient has previously taken addiction medication, did they have difficulty
- 16 initiating, titrating, or adhering to the medication? Did they have serious or
- 17 bothersome side effects?

18 *D1 Treatment Planning Assessment*

19 *Intoxication and Withdrawal [TP Assessment]*

- 20 • The patient should be monitored over the course of treatment for any new intoxication or
- 21 withdrawal risks, and results of any drug testing should be reviewed with them and with the
- 22 family (with appropriate assent/consent). However, if the patient is intoxicated or there is
- 23 concern for new withdrawal risk, the appropriateness of the current level of care should be
- 24 reassessed.

25 *Addiction Medication Needs [TP Assessment]*

- 26 • The Treatment Planning Assessment should evaluate the patient’s addiction medication
- 27 needs.
- 28 ○ This part of the assessment should be conducted by a physician or advanced
- 29 practice provider with experience treating addiction. In a clinically managed level of
- 30 care, this assessment should occur during the initial physical examination or
- 31 psychiatric assessment or sooner.
- 32 • The clinician should determine the following:
- 33 ○ If the patient has an SUD for which medications are available (ie, FDA-approved
- 34 medications for OUD, AUD, and TUD; off-label medications for other SUDs,
- 35 including StUD and CUD; and medications to manage post-acute withdrawal
- 36 symptoms), are they currently prescribed addiction medications?
- 37 ○ If NO:
- 38 ○ Has the patient been evaluated by a medical provider for addiction
- 39 medication needs?
- 40 ○ Does the patient/family need education on available treatment
- 41 options?
- 42 ○ If YES:

- 1 ○ Does the patient consistently take the medications as prescribed?
- 2 ○ Are the patient's cravings and post-acute withdrawal symptoms
- 3 well-controlled with current treatment?
- 4 ○ When was the patient's last medical visit for their addiction
- 5 medication needs? Document the date of, reason for, and outcome
- 6 of the visit.
- 7 ○ Does the patient need a new appointment to address their addiction
- 8 medication needs?
- 9

10 *Family Assessment – Addiction Medication Needs*

- 11 ● If addiction medications are recommended, does the patient or family have concerns about
- 12 initiating medication? If so, does the patient or family need education or psychosocial
- 13 interventions (eg, motivational interviewing) to address these concerns?
- 14 ● If there are concerns about medication adherence or diversion, is the family able to support
- 15 the patient in taking addiction medications as directed? If not, does the family need
- 16 education or psychosocial interventions (eg, motivational interviewing) to assist them in
- 17 monitoring the patient's medication adherence?

18

19 *Other Systems of Care Considerations – Addiction Medication Needs*

- 20 ● Will the patient require administration of their addiction medication(s) while in their school
- 21 setting?
- 22 ● Will the school need to be made aware of the addiction medication(s) prescribed to the
- 23 patient (eg, to respond appropriately to potential side effects)?
- 24 ● Is the patient involved with any other systems that need to be made aware of the addiction
- 25 medication(s) prescribed (eg, juvenile legal system, child welfare)?

26 **Dimension 2: Biomedical Conditions**

27 *D2 Level of Care Assessment*

28 **Physical health concerns [LOC Assessment]**

- 29 ● Is the patient experiencing physical health problems (per self-report, collateral report, or
- 30 practitioner determination)? If so, and as per protocol reviewed by a qualified medical
- 31 professional:
 - 32 ○ Are they medically stable? [If NO, transfer to an emergency department]
 - 33 ○ What is the current severity of the patient's physical health problem(s)?
 - 34 ○ Is integrated medical management required?
 - 35 ■ If YES, what level of medical management and/or monitoring does the
 - 36 patient require for their physical health problem(s)?
 - 37 ● Is afterhours medical management required?
 - 38 ● What level of nurse monitoring does the patient need (ie, extended
 - 39 nurse monitoring during the day, afterhours nurse monitoring)?

- 1 • Is the patient expected to need IV fluids, IV medications, or services
- 2 that are only available in an acute care hospital (eg, frequent lab
- 3 testing, mechanical ventilation, etc.)
- 4 ○ Does the patient have adequate monitoring and support at home to effectively
- 5 manage their physical health problems, including accessing and adhering to
- 6 treatment?

7 *Family Assessment – Physical health concerns*

- 8 • (if applicable) Does the family have any concerns about the patient’s health? Are these
- 9 concerns currently being addressed by a medical provider?
- 10 • (if applicable) Does the family have any additional information about the patient’s medical
- 11 history that might support level of care decision making?
- 12 • (if applicable) Is the family able to monitor the patient’s symptoms and help the patient
- 13 adhere to the treatment plan, including medications and follow up appointments?
- 14

15 *Pregnancy-related concerns [LOC Assessment]*

- 16 • Is the patient currently pregnant? If so, and as per protocol reviewed by a qualified medical
- 17 professional:
- 18 ○ What is the status of the pregnancy?
- 19 ○ Is the patient receiving adequate pregnancy-related services?
- 20 ○ What level of medical management and/or monitoring is required?

21 *Family Assessment - Pregnancy-related concerns*

- 22 • (if applicable) Does the family have any concerns about the patient’s health related to their
- 23 pregnancy? Can they provide any additional information from their observations or the
- 24 patient’s medical history that might support level of care decision making?
- 25 • (if applicable) Is the family able to monitor the patient’s symptoms and help the patient
- 26 adhere to the treatment plan, including medications and follow up appointments?
- 27

28 *D2 Treatment Planning Assessment*

- 29 • All patients admitted to a medically managed level of care should have a medical
- 30 evaluation, including complete medical history and physical, in accordance with the
- 31 standards for the level of care at which they have been placed.
- 32 • While a medical professional should complete a full medical history, clinical (ie,
- 33 nonmedical) staff (eg, psychologists, clinical social workers, SUD and mental health
- 34 counselors) can collect a partial history.
- 35 • Patients admitted to a clinically managed level of care should either have a physical
- 36 examination or a psychiatric assessment, which includes an evaluation of the need for a
- 37 physical examination and coordinated referral for a physical examination when needed.

38 *Physical Health Concerns [TP Assessment]*

- 39 • Are there ongoing physical health concerns— including any pain— that require medical
- 40 treatment or referral?

- 1 ○ If YES: Is the patient currently receiving treatment from an external provider for their
2 physical health concern(s)?
3 ▪ If YES, determine:
4 • if each condition is controlled with current treatment;
5 • does the condition or its treatment impact the patient’s SUD
6 treatment (eg, interfere with treatment participation or limit the
7 medications that may be used);
8 • when the last medical visit was for each issue, documenting visit
9 date(s), reason(s), and outcome(s);
10 • if additional or different treatment or medical evaluation is needed,
11 and if so, does the patient need a referral? How urgently?; and
12 • if care coordination is needed.
13 ▪ If NO, document plan for referring the patient to external medical treatment
14 (if the patient’s physical health concerns do NOT require active or integrated
15 medical management).
16 • If the patient’s physical health concerns require medically managed
17 care, and the patient is in a clinically managed level of care that is
18 unable to coordinate sufficient medical services, reassess the
19 patient’s level of care recommendation.

20 Does the patient’s continued use of substances, including nicotine/tobacco, exacerbate
21 any current physical health concerns (eg, asthma, diabetes, dental disease)?

- 22 • Are the patient’s physical health concerns impacted by substance use discontinuation?
23 ○ Does the patient have significant sleep concerns associated with the cessation of
24 substance(s)?
25 ○ Have the patient’s biomedical conditions become more difficult to treat since the
26 cessation of substance(s)?
27 ○ For serious health problems, does the patient have sufficient caregiver and/or home
28 support if they are receiving addiction treatment in an outpatient level of care (ie,
29 Levels 1 and 2)?
30 ▪ What services does the patient require (eg, daily nursing, rehabilitation) to
31 manage their chronic physical health symptoms and maintain function?
32 ▪ Does the patient require accommodation for any chronic physical health
33 problems (eg, mobility assistance for a physical disability)?
34 ▪ Does the patient need educational interventions to prevent biomedical
35 issues from arising or worsening?

36 *Family Assessment – Physical health concerns*

- 37 • (if applicable) Does the family need additional resources or support to effectively care for
38 the patient? If so, what additional resources or support do they need?
39 • (if applicable) Does the family need education to help monitor and ensure appropriate care
40 for the patient’s physical health concerns?

41 **Pregnancy-Related Concerns [TP Assessment]**

42 For patients with child-bearing potential, determine if the patient:

- 1 • is currently on medications or has received other medical interventions for contraception,
- 2 • desires medications or interventions for contraception, and/or
- 3 • is currently pregnant or planning to become pregnant.
 - 4 ○ If YES, determine:
 - 5 ▪ What, if any, decisions have the patient and family made regarding the
 - 6 pregnancy (ie, raising the baby, adoption, termination)?
 - 7 ▪ Does the patient need psychoeducational interventions related to
 - 8 pregnancy (eg, preparing for parenthood, potential involvement of child
 - 9 welfare services)?
 - 10 ▪ Is coordination with child welfare agency needed?
 - 11 ▪ If there are any current pregnancy-related concerns?
 - 12 • If YES: The patient should be referred to an obstetrics provider.
 - 13 ▪ If the patient is receiving appropriate prenatal care)
 - 14 ▪ The patient’s pregnancy history, including history of any complications.
 - 15 • If the patient is currently pregnant and taking addiction medication, does the patient need
 - 16 to be assessed for the need to titrate the medication?

17

18 *Family Assessment – Pregnancy-related concerns*

- 19 • If applicable and the patient has consented to sharing information about their pregnancy
- 20 with their family:
 - 21 ○ Does the family have the resources and ability to provide appropriate support for the
 - 22 patient’s pregnancy-related concerns? If not, what additional resources or support
 - 23 do they need to do so?
 - 24 ○ Does the family need additional education or support to effectively care for the
 - 25 patient’s pregnancy concerns and/or prepare for the birth of the baby?

26 *Other Systems of Care Considerations – Pregnancy-related concerns*

- 27 • (if applicable) Do the patient’s pregnancy-related concerns require coordination of care
- 28 across their primary environments (eg, school)?

29

30 **Sleep Concerns [TP Assessment]**

- 31 • Are there sleep concerns (eg, insomnia, sleep deprivation, sleep inversion, sleep latency,
- 32 daytime sleepiness) warranting a medical evaluation?
- 33 • Does the patient need psychosocial services to help address sleep concerns (eg,
- 34 behavioral interventions, psychoeducation on sleep hygiene)?
- 35 • Are Dimension 3 concerns—such as PTSD— interfering with sleep? If so, do the patient’s
- 36 sleep concerns require specific treatments or referral to a qualified external provider?

37

38

1 Dimension 3: Psychiatric and Cognitive Conditions

- 2 ■ Adolescent patients should be screened for active psychiatric symptoms as well as intellectual
3 and developmental concerns.
 - 4 ○ Patients who screen positive for intellectual or developmental concerns should be
5 offered or referred for a neuropsychological evaluation as appropriate and findings
6 should guide development of the treatment plan, ascertaining if the patient has the
7 supports needed to effectively engage in addiction treatment.*

8 ---

9 * Referral for neuropsychological evaluation should not delay initiation of SUD treatment.

10 *D3 Level of Care Assessment*

11 *Active psychiatric concerns [LOC Assessment]*

- 12 ● Does the patient have active co-occurring mental health symptoms?
 - 13 ● If so, does the patient require medical management for these concerns?
 - 14 ○ If YES, determine:
 - 15 ● If the patient is at risk of harm to self or others;
 - 16 ○ If so, what is the acuity of risk?
 - 17 ● The level of medical management required;
 - 18 ● The need for specialty psychiatric management within the addiction
19 program or if transfer to an acute psychiatric setting is needed; and
 - 20 ● The need for a higher staff-to-patient ratio in addition to medical
21 management.
 - 22 ○ If NO, determine:
 - 23 ● The level of support, supervision, and monitoring needed to
24 manage the patient's active co-occurring psychiatric concerns,
25 including need for higher staff-to-patient ratio; and
 - 26 ● The need for integrated skilled mental health interventions.

27

28 *Family Assessment – Active psychiatric concerns*

- 29 ● Is the patient's family able to provide the monitoring and support necessary to help the patient
30 safely manage their current mental health needs?

31

32 *Intellectual and Developmental Concerns [LOC Assessment]*

- 33 ● Does the patient have intellectual or developmental concerns? Does the patient require
34 more individualized support (eg, a higher staff-to-patient ratio) to support effective
35 participation in addiction treatment?
 - 36 ● If YES:
 - 37 ○ What level of additional support does the patient need to participate in
38 addiction treatment?

- 1 • Specific areas of questioning to determine need for more individualized support may
2 include:
- 3 • Is the patient able to participate in basic activities of daily living?
 - 4 • Are there concerns about aggression or behavioral dysregulation that may cause
5 harm to self or others?
 - 6 • Are there concerns about neurodiversity-related symptoms that may interfere with
7 the patient’s ability to participate in addiction treatment without individualized
8 support (e.g., sensory processing disorders)?
 - 9 • If the patient is in school, do they have an active IEP or 504 plan?
 - 10 ○ If YES, have they been receiving accommodations? How well have those
11 been working? What other supports might the adolescent need in the
12 treatment setting?
 - 13 ○ If NO, determine:
 - 14 • Was the patient previously assessed for their learning needs and is a
15 report available?
 - 16 • Has an IEP assessment been recommended?
 - 17 • Are there signs they might need to be assessed for an IDD?

18 *Family Assessment – Intellectual and developmental concerns*

- 19 • Does the family have any concerns about the patient’s development?
- 20 • What support does the family provide to help the patient manage any intellectual or
21 developmental concerns?
- 22 • Are other family members affected by intellectual or developmental disorders?
- 23 • Is the family able to provide sufficient stability and support to enable effective participation in
24 addiction treatment? If not, what additional services or support might the patient and/or family
25 need?

26

27 *D3 Treatment Planning Assessment*

- 28 • If significant mental health concerns were identified during the Level of Care Assessment, the
29 patient should be assessed by a clinician with the appropriate training, experience, and scope
30 of practice to conduct an adolescent mental health assessment.
- 31 • If undiagnosed intellectual or developmental concerns are noted, referral for
32 neuropsychological evaluation should be coordinated.

33

34 *Active Psychiatric Concerns [TP Assessment]*

- 35 • Does the patient have ongoing mental health conditions that require treatment?
 - 36 • If YES: Is the patient currently receiving treatment from an external provider for their
37 mental health problems? If YES, determine:
 - 38 ○ If diagnostic clarification is needed;
 - 39 ○ If each condition is effectively managed with current treatment
 - 40 • What is the duration of treatment?
 - 41 • What is the patient’s level of treatment adherence?

- 1 ○ When the last medical visit was for each issue, documenting visit date(s),
- 2 reason(s), and outcome(s);
- 3 ○ If additional or different treatment or referrals are needed; and
- 4 ○ If care coordination is needed.
- 5 ● If NO:
- 6 ○ What mental health interventions are needed to address the patient's
- 7 mental health conditions?
- 8 ○ Does the patient need a referral for any mental health services that cannot
- 9 be provided by the program?
- 10 ○ If the patient is at risk of harm to self or others, what interventions are
- 11 needed to support safety?
- 12 ● Does the patient have new challenges involving emotional regulation?
- 13 ● How do substance use, withdrawal, and SUD impact the patient's mental health condition?
- 14 ○ Does the patient's continued use of substances, including nicotine/tobacco,
- 15 exacerbate any current mental health concerns (eg, anxiety, suicidality)?
- 16 ○ How is acute substance withdrawal expected to impact the patient's mental health
- 17 symptoms? How are the patient's mental health symptoms impacted during post-
- 18 acute withdrawal?
- 19 ○ Have the patient's mental health concerns become more difficult to treat since the
- 20 cessation of the substance(s)? For example, does the patient have new challenges
- 21 with exerting emotional control since the cessation of the substance(s)?
- 22 ○ (if applicable) Have addiction and/or psychiatric medications provided sufficient
- 23 symptom relief from any withdrawal-related mental health concerns? If not, does
- 24 the patient need prompt evaluation for addiction and psychiatric medication needs?
- 25 ● Does the patient have any Dimension 2 concerns (eg, physical health concerns, pain,
- 26 pregnancy) that could impact their mental health?
- 27 ● If YES:
- 28 ○ Has the patient received treatment for these physical health concerns?
- 29 ● If YES: Have any of these interventions helped alleviate the physical
- 30 health concerns? How do the patient's mental health symptoms
- 31 change with treatment for their physical health problems?
- 32 ● If NO: Does the patient need referral to an external medical provider?
- 33 ● If the patient's mental health continues to be impacted beyond resolution of the
- 34 physical health concerns, what kind of treatment does the patient need to address
- 35 ongoing mental health symptoms?
- 36 ● What other factors influence the patient's mental health condition (eg, family interaction,
- 37 school, etc.)

38 *Family Assessment – Active psychiatric concerns*

- 39 ● In what ways has the family observed the patient's substance use affecting their mental
- 40 health, and vice versa?
- 41 ● Does the family adequately understand their role in supporting the patient to manage their
- 42 mental health concerns? Do they need education or other resources (eg, referrals for
- 43 individual therapy or support groups) to better support the patient?

- 1 • Do other family members have current mental health concerns? If so, how might these
2 mental health concerns affect their ability to support the patient during treatment and
3 recovery?

4 *Other Systems of Care Considerations – Active psychiatric concerns*

- 5 • Is care coordination needed with other systems (eg, school, juvenile legal, child welfare,
6 etc.) to help support monitoring of the patient’s active psychiatric concerns?

7 **Intellectual and Development Concerns [TP Assessment]**

- 8 • Does the patient have any intellectual or developmental concerns that may require
9 accommodations or more individualized staff support to enable effective participation in
10 addiction treatment?
11 • If YES: Is the patient currently receiving sufficient support within the addiction
12 treatment program to enable effective participation?
13 • If NO: What additional supports does the patient need?
14 • Does the patient have any intellectual or developmental concerns that may require
15 screening, evaluation, and/or referral to external treatment services?
16 • If intellectual functioning impairments are suspected (eg, due to developmental
17 delay) and have not been assessed, the patient should be referred for
18 neuropsychological evaluation.
19 ▪ For instance, if concerns such as autism spectrum disorder (ASD) or fetal
20 alcohol syndrome (FAS) are suspected, refer for full evaluation.
21 • If intellectual or developmental functioning impairments are present, is the patient
22 currently receiving treatment from an external provider for their impairments?
23 • If YES, determine:
24 ○ If each condition is effectively managed with current treatment;
25 ○ When the last medical visit was for each issue, documenting visit date(s),
26 reason(s), and outcome(s);
27 ○ If additional or different treatment is needed; and
28 ○ If care coordination is needed.
29 • If NO, provide or refer the patient to appropriate services.

30 *Family Assessment – Intellectual and developmental concerns*

- 31 • What de-escalation techniques or types of support are helpful in situations when the
32 patient is stressed/dysregulated? (eg, quiet space; access to music or art supplies)
33 • Does the family have a full understanding of their role in supporting the patient to manage
34 their intellectual and developmental concerns? If not, do they need education to better
35 support the patient?

36 *Other Systems of Care Considerations – Intellectual and developmental concerns*

- 37 • Is care coordination/navigation needed with other systems (eg, school, Individuals with
38 Disabilities Education Act (IDEA) Services, etc.) to obtain necessary supports (eg, home-
39 and community-based services) for the patient’s intellectual and developmental concerns?

1 **Trauma Exposure and Related Needs**

- 2 • Has the patient been exposed to physical, sexual, and/or emotional abuse and/or neglect?
3 Have they been exposed to sex trafficking and/or substance use coercion? Has the patient
4 been exposed to other trauma (e.g., witnessing domestic violence)?
5 • If YES, how has the patient been impacted by the trauma they have experienced?
6 • The clinician should also assess need for child welfare intervention and
7 trauma-related mental health services.
8 • Has the patient experienced recent grief (eg, loss of a loved one, relationship loss, family
9 separation, loss of home)? How has it affected their mental health?

10 *Family Assessment – Trauma exposure and related needs*

- 11 • Does the family have additional information about the patient’s experiences with trauma?
12 About potential ongoing sources of trauma in the home, family, or in other areas of the
13 patient’s life?
14 • Does the family have a full understanding of the impact of patient’s experience with trauma
15 and their role in helping the patient manage their trauma symptoms? Do they need
16 additional resources (eg, education, referral to individual therapy or support group) to better
17 support the patient?

18 **Psychiatric and Cognitive History**

- 19 • Does the patient have any current or past psychiatric and/or cognitive diagnoses? If YES:
20 • Determine symptomatology present before and after substance use;
21 • Conduct an intensive review of prior psychiatric diagnoses;
22 ○ Consider the history of the patient’s attachments including loss, separation,
23 disruption, and neglect and how they contribute to the patient’s substance
24 use and co-occurring mental health conditions.
25 ○ Consider how other adverse childhood experiences (ACEs) may contribute
26 to current problems and treatment/recovery support needs.
27 • Determine history of medications—specifying medication name(s), dose(s),
28 route(s), frequency, duration, purpose(s), dose adherence, and effectiveness—and
29 psychotherapies (eg, cognitive behavioral therapy [CBT], dialectical behavioral
30 therapy [DBT]) for psychiatric and cognitive conditions—specifying modalities,
31 duration, adherence, and effectiveness; and
32 • Document response to treatment interventions, including any medication allergies
33 and adverse events.

34 *Family Assessment – Psychiatric and cognitive history*

- 35 • Can the family provide any additional information about the patient’s psychiatric and
36 cognitive history?
37 • Is there any other family psychiatric or cognitive history of which the clinician should be
38 aware?

39

1 Dimension 4: Substance Use-Related Risks

2 *D4 Level of Care Assessment*

3 Likelihood of Engaging in Risky Substance Use [LOC Assessment]

- 4 • How likely is the patient to engage in substance use in their current environment without
5 appropriate treatment?
- 6 • What is the level of risk associated with the patient’s substance use? Both current and
7 historical risk should be considered.
- 8 • If the patient were to continue or return to use:
 - 9 ○ Would they be at risk for serious harm such as:
 - 10 ▪ overdose or toxicity (based on their use patterns and previous overdose
11 history)?
 - 12 ▪ serious medical consequences from substance use (eg, physical
13 trauma; HIV; hepatitis C; abscesses; STIs; exacerbation of chronic
14 conditions like asthma or diabetes; GI issues, mental health crises,
15 etc.)?
 - 16 ▪ victimization or exploitation—such as human trafficking, intimate
17 partner violence (IPV), or other types of violence (based on history)?
 - 18 ○ Would they be at risk for **destabilizing loss, such as** expulsion from school,
19 displacement from home, serious legal consequences, loss of important
20 relationships [including peer and family relationships], loss of home or housing?
 - 21 ○ What other **negative** consequences might the patient experience (eg, poor
22 school performance, truancy, relationship difficulties, disassociation with extra-
23 curricular activities)? What secondary consequence are likely to occur as a
24 result of these negative consequences (eg, expulsion from school,
25 displacement from home, loss of scholarship)? Could these lead to
26 destabilizing losses? If so, in what timeframe?
- 27 • What level of structure, supervision, and support does the patient need to prevent
28 **harmful and destabilizing** consequences of substance use?
- 29 • What level of structure, supervision, and support does the patient need to learn the
30 skills and gain the insights necessary for recovery?

31

32 *Family Assessment – Likelihood of engaging in risky substance use*

- 33 • Is there any indication that the patient’s substance use history may be more concerning
34 than reported by the patient (ie, higher quantity, frequency, duration)?
- 35 • How aware are the parents/guardians of the patient’s substance use patterns?
- 36 • In what ways does the family contribute to risk or protective factors for the patient’s
37 risky substance use? For example:
 - 38 ○ Are the parents/guardians able to provide sufficient supervision and structure
39 outside of school hours to help the patient avoid risky use? Are there other
40 trusted adults who are able to provide needed supervision and support?
 - 41 ○ Is there substance use in the home?

- 1 ○ Does the family support or encourage substance use? Does the patient use
- 2 substances with family members?
- 3 ○ Does the family support pro-recovery behaviors, such as helping the patient
- 4 remember to take medications, helping the patient make appointments,
- 5 providing transportation to appointments, etc.?
- 6 ○ What are the parents'/guardians' attitudes toward the patient's substance use,
- 7 and how might these attitudes impact the patient's recovery?

8 Likelihood of Engaging in Risky SUD-Related Behaviors [LOC Assessment]

- 9 ● How likely is the patient to engage in risky SUD-related behaviors in their current
- 10 environment without appropriate treatment? The assessor should inquire about:
- 11 ○ Risky behaviors to acquire drugs (eg, drug dealing/conveyance, trading sex for
- 12 drugs [including risk of trafficking], theft/robbery; gang involvement);
- 13 ○ Risky behaviors while intoxicated (eg, problem gambling [eg, sports betting];
- 14 driving while impaired or being passenger with impaired driver; unprotected
- 15 sex/risk of victimization due to impairment; interpersonal violence – victim or
- 16 perpetrator; problem social media or internet use; problem gaming)
- 17 ● If the patient engages in risky SUD-related behaviors, what is the likelihood that they will
- 18 experience:
- 19 ○ **serious harm** (eg, medical or psychiatric complications)
- 20 ○ **destabilizing loss** (eg, expulsion from school, displacement from home, loss of
- 21 important relationships)?
- 22 ● What other **negative** consequences might the patient experience (eg, poor school
- 23 performance, truancy, relationship difficulties, disassociation with extra-curricular
- 24 activities)? What secondary consequence are likely to occur as a result of these
- 25 negative consequences (eg, expulsion from school, displacement from home, loss of
- 26 scholarship)? Could these lead to destabilizing losses? If so, in what timeframe?
- 27 ● What level of structure, supervision, and support does the patient need to prevent
- 28 **harmful and destabilizing** consequences of risky SUD-related behaviors?
- 29 ● What level of structure, supervision, and support does the patient need to learn the
- 30 skills and gain the insights necessary to prevent risky SUD-related behaviors?

31 *Family Assessment - Likelihood of engaging in risky SUD-related behaviors*

- 32 ● Is there any indication that the patient's SUD-related behaviors may be more
- 33 concerning than reported by the patient?
- 34 ● How aware are the parents/guardians of the patient's risky SUD-related behaviors (if
- 35 applicable)?
- 36 ● In what ways does the family contribute to risk or protective factors for the patient's
- 37 risky SUD-related behaviors (if applicable)? For example:
- 38 ○ Are the parents/guardians able to provide sufficient supervision and structure
- 39 outside of school hours to help the patient avoid risky SUD-related behaviors (if
- 40 applicable)? Are there other trusted adults who are able to provide needed
- 41 supervision and support?
- 42 ○ Are there risky SUD-related behaviors by others in the home?

1 *D4 Treatment Planning Assessment*

2 Likelihood of Engaging in Risky Substance Use [TP Assessment]

- 3 • The patient's **substance use history**—self-reported or otherwise documented—should
4 include:
- 5 ○ age of use onset for each problem substance;
 - 6 ○ pattern of use for each problem substance, including nicotine/tobacco
7 products, detailing:
 - 8 ○ set and setting;
 - 9 ○ amount;
 - 10 ○ frequency [episodic, weekend, binge, daily]);
 - 11 ○ chronicity;
 - 12 ○ route(s) of administration; and
 - 13 ○ date(s) of last use for each problem substance;
 - 14 ○ longest period of time without substance use;
 - 15 ○ significant consequences of substance use (eg, physical and mental health,
16 legal, family/other important relationships, educational, social isolation);
 - 17 ○ addiction treatment history, including treatment for TUD;
 - 18 ○ history of unintentional overdose*, patient and family concerns regarding
19 unintentional overdose risk, and need for overdose reversal training and
20 medication;
 - 21 ○ triggers for use, including:
 - 22 ■ identifying which triggers have most often resulted in substance use in the
23 past month (eg, substance-using peer groups; mental health symptoms);
 - 24 ■ determining how the patient responds to these triggers, and
 - 25 ■ determining if the patient requires interventions to improve their insight into
26 triggers and/or strengthen their ability to respond to triggers; and
 - 27 ○ supports for avoiding use, including:
 - 28 ■ identifying what helps the patient engage in alternatives to substance use
29 (eg, family support, healthy peer group support)
 - 30 ■ identifying what additional supports they need from family, school, etc., and
 - 31 ■ determining if the patient requires interventions to strengthen their ability to
32 develop and maintain supports for engaging in alternatives to substance use
 - 33 • The substance use history should also:
 - 34 ○ document if the patient takes prescription or OTC medication(s); also consider
35 performance-enhancing drugs for athletics and/or academics; caffeine intake;
36 use of inhalants; use of dextromethorphan or other OTC cold medicine,
37 diphenhydramine; etc.
 - 38 ○ ascertain the risks posed by the patient's continued substance use (eg,
39 overdose, infectious disease transmission, skin infections, exacerbation of
40 physical health conditions [eg, asthma, diabetes], expulsion from school, family
41 disintegration, loss of significant relationships, fire safety due to use of
42 combustible tobacco or cannabis).

- 1 • Standardized tools—such as the [BAM](#) for risk and protective scores and the [VAS](#) for
2 craving—should be administered as needed to establish baseline addiction symptom
3 severity, inform interventions, and support MBC.
- 4 • The Treatment Planning Assessment should evaluate the patient and family’s access to
5 overdose reversal medication (eg, naloxone) and need for overdose prevention and
6 reversal training.

7 ---

8 * intentional overdoses should be considered in Dimension 3

9

10 *Family Assessment: Likelihood of Engaging in Risky Substance Use*

- 11 • Does the patient’s family need additional resources or support (eg, education, referral for
12 mental health or SUD treatment, referral to support groups) to help minimize risk factors
13 associated with substance use/maximize protective factors and support the patient to
14 prevent substance use and related risks?

15 *Other Systems of Care Considerations: Likelihood of Engaging in Risky Substance Use*

- 16 • Is care coordination needed with other systems (eg, school, juvenile legal, child welfare) to
17 help decrease the patient’s likelihood of engaging in substance use, and/or mitigate
18 negative consequences associated with substance use?

19 **Likelihood of Engaging in Risky SUD-Related Behaviors [TP Assessment]**

- 20 • What is the longest period of time that the patient has gone without engaging in risky SUD-
21 related behaviors (eg, risky sexual behaviors, DWI/DUI, violence, behaviors that increase
22 vulnerability to victimization such as running away from home; spending time with
23 substance using adults; engaging in illegal activities)?
 - 24 ○ When did the current period of risky SUD-related behaviors begin?
 - 25 ○ What are the patient’s triggers for risky SUD-related behaviors?
 - 26 ■ Which triggers have most often resulted in risky SUD-related behaviors in
27 the past month?
 - 28 ■ How does the patient respond to these triggers?
 - 29 ■ Does the patient require interventions to improve their insight into triggers
30 and/or to strengthen their ability to respond to triggers/make less risky
31 choices?

32 *Family Assessment: Likelihood of Engaging in Risky SUD-Related Behaviors*

- 33 • Will the patient’s family need additional resources or support (eg, education, referral for
34 mental health or SUD treatment, referral to support group) to help minimize risk factors
35 associated with risky SUD-related behaviors/maximize protective factors to help the
36 patient prevent these behaviors?

1 *Other Systems of Care Considerations: Likelihood of Engaging in Risky SUD-Related Behaviors*

- 2 • Is care coordination needed with other systems (eg, school, juvenile legal, child welfare) to
3 help decrease the patient's likelihood of engaging in risky SUD-related behaviors, and/or
4 mitigate the consequences associated with these behaviors?

5
6 **Dimension 5: Recovery Environment Interactions**

7 *D5 Level of Care Assessment*

8 **Ability to function in current environment [LOC Assessment]**

- 9 • How able is the patient to function effectively in their current home and school environments
10 (ie, able to maintain hygiene/basic self-care; accomplish daily tasks like adhere to daily
11 schedule, attend and engage in school; interact with family and peer groups in a healthy way)?
- 12 ▪ Does the patient need services to learn prosocial skills and/or developmentally
13 appropriate living skills?
- 14 • If YES: What level of services is needed?
- 15 • Does the patient need external support to learn and/or practice
16 basic interpersonal skills and developmentally appropriate living
17 skills? If so, what level of support is needed (ie, residential
18 therapeutic milieu, daily therapeutic milieu, low intensity
19 therapeutic milieu, peer support)
- 20 • Do the patient and/or family need clinical services to better support
21 the patient's functioning in their current environment? If so, what
22 intensity of clinical services is required to provide these skills?
- 23 • Specific areas to explore when assessing daily life functioning may include:
- 24 ○ Capacity for self-care
- 25 ○ Daily routine
- 26 ○ School attendance, engagement, and progress
- 27 ○ Involvement in family activities
- 28 ○ Family attachment
- 29 ○ Involvement in extracurricular/community activities
- 30 ○ Peer attachment and support (and the health of these relationships)
- 31 ○ History of employment
- 32 ○ Juvenile legal involvement

33 *Family Assessment – Ability to function effectively in current environment:*

- 34 • What are the family's observations about the patient's daily functioning (eg, social; fulfilling
35 obligations such as school, chores, work, etc.)? Have there been any recent changes?
- 36 ○ If functioning has worsened, how different is it from the patient's prior baseline level
37 of functioning?
- 38 • Is the family able to provide daily support for the patient's functioning, if needed?

39 **Safety in current environment [LOC Assessment]**

- 40 • What is the patient's current living situation?

- 1 • Is the patient's current environment safe?
- 2 ○ Does the patient's current environment pose a threat to their safety or well-being,
- 3 such as housing or food insecurity, neglect, and/or exposure to physical, sexual,
- 4 emotional, economic, or any other type of harm or abuse, including substance use
- 5 coercion and sex trafficking?
- 6 ○ Is there adequate supervision in the patient's current environment? Are
- 7 parents/caregivers present and able to safely supervise the patient?
- 8 ■ If the home environment is safe, but other environments (eg, school, social)
- 9 that the patient is regularly exposed to are not safe, is there enough
- 10 parental/caregiver supervision to help protect the patient?
- 11 • Is the patient at risk of running away from home?
- 12 ○ If yes, where are they likely to go? What threats are they likely to be exposed to?

13

14 *Family Assessment: Safety in current environment*

- 15 • Does the family currently have a place to live?
- 16 • Do they have any concerns about the safety of the patient's home environment? Is there any
- 17 potential abuse or neglect in the home or other environments that the patient is exposed to?
- 18 • Does the adolescent have people in the family they feel safe sharing private information
- 19 with? Would they be likely to share concerns about their safety (eg, suicidality, bullying,
- 20 etc.)?

21 *Support in current environment [LOC Assessment]*

- 22 • How supportive are the patient's current environments (home, social, school)?
- 23 ○ How much support do the patient's current environments provide to help them cope
- 24 with cravings and other recovery threats, and strengthen refusal skills?
- 25 ○ To what extent do the patient's current environments expose them to substance use
- 26 and/or substance use triggers?
- 27 ○ If there is substance use, to what extent can environment(s) be modified to support
- 28 the patient's treatment goals?
- 29 ○ Are the treatment goals of the parent(s) or guardian(s) sufficiently aligned with those
- 30 of the patient such that they will provide a supportive home environment?
- 31 • What are possible effects (both positive and negative) of removal from current
- 32 environments?
- 33 ○ What are the risks and benefits of the patient remaining in their current home
- 34 environment?
- 35 ○ What are the risks and benefits of the patient remaining in their current school
- 36 setting?
- 37 ■ In their current school environment, do they have access to substances? A
- 38 healthy peer group? Are there other supports available in the school (eg,
- 39 trusted recovery supportive adults, extracurricular activities)? Are there
- 40 other risks present in the school that may make continued participation in
- 41 the school unhealthy (eg, unhealthy relationships with adults, exposure to
- 42 triggers)?

1 *Family Assessment: Support in current environment*

- 2 • Can the patient’s caregivers provide enough support in their home environment to enable
3 the patient to prevent substance use and learn the skills necessary for recovery?
4 ○ If NO:
5 ▪ Is additional family support available? If so, will it be sufficient to enable the
6 patient to safely remain in the home during addiction treatment? OR
7 ▪ Are there alternative options to the current home environment available that
8 can better serve the patient’s needs (eg, living with another family
9 member)?

10

11 *D5 Treatment Planning Assessment*

12 *Ability to function in current environment [TP Assessment]*

- 13 • What are the patient and family’s goals for increasing social, emotional, and physical well-
14 being and improving functioning in their current environments?
15 ○ What types of support and/or services, including cultural and spiritual resources,
16 does the patient need to achieve these goals?
17 • Does the patient require services and/or support to:
18 ○ build a daily routine or structure (eg, home, school, work) that is supportive of
19 recovery,
20 ○ develop social and recreational activities supportive of recovery?
21 • Is the patient able to interact with others in an age-appropriate prosocial manner (eg,
22 engaging in safe leisure activities; establishing healthy boundaries with peers; conflict
23 resolution skills)?

24 *Family Assessment – Ability to function in current environment*

- 25 • Can the family provide insight into the patient’s functional well-being beyond what the
26 patient can provide (eg, due to functional impairments and/or discomfort discussing
27 functional impairments)?
28 • Is the family able to help the patient access community resources to address functional
29 impairments (eg, social services, medical care, peer support) as needed?

30 *Other Systems of Care Considerations – Ability to function in current environment*

- 31 • Is care coordination needed with other systems (eg, school, Individuals with Disabilities
32 Education Act [IDEA] services) to help support the patient’s level of functioning?

33 *Safety in Current Environment [TP Assessment]*

- 34 • What services or supports do the patient and family need to address any safety threats in
35 their current environment (eg, housing services, domestic violence services, etc.)? How
36 can the treatment program help the patient and family access services available in their
37 community?
38 • If in a residential treatment setting, what services or supports (if any) are needed to address
39 any safety concerns in the patient’s home environment or to identify an alternative
40 environment where they can stay when they transition to outpatient treatment?

- 1 • How will the patient’s current environment—or the environment to which they will return
2 following transition from residential treatment—affect their ability to engage in treatment
3 and recovery?
 - 4 ○ What is the patient’s perspective on how safe their environment is?
 - 5 ▪ (If the patient does not feel that their current environment is safe) What,
6 from the patient's perspective, is needed for the recovery environment to
7 feel safe?

8 *Family Assessment - Safety*

- 9 • Does the family feel that the patient’s current environments are safe?
 - 10 ○ (If NO) What do they think is needed to improve the safety of the patient’s current
11 environments? Do they need additional resources or support to help improve the
12 safety of the patient’s current environments, or to help the patient access safer
13 environments?
- 14 • Does the patient’s use of substances pose safety risks for other children in the
15 environment)? What can be done to mitigate those risks?

16 *Support in Current Environment [TP Assessment]*

- 17 • Is the patient being exposed to substance use in their living environment? (eg, if parent
18 drinks, are they drinking in front of the adolescent?)
- 19 • Does the patient have a network of individuals (eg, family, significant others, friends,
20 community) who are supportive of recovery? If not, how can the patient and family build
21 recovery support?
 - 22 ○ Are the patient’s peers supportive of their recovery?
 - 23 ○ Which social activities are high-risk? What alternative activities might they put in
24 place? How can they identify peers that will support them?
 - 25 ○ Is social media use or gaming a trigger? Is there appropriate social media or gaming
26 monitoring available?
- 27 • Does the patient have a supportive daily structure? How can they plan for unstructured
28 periods (boredom)?
- 29 • Is the patient being exposed to substances and/or triggers in school?
 - 30 ○ (if applicable) How would an alternative educational setting (e.g., virtual school;
31 different school; recovery school) affect the patient’s ability to recovery and achieve
32 educational goals?
- 33 • Is spirituality (and/or religion) an important component of treatment for the patient? Is it a
34 point of conflict between the adolescent and their family?
 - 35 ○ If spirituality is important to the patient, do they have access to spiritual support as
36 part of their recovery?
 - 37 ○ Aside from spirituality, are there other protective personal values/practices (eg,
38 community service, sports, yoga) or sources of support the adolescent can draw
39 upon to support recovery?

40

1 *Family Assessment - Support*

- 2 • Is the family currently restricting access to substances? If not, are they willing and able to
3 limit patient access to substances in the home?
4 • Is spirituality/religion important to the family? Does the family find that spirituality/religion
5 works to support the adolescent or is there conflict in this area?

6 **Cultural Perception of Substance Use and Addiction**

- 7 • Does the patient identify any cultural factors that promote or inhibit their use of
8 substances?
9 • Does the patient identify any cultural factors that promote or inhibit their participation in
10 addiction or mental health treatment or require modification of the treatment plan?

11 **Family Assessment - Cultural Perception of Substance Use and Addiction**

- 12 • Are there any familial cultural factors or aspects of the patient's culture of origin that may
13 impact treatment or recovery? How can any risks be mitigated? How can any protective
14 factors be maximized?
15 • Does the family strongly identify with a specific recovery ideology (eg, 12-step)?

16 **Academic Educational Considerations**

- 17 • Will treatment interfere with the patient's education?
18 ○ If YES: How can educational disruption be minimized?
19 • Will the patient be able to meet their educational requirements/goals at the current level of
20 care?
21 ○ If YES: How will the patient meet educational requirements/goals while receiving
22 treatment?
23 ○ If NO: Are additional supports available to help the patient?
24 • Does the program need to coordinate access to IEP or 504 plan supports?
25 • Does the patient have the appropriate support to meet their educational requirements
26 when considering physical and mental health needs, as well intellectual and
27 developmental disabilities?
28 ○ If YES, what services will the program provide to help the patient to meet their
29 educational goals?
30 ○ If NO, a professional with the appropriate scope of practice should determine what
31 accommodations are needed for the patient to meet their educational goals.
32 • If a patient is unable to be schooled in their typical environment during any point of
33 treatment:
34 ○ what coordination is needed with the school while the patient is out of school?
35 ○ what coordination and supports (considering all dimensional needs) will be needed
36 for a seamless transition back to their school setting?
37 • Is the patient's typical educational setting supportive of recovery or does it increase the
38 patient's vulnerability? What can be done to mitigate these risks?

39

1 Dimension 6: Person-Centered Considerations

2 *D6 Level of Care Assessment*

3 Patient Needs and Preferences [LOC Assessment]

- 4 • Assuming the patient and family have sufficient resources and that services are available, is
- 5 the patient willing to attend the recommended level of care?
- 6 • If NO:
- 7 ○ What treatment and/or harm reduction services are acceptable to the patient?
- 8 ○ If the patient's preferred treatment setting is deemed unsafe or unlikely to be
- 9 effective, what can be done to increase the patient's willingness to attend treatment
- 10 at the recommended level of care (eg, motivational interviewing)?

11 Family and Support System Needs and Preferences [LOC Assessment]

- 12 • Is the patient's family willing and able to support them in attending the recommended level
- 13 of care?
- 14 ○ If NO:
- 15 ■ What treatment and/or harm reduction services are acceptable to the
- 16 patient's family?
- 17 ■ If the family's preferred treatment setting is deemed unsafe or unlikely to be
- 18 effective, what can be done to increase the family's willingness to support
- 19 the patient at the recommended level of care (eg, family counseling)?

20 Barriers to Care [LOC Assessment]

- 21 • Is the patient able to attend the recommended level of care?
- 22 ○ Does the patient and/or their family need any services, support, and/or
- 23 resources (eg, transportation, childcare, financial) to enable participation in the
- 24 recommended level of care?
- 25 ○ Are sufficient services, support, and/or resources available to the patient and/or
- 26 their family to enable participation in the recommended level of care?
- 27 ■ If NO: What addiction treatment services can the patient access?
- 28 • Does the patient have any limitations on where they can receive treatment (eg, due to
- 29 school schedules, custody agreements, transportation access, program age
- 30 limitations)?
- 31 • Does the level of care need to be adjusted due to the patient's educational needs?
- 32 • Is the patient compelled to follow clinical recommendations from an external source
- 33 (eg, juvenile legal system mandates)?
- 34 ○ If YES: What are the requirements?

35

36 *D6 Treatment Planning Assessment*

37 Patient Needs and Preferences [TP Assessment]

- 38 • Is the patient willing to participate in the services recommended by the treatment program?
- 39 Why or why not?

- 1 ○ Are there specific recommended services that the patient is not willing to
- 2 participate in (eg, concurrent treatment for nicotine/tobacco use)?
- 3 ▪ If YES: Why is the patient not willing to participate in the specific
- 4 recommended service?
- 5 • Would the patient prefer that treatment services be provided in a different way (eg, different
- 6 modalities, clinicians, or setting)?
- 7 ○ What does the patient believe needs to be addressed or improved with treatment
- 8 (eg, substance use, mental health, physical health)?
- 9 ○ What adjustments can be made to the recommended treatment services given
- 10 clinical indications and local availability?
- 11 ○ If the patient’s preferences can be accommodated, are the resulting service
- 12 changes likely to have any effect—positive or negative—on treatment and recovery
- 13 outcomes?
- 14 • Has the patient experienced discrimination (eg, racism, ableism, homophobia, ageism) that
- 15 may impact their experience in treatment?

16 Family and Support System Preferences [TP Assessment]

- 17 • Is the family willing to support the patient in participating in the recommended treatment
- 18 services? Why or why not?
- 19 ○ Are there specific recommended services in which the family is not willing to
- 20 participate?
- 21 • Would the family prefer that treatment services be provided in a different way?
- 22 ○ What does the family believe needs to be addressed or improved with treatment?
- 23 ○ If the family’s preferences can be accommodated, are the resulting service changes
- 24 likely to have an impact on treatment and recovery outcomes?
- 25 • Has the family experienced discrimination (eg, racism, ableism, homophobia, ageism) that
- 26 may impact their preferences for the treatment of the patient?
- 27 • Are there discrepancies between the patient’s and their family’s goals for the patient’s
- 28 treatment?
- 29 ○ If YES,
- 30 ▪ How can the treatment plan balance the needs of the patient and their
- 31 family while remaining patient-centered and empowering?
- 32 ▪ Would the patient and their family benefit from family therapy to improve
- 33 consensus between their goals?

34 Barriers to Care [TP Assessment]

- 35 • Does the patient or family have ongoing needs related to SDOH that impact their ability to
- 36 fully participate in treatment? Considerations may include:
- 37 ○ transportation and/or mobility challenges;
- 38 ○ food or housing security;
- 39 ○ childcare responsibilities;
- 40 ○ family income and financial insecurity;
- 41 ○ educational or employment needs/concerns;
- 42 ○ lack of or limited healthcare coverage;

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 ○ lack of appropriate social and community supports, including potential community
- 2 stigma related to addiction and/or mental health treatment; and
- 3 ○ language and/or literacy barriers.
- 4 • Are the support services that the patient and family needs available in the community?
- 5 ○ If YES: How long will the patient and family need to wait to receive these services?
- 6 • What care coordination or recovery support services (RSS) do the patient and family need to
- 7 maximize their chances of success?
- 8 ○ Are the patient’s cultural needs being met at the current level of care?
- 9 ○ Does the patient have access to needed or requested culturally specific providers,
- 10 peer networks, and/or behavioral health services?
- 11 ▪ If NO:
- 12 • Does this present a barrier to treatment for the patient?
- 13 • How can any identified barriers be addressed through treatment planning?
- 14 • What sources of strength does the patient feel that they already have to support their
- 15 recovery?
- 16 ○ How can these strengths be built upon?

17 Need for Motivational Enhancement [TP Assessment]

- 18 • How ready does the patient feel to address the identified issues? How ready is the patient’s
- 19 family to support them in addressing the identified issues? Are motivational enhancement
- 20 services needed to support engagement in recommended care?
- 21 • Does the patient/family have concerns or fears that make it difficult for them to attend or
- 22 remain in treatment?
- 23 • What external pressures are motivating the patient to enter and complete treatment? Do
- 24 these include legal mandates (ie, from juvenile drug treatment court)?
- 25 ○ What external factors are negatively impacting the patient’s motivation for
- 26 treatment?
- 27 • What factors—based on clinician judgment—need to be addressed to improve the patient
- 28 and/or family’s motivation for change?
- 29 ○ What services and/or interventions are needed to improve the patient’s/family’s
- 30 motivation for change?

31 Adolescent Treatment Planning Standards

- 32 • Treatment planning should focus on addressing:
- 33 ○ the Dimensional Drivers that have led the patient to require treatment at a given
- 34 level of care.
- 35 ○ any anticipated barriers to the patient’s transition to a less intensive level of care
- 36 ○ patient and family priorities
- 37 • All patients, whether mandated to treatment or pursuing treatment voluntarily, should
- 38 participate in shared decision-making to develop a treatment plan following the Treatment
- 39 Planning Assessment. The patient’s family should also be included as appropriate.
- 40 Treatment planning should be an interdisciplinary process led by the patient’s primary
- 41 clinician (with appropriate supervision).

- 1 • If the patient has concerns in Dimensions 1 or 2 that require medical care, the relevant part
2 of the treatment plan should be led by medical staff in medically managed levels of care or
3 in coordination with appropriate external medical professionals.
- 4 • If the patient has concerns in Dimension 3 that require psychiatric services, the relevant
5 part of the treatment plan should be developed by or in coordination with an appropriately
6 qualified mental health professional.
- 7 • In programs that do not have medical staff, the treatment plan may include care
8 coordination, including supporting the patient to follow through with medical appointments
9 and other elements of their medical treatment plan (eg, taking medications as directed,
10 performing physical therapy exercises, adopting nutritional changes, monitoring glucose).
- 11 • The patient's primary clinician in the addiction treatment program should build a
12 therapeutic alliance with the patient by establishing shared meaning with understanding
13 and empathy. The patient should participate fully and actively in a shared decision-making
14 process to develop an individualized treatment plan.

15 Problem Statements and Goals

- 16 • The treatment plan should:
 - 17 ○ reflect the patient and family's goals;
 - 18 ○ be tailored to the patient's developmental age and cognitive abilities (ie, in language
19 they can understand);
 - 20 ○ incorporate the patient and family's inherent strengths and supports;
 - 21 ○ be informed by the patient's cultural identities, practices, and preferences; and
 - 22 ○ consider potential vulnerabilities resulting from the patient's trauma history.
- 23 • An individualized treatment plan includes the following components:
- 24 • Problem statements should identify concerns to be addressed in the current level of care.
25 At minimum, the problem statements should address the Dimensional Drivers of admission
26 to the patient's current level of care.
 - 27 ○ Example problem statement: Continued cannabis use despite negative impacts on
28 [patient's] school performance.
- 29 • Goals should be clear and focused on what the patient and family wants to achieve in this
30 phase of treatment. Goal statements should be written in the patient's own words.
 - 31 ○ Example goal: I want to cut down on my drinking so that I can do better at school.
- 32 • Objectives should identify short-term aims that will help the patient and family move
33 toward their goals. Objective statements should be Specific, Measurable, Attainable,
34 Realistic, and Timebound (SMART) and written in the patient's own words.
 - 35 ○ Example objective: In the next month, will learn to identify at least three triggers for
36 heavy alcohol use and three healthy coping skills to manage triggers, urges, or
37 cravings.
- 38 • Action steps should identify:
 - 39 ○ the steps that the patient will take to meet an objective;
 - 40 ○ the steps that the family will take to support the patient in meeting their objectives;
 - 41 ○ the services that the addiction treatment program will provide to help the patient
42 meet an objective, including any:
 - 43 ■ medical services,

- 1 ▪ psychotherapeutic services,
- 2 ▪ psychoeducational services,
- 3 ▪ recovery support services,
- 4 ▪ referrals, and
- 5 ▪ coordination with external providers
- 6 • Individualized treatment plans should also include:
 - 7 ○ Transition plans that address:
 - 8 ▪ continuity of care for SUDs and comorbid biomedical and psychiatric
 - 9 conditions, and
 - 10 ▪ Dimension 5 and 6 concerns (eg, need for recovery- supportive housing,
 - 11 transportation) that may impact the transition to a less intensive level of
 - 12 care.
 - 13 ○ Contingency plans that address:
 - 14 ▪ how the program will respond should an instability arise in resources, family
 - 15 dynamic, or home or community environment (eg, transition to a more
 - 16 intensive level of care, recommend an alternative recovery supportive home,
 - 17 etc.).
 - 18 ○ Safety plans
 - 19 ○ For patients in outpatient treatment programs (ie, Levels 1 and 2), the treatment
 - 20 plan should include or reference a safety plan that addresses how the patient and
 - 21 family should seek help in the event of urgent or emergent issues that arise after-
 - 22 hours.
 - 23 ▪ The safety planning should consider safety in all environments to which the
 - 24 patient is regularly exposed (eg, home, school, etc.).

25 Transition Planning

- 26 • Transition plans should address:
 - 27 ○ addiction treatment service needs;
 - 28 ○ physical health service needs;
 - 29 ○ mental health service needs—when possible, patients with co-occurring mental
 - 30 health disorders should be transitioned to a setting that can provide integrated care
 - 31 for their continuing SUD and mental health needs;
 - 32 ○ Family support needs to facilitate a smooth transition;
 - 33 ○ Recovery support services (RSS) needs, including those related to SDOH;
 - 34 ○ continued access to medications, including addiction medications; and
 - 35 ○ overdose prevention and harm reduction, including access to overdose reversal
 - 36 medication.
 - 37 ○ educational needs, for adolescents who have been receiving alternative instruction
 - 38 while in addiction treatment, to ensure a smooth transition back into the school
 - 39 system.

40

1 Safety Planning

- 2 • In outpatient settings, the treatment planning process should include the creation of a
3 safety plan. Safety plans should clearly identify the steps that the patient and/or family
4 should take in the event of an emergency outside of treatment hours and include resources
5 that are accessible in the patient’s geographic location.
- 6 • Safety plans may also be included in residential or inpatient settings when needed, such as
7 when a patient is at risk for self-harm or violent behavior.

9 Treatment Plan Reviews

- 10 • Treatment planning should be a continuous process, with updates incorporated as needed
11 when new information is learned or the patient’s circumstances evolve. Treatment Plan
12 Reviews should be conducted at regular intervals (as specified in the level of care
13 standards) to capture the patient’s progress toward their goals and make appropriate
14 adjustments to their treatment plan.
- 15 • Treatment Plan Reviews should ideally involve representation from all members of the
16 patient’s interdisciplinary treatment team, including their primary clinician, medical
17 providers, nurses, social workers, peer support specialists and recovery coaches, and
18 housing managers and staff as applicable.
- 19 • All treatment team members should understand and agree upon adjustments to the plan.
- 20 • The patient’s primary clinician is responsible for reviewing, documenting, and keeping
21 records of all updated treatment plans.

23 The ASAM Continuum of Care – Adolescent

24 Adolescents with SUD have unique needs and thus *The ASAM Criteria: Adolescent and Transition*
25 *Age Youth Volume* will propose a continuum of care that is tailored to meet these as needed.

26 The adult volume of the ASAM Criteria included a few key changes to simplify the continuum and
27 align with the types and intensities of care that are available in communities across the country:

- 28 • Expanding Levels of Care within Level 1 to differentiate between medically managed
29 outpatient care and outpatient therapy and to add a new level (Level 1.0) for long term
30 remission monitoring.
- 31 • Updating the Level 3.7 standards to reflect care in residential settings
- 32 • Better integration of biomedical care and withdrawal management into the continuum
- 33 • Better integration of co-occurring capability along the continuum
- 34 • Encouraging better continuity of care during transitions between levels of care.

1 The proposed continuum for the Adolescent and Transition Aged Volume builds on these changes
2 to propose a continuum appropriate for Adolescents and Transition Aged Youth (see Figure 3).

3 These changes include:

- 4 • Fully integrating mental health and SUD treatment
- 5 • Addressing challenges with adolescent access to medically managed care
- 6 • Facilitating access to addiction and psychiatric medication
- 7 • Incorporating intensive home and community-based services
- 8 • Incorporating medical monitoring in intensive levels of care
- 9 Support access to specialty early intervention and prevention services for youth who are
10 using substances and at high risk for SUD

11 Integrating mental health and SUD treatment

12 A primary focus of the updated continuum of care is integration with the adolescent mental health
13 treatment system. As noted above, **for adolescent patients, mental health conditions are very**
14 **often a primary condition along with the SUD.** Therefore, a higher intensity of mental health care
15 is needed in standard adolescent addiction treatment programs. This edition of *The ASAM Criteria*
16 will set the expectation that all adolescent SUD treatment programs will be able to provide
17 integrated care for mental health conditions.

18 Because adolescent patients often have mental health conditions that are a primary concern
19 (along with the SUD) the baseline expectations for providing integrated mental health treatment
20 will be higher. Standard (co-occurring capable) adolescent addiction treatment programs will be
21 expected to provide integrated psychiatric services and skilled mental health interventions. Some
22 adolescent patients with severe psychiatric symptoms may need a higher level of individualized
23 care than can be provided by standard adolescent addiction treatment programs. In these cases,
24 The Adolescent and Transition Age Youth Volume of the Fourth Edition of *The ASAM Criteria* will
25 recommend co-occurring enhanced (COE) care (with the level determined by the patient's
26 multidimensional needs). All Level 3.5Y programs will be expected to be able to provide COE care.
27 This is recommended because Level 3.5Y programs serve some of the most seriously ill patients,
28 who often have severe and/or complex co-occurring conditions who will commonly require more
29 flexible, individualized care.

30 Given the importance of integration of mental health and SUD treatment for adolescents
31 (regardless of whether they are treated in a mental health treatment program or a SUD treatment
32 program), ASAM aligned the proposed youth continuum of care with the adolescent mental health
33 treatment system standards. We worked with the American Academy of Child and Adolescent
34 Psychiatry, including developers of The Child and Adolescent Level of Care/Service Intensity
35 Utilization System (CALOCUS-CASII), which defines standards for determining the intensity of
36 services needed for children and adolescents from ages 6-18 years with mental health conditions.
37 See Appendix B for an overview of how the proposed levels of care align with the CALOCUS-CASII
38 levels of care. See Appendix C for an overview of how *The ASAM Criteria* dimensions and
39 subdimensions align with the CALOCUS-CASII dimensions.

1 Addressing challenges with adolescent access to medically managed 2 care

3 Historically significant withdrawal and biomedical comorbidities have been rare among adolescent
4 patients, and most areas of the country have had insufficient demand for adolescent specific
5 programs that deliver withdrawal management and biomedical care. However, anecdotal evidence
6 suggests that with the increasing prevalence of high potency synthetic opioids (eg, fentanyl) in the
7 drug supply the need for medical management may be increasing among adolescents. Currently,
8 many adolescents receiving these services do so in hospitals or facilities that also serve adult
9 patients.

10 The Adolescent and Transition Age Youth Volume will include standards for youth medically
11 managed levels of care. Because these programs are currently rare across the country, significant
12 work will be needed to support access to these levels of care. We anticipate youth medically
13 managed programs to be organized within existing settings, such as:

- 14 • Adolescent-focused units within programs that also provides adult medically managed
15 levels of care
- 16 • Medically managed units within adolescent SUD treatment programs. For example:
 - 17 ○ A Level 2.5Y program that has a unit with the capacity to provide daily medical
18 management and extended nurse monitoring during the day (eg, Level 2.7Y
19 services)
 - 20 ○ A Level 3.5Y program that has a unit with the capacity to provide daily medical
21 management and 24/7 nursing care (eg, Level 3.7Y services)
- 22 • Medically managed SUD treatment unit within adolescent mental health treatment
23 programs. For example, a residential mental health treatment program that has a unit with
24 the capacity to provide daily medical management and 24/7 nursing care for withdrawal,
25 addiction medication initiation, and biomedical comorbidities (eg, Level 3.7Y services).

26 The standards will address how adult programs could adapt services to serve adolescent and
27 young adult patients. Adult programs that provide services to adolescents should have clear
28 policies and procedures that protect adolescent and transition age patients and ensure their
29 unique developmental needs are considered and addressed. Adolescent patients should be
30 treated in separate spaces from adult patients with close staff supervision in the limited instances
31 where adults and adolescents are in the same spaces (eg, in waiting areas). In addition, programs
32 treating adolescents should deliver adolescent-specific content aligned with the principles
33 articulated above. They should also have established relationships with adolescent treatment
34 specialists to support consultation when developing adolescent treatment plans.

35 Access to addiction and psychiatric medication

36 Adolescent and young adult patients may benefit from addiction and psychiatric medications. This
37 Fourth Edition recommends that all programs have systems in place to support medication
38 access, including the ability to continue (without lapse) current medications that are necessary for

1 ongoing mental health and SUD symptom management. All patients should be evaluated by a
2 qualified physician or advanced practice provider for need for addiction and psychiatric
3 medications within a reasonable timeframe (specific timeframes will be defined for each level of
4 care). These exams should be conducted by providers with training and experience in the provision
5 of addiction and psychiatric medications for adolescent patients. Level 2.5Y and 3.5Y programs will
6 be expected to initiate and titrate addiction and psychiatric medications when needed. Patients
7 with more complex needs related to medication initiation may be recommended a medically
8 managed level of care.

9 **Incorporating intensive home and community-based services**

10 As discussed above, family and community have a profound effect on adolescent SUD and
11 recovery. Home and community-based services can allow for the delivery of more intensive care in
12 a less restrictive environment. Level 2.1Y and 2.5Y programs should be able to provide home- and
13 community-based services, with the specific services delivered individualized to the patient's
14 needs. While there may be challenges with the availability of these services in some states, they
15 are critical for effective care of adolescent patients with significant SUD and co-occurring
16 conditions. These services often exist for the treatment of adolescent mental health conditions and
17 may be expanded to provide integrated care for SUD. Integration of treatment services in home and
18 community settings can also increase access and reduce the burden on families. For example,
19 some Level 2.1Y treatment services may be integrated into school, reducing the number of
20 sessions where the family needs to travel to a treatment setting. For patients in residential care,
21 community-based treatment teams should be formed early in the treatment process, prior to the
22 transition to outpatient care.

23 **Medical monitoring in intensive levels of care**

24 Given the high rates of co-occurring conditions among adolescent patients with SUD and the
25 inherent complexity of treating adolescent patients with co-occurring conditions, all high intensity
26 levels of care (Levels 2.5Y and above) have a medical director who can provide ongoing medical
27 monitoring and management of psychiatric and addiction medication needs. Level 2.1Y has (at
28 minimum) a formal affiliation with a physician or advanced practice provider who can provide
29 medical services when needed.

30 **Accommodation for missed school**

31 Residential treatment can be disruptive to adolescent educational development. Treatment
32 programs should consider how to mitigate these disruptive effects. While educational services may
33 not be appropriate during episodes of acute care, as the patient transitions to less restrictive levels
34 of care the clinicians (in coordination with the family as appropriate) should coordinate with the
35 patient's school to determine what interventions are needed to help the patient make up missed
36 work. If patients are expected to be away from school for a significant amount of time (eg, more
37 than 2 weeks) educational programming should be arranged by the treatment program; this may

1 include coordination of remote learning with appropriate support services. Minimizing educational
2 disruption is one reason *The ASAM Criteria* is focused on supporting patients to transition to the
3 least restrictive level of care as quickly as possible while maintaining safety and effectiveness.


4 **Incorporating early intervention and prevention**

5 It may be appropriate to provide specialty care for adolescent patients who are using substances
6 and have a high risk of escalation to a SUD. Early intervention and prevention services, including
7 treatment as prevention, will be incorporated into adolescent Levels 1.5Y and 2.1Y. In other words,
8 for adolescents and transition age youth who are using substances and have a high risk for SUD,
9 but do not currently meet the DSM criteria for a SUD, *The ASAM Criteria* Dimensional Admission
10 Criteria may recommend Level 1.5Y or 2.1Y specialty care where the patient can receive treatment
11 services to prevent the escalation to a SUD. While this change will require workforce development
12 and updated payment models, a full assessment for potential underlying mental health concerns
13 and substance use disorder by appropriately trained clinicians (eg, a master's level clinician) and
14 early intervention services are critical for this patient population.

15

16 Figure 3. *The ASAM Criteria* Continuum of Care: Adolescent

The ASAM Criteria Continuum of Care: Adolescent



Note: This represents a current DRAFT. Standards are still in development

17

18

1 Level of Care Service Characteristic Standards

2 Overview of Service Characteristic Standards

3 Tables 1a and 1b represent an overview of the core standards in the levels of care in the Youth
 4 Continuum.

5 Table 1a. Summary of Service Characteristics for the Adolescent Clinically Focused Levels of Care

	1.0Y	1.5Y	2.1Y	2.5Y	3.5Y
	Long term remission monitoring	Youth and Family Outpatient	Intensive Community-Based Services	High Intensity Outpatient and Home Based	Youth Residential
Medical Director	Variable	Not typical	Variable	Yes	Yes
Physicians and Advanced Practice Providers	Established relationship	Encouraged to have formal affiliation	Formal affiliation	Yes On call 24/7	Yes On call 24/7
Psychiatric and Addiction Expertise***	At minimum, established relationship(s) with psychiatric and addiction specialist(s)	At minimum, established relationship(s) with psychiatric and addiction specialist(s)	At minimum, formal affiliation(s) with psychiatric and addiction specialist(s)	Program leadership should include both psychiatric and addiction specialty expertise. Psychiatric specialist should be available 24/7*	Program leadership should include both psychiatric and addiction specialty expertise. Psychiatric specialist should be available on site or via telemedicine 24/7
Nursing services	Not typical	Not typical	Established relationship to support coordinated access to nursing services‡ when needed	Available as needed. Formal affiliation to support coordinated access to nursing services‡ when needed	Yes. Nursing services should be available 24/7

	1.0Y	1.5Y	2.1Y	2.5Y	3.5Y
Program Director	Variable*	Yes	Yes	Yes	Yes
Clinical Staff	Available during program hours	Available during program hours	Available during program hours and on call 24/7	Available during program hours and on call 24/7	Onsite 24/7
Mental Health Trained Clinical Staff	Able to refer for MH services	Yes	Yes	Yes	Yes
Allied Health Staff	Variable	Variable	Yes*	Yes	Yes
Psychiatric Assessment	Able to refer as needed	Able to refer as needed; physical exam should assess the need for a psychiatric assessment	Within 14 days	Within 7 days. Able to provide within 24 hours, when needed.	Generally, within 48 hours, but not more than 72 hours. Able to provide within 24 hours, when needed.
Physical exam	Verify a physical exam in the last year or refer	Within one month of treatment initiation if no recent physical exam	Within reasonable timeframe determined by psychiatric assessment	Within reasonable timeframe determined by psychiatric assessment	Within reasonable timeframe determined by psychiatric assessment
Nursing Assessment	Not typical	Not typical	As needed*	As needed*	Within 24 hours
Treatment Plan	Recovery management plan developed in the first session	Within the first 3 sessions	Within 7 days of admission	Within 72 hours of admission	Within 72 hours of admission
Formal Reassessment	Quarterly Recovery management checkups	At least quarterly	At least monthly	At least monthly	At least monthly
Clinical Services	Recovery/remission management services	Direct psychosocial services (for SUD and MH)	Direct psychosocial services (for SUD and MH);	Direct psychosocial services (for SUD and MH);	Direct psychosocial services (for SUD and MH); high-intensity

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

	1.0Y	1.5Y	2.1Y	2.5Y	3.5Y
		Family services [†] Able to coordinate psychiatric services as needed Treatment as prevention	therapeutic milieu Family services [†] Direct psychiatric services Treatment as prevention	therapeutic milieu Family services [†] Direct psychiatric services	therapeutic milieu Family services [†] Direct psychiatric services
Clinical Service Hours	Quarterly services at minimum	<6 hours/week; typically, 1-2 hours per week	6-19 hours/week; structured services at least 2 days per week	≥20 hours/week; structured services at least 5 days per week	≥20 hours/week, structured services 7 days a week
Recovery Support Services (RSS)	Yes, including recovery management checkups	Yes*	Yes*	Yes*	Yes*
<p>*directly or through formal affiliation; **Yes, if clinically managed *** Psychiatric specialty expertise includes psychiatrists and advanced practice providers with specialty psychiatric certification. Addiction specialty expertise includes physicians who are board certified in addiction medicine or addiction psychiatry ‡ nursing services should be provided by a professional with the scope of practice to collect vitals and inject medications † family services include parent skills training, family therapy, and informal family-oriented recovery support (eg, family resource centers, peer and mutual support for family, faith-based support services, etc.)</p>					

1

2

1 Table 1b. Summary of Service Characteristics for the Adolescent Medically Managed Levels of Care

	Level 1.7Y	Level 2.7Y	Level 3.7Y	Level 4Y
Medical Director	Yes	Yes	Yes	Yes
Physicians and Advanced Practice Providers	Yes	Available on-site or via telemedicine during program hours of operation	Available on-site or via telemedicine 24/7	Typically available on-site 24/7
Nursing	Variable	Yes (extended nurse monitoring)	Yes (24/7)	Yes (24/7)
Program Director	Variable	Yes	Yes	Variable
Allied Health Staff	Variable	Typically Available	Yes	Yes
Physical Exam	Typically at initial assessment	Within 24-48 hours of initial assessment	Within 24 hours of admission	Within 24 hours of admission
Nursing Assessment	Variable	At admission	At admission	At admission
Clinical Services	Direct withdrawal management and biomedical services Management of common psychiatric disorders Psychosocial Services†	Direct withdrawal management and biomedical services, with extended nurse monitoring Management of common psychiatric disorders Psychosocial services†	Direct withdrawal management and biomedical services Management of common psychiatric disorders Psychosocial services†	Direct withdrawal management and biomedical services (ICU available) Management of common psychiatric disorders Psychosocial services†
Clinical Service Hours	<9 h/wk	≥20 h/wk	≥20 h/wk	Variable
Recovery Support Services (RSS)	Yes*	Yes*	Yes*	Yes*
* Directly or through formal affiliation				

2

3 Universal Standards

4 Overdose Reversal Medication

5 All programs across all levels of care should have overdose reversal medication (eg, naloxone) available

1 on-site.

2 **Trauma and Culture**

3 All programs across all levels of care should adopt trauma-sensitive practices (TSP) in all aspects
4 of program operations; that is, performing assessment and treatment planning and providing
5 services in a way that is designed to prevent re-traumatization and delivered with gender sensitivity
6 and cultural humility.

7 **Universal Setting Standards**

8 The setting should be comfortable and responsive to the needs of adolescent patients

9 **Universal Staff Standards**

10 All staff should be trained in the administration of overdose reversal medication (eg, naloxone).

11 All programs should have sufficient staff with the training, experience, and scope of practice to
12 assess, diagnose, and treat SUD and co-occurring mental health conditions available during
13 program hours of operation.

14 All clinical and allied health staff should have competency to care for individuals who have SUD
15 and active co-occurring mental health conditions.

16 *Staffing Levels*

17 Programs should have sufficient staff on-site or on-call during their hours of operation (ie, 24/7 in
18 residential and inpatient programs) to maintain integrity of care for the range and severity of
19 problems that may be addressed at the level(s) of care that they provide. Programs should identify
20 the positions that are critical for running the program and the level of staffing needed to safely
21 operate the program.

22 In clinically managed levels of care this should include:

- 23 • supervisory staff with at least 2 years of adolescent treatment experience available to
24 respond to urgent situations;
- 25 • sufficient clinical staff to meet patient psychosocial treatment needs for SUD and co-
26 occurring mental health conditions; and
- 27 • staff trained in de-escalation.

28 In medically managed levels of care this should include:

- 29 • sufficient nursing staff to provide coverage during program hours of operation (ie, 24/7 in
30 residential and inpatient programs) with a sufficient staff-to-patient ratio to safely
31 manage the program's patient population†; and
- 32 • physicians and/or advanced practice providers available on-site, on-call, or via
33 telemedicine to provide medical management

1 Independently licensed clinical staff with competency to supervise co-occurring mental health
2 treatment should be on- site or on- call during program hours of operation (ie, 24/7 in residential
3 and inpatient programs).

4 _____

5 † Does not apply to Level 1.7Y programs that may not have nursing staff.

6 *Medical Staff*

7 In all levels of care except Level 1, psychiatrists and/or advanced practice providers with specialty
8 certification in psychiatry (eg, psychiatric nurse practitioners [NPs]) should be available in person
9 or via telemedicine to:

- 10 • provide psychiatric assessments as needed within a time frame appropriate to the severity
- 11 and urgency of the mental health signs and/or symptoms;
- 12 • assess medication needs within 24 hours when needed;
- 13 • initiate psychiatric medications;
- 14 • provide regular (eg, weekly) titration of medication;
- 15 • coordinate access to psychiatric medications and laboratory testing, and manage
- 16 medications and side effects; and
- 17 • review admission decisions as needed (eg, if a patient presents with Dimension 3 concerns
- 18 that may require medical evaluation).

19 In all levels of care except Level 1, a psychiatrist and/or advanced practice provider with specialty
20 certification in psychiatry (eg, psychiatric NPs) should regularly review and approve the program’s
21 policies, procedures, and protocols for making admission decisions related to Dimension 3
22 concerns.

23 Level 1 programs should have established relationships with physicians and/or advanced practice
24 providers who have experience in addiction treatment and co-occurring mental health conditions
25 to coordinate access to psychiatric medications and laboratory testing, and manage medications
26 and side effects.

27 In clinically managed levels of care, the medical director or a formally affiliated physician and/or
28 advanced practice providers with specialty certification in psychiatry (eg, psychiatric NP) should
29 regularly review and approve the program’s policies, procedures, and protocols for making
30 admission decisions regarding assessment of Dimension 3 concerns and related admission
31 policies, including when medical clearance is needed prior to admission.

32 *Clinical Staff*

33 Competency in both adolescent mental health and SUD treatment should be represented on the
34 program’s clinical staff.

35 Clinical staff with competency to manage mental health-related crises should be on-site or on-call
36 during program hours of operation (ie, 24/7 in residential and inpatient programs).

1 In all levels of care, the program director (or an independent clinician in a Level 1.5Y or 1.7 level of
2 care) should have competency in addiction, mental health, and family systems interventions.

3 In all levels of care, clinical staff with the appropriate training and scopes of practice should:

- 4 • deliver planned regimens of professionally directed psychosocial services, including
5 counseling, psychoeducation, and psychotherapy;
- 6 • assess and treat SUD, other addictive disorders, and co-occurring mental health
7 conditions;
- 8 • support coordinated treatment planning;
- 9 • support care coordination*; and
- 10 • coordinate the delivery of recovery support services (RSS).

11 Mental health trained and SUD trained treatment providers should be equal partners on the
12 interdisciplinary team, supporting one another to deliver effective, integrated co-occurring capable
13 care.

14 Programs should have clinical staff on the interdisciplinary team with:

- 15 • mental health training and experience who provide integrated skilled mental health
16 interventions during program hours of operation.
- 17 • the scopes of practice to assess and treat common co-occurring mental health conditions
18 who are available on-site or via telemedicine

19 Clinical staff involved in the assessment and treatment of patients should be:

- 20 • knowledgeable about the biopsychosocial dimensions of addiction, mental health, and
21 other behavioral health disorders;
- 22 • trained to conduct and interpret multidimensional developmentally appropriate
23 assessments according to The ASAM Criteria Dimensional Admission Criteria, particularly if
24 they are involved with making level of care recommendations;
- 25 • trained to administer and interpret standardized screening tools and multidimensional
26 assessments to determine individual patient needs;
- 27 • trained to engage families into the care process;
- 28 • trained to communicate in a developmentally responsive manner, including adjusting
29 assessments, educational content, and program curriculum to be developmentally
30 appropriate; and
- 31 • trained in de-escalation, trauma-informed approaches, and other behavior management
32 strategies to care for patients who are experiencing mental health signs or symptoms
33 including agitation, aggression, and risk of self-harm.

34 Clinical staff should also have specialized training in behavior management techniques and
35 psychosocial evidence-based interventions (EBIs) aligned with their scopes of practice.

36 All programs should have clinical staff with the training and competency to:

- 37 • Triage of mental health concerns

- 1 • Provide family services for co-occurring mental health concerns
- 2 • Providing mental health care in a trauma informed, culturally humble, and developmentally
- 3 appropriate context

4 _____

5 * The staff member responsible for care coordination for a given patient should be clearly documented.

6 **Program Director**

7 The program director (in applicable levels of care) is responsible for:

- 8 • leading development of program policies and procedures,
- 9 • providing administrative oversight,
- 10 • providing clinical supervision and oversight, and
- 11 • overseeing implementation of the therapeutic milieu.

12 *Care Manager*

13 All programs except Level 1 should have appropriately qualified staff tasked with providing care
14 management services (eg, services to help patient’s access and coordinate healthcare, social
15 service, and educational needs). Level 1 programs are encouraged to provide these services.

16 *Allied Health Staff*

17 In all levels of care, allied health staff—such as certified peer support specialists, patient and
18 family navigators, health educators, counselor aides, certified recovery coaches, and group living
19 workers—may serve a variety of roles, including helping patients and families:

- 20 • get oriented to the program’s therapeutic milieu (if applicable),
- 21 • engage in the program,
- 22 • attend mutual support group and/or mutual aid meetings,
- 23 • access benefits and social support services (eg, health insurance, transportation
- 24 assistance, nutrition benefits),
- 25 • access academic coordinators and engage with the education system,
- 26 • support referrals and transitions in care, and
- 27 • coordinate with social service agencies.

28 Allied health staff may also support the delivery of RSS, including:

- 29 • peer support services for patients and families;
- 30 • health education and harm reduction services, such as prevention of infectious
- 31 diseases (eg, HIV, hepatitis C virus [HCV]), safe sex practices, and overdose prevention
- 32 and reversal training;
- 33 • coordinating access to parenting skills training;
- 34 • patient navigation services; and
- 35 • level of care transition support.

36 Allied health staff, when available, should be part of the interdisciplinary team and the services they
37 provide should be coordinated with clinical staff.

1 Universal Assessment and Treatment Planning Standards

2 Assessment and treatment planning should be conducted in a developmentally responsive
3 manner.

4 Mental health trained clinical staff should be involved in assessment and treatment planning for
5 patients' Dimension 3 needs and should coordinate with the psychiatric care provider as needed.

6 *Assessment*

7 A Level of Care Assessment should be conducted or reviewed prior to admission to determine the
8 recommended level of care.

9 All programs should support access to routine psychiatric assessment and consultation, when
10 needed.

11 All programs should be able to coordinate access to an assessment for intellectual and
12 developmental disabilities (IDD).

13 A treatment planning assessment should be conducted within a reasonable timeframe to guide
14 development of the treatment plan.

15 *Physical Examinations*

16 All levels of care should either directly provide or coordinate referral for a medical history and
17 physical examination as needed. The medical history and physical examination should include an
18 assessment for:

- 19 • addiction medication needs¹
- 20 • need for psychiatric assessment or medications
- 21 • need for management of symptoms of post-acute withdrawal
- 22 • common sequelae of SUDs (eg, skin infections)
- 23 • common co-morbid conditions (eg, eating disorders)
- 24 • infectious disease screening and treatment or referral needs
- 25 • vaccination needs
- 26 • screening for traumatic brain injury and treatment or referral needs
- 27 • developmental concerns

28 *Reassessment*

29 Families should be updated routinely on treatment plan progress.

¹ Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal symptoms.

1 Universal Support System Standards

2 To support patient engagement in ongoing addiction treatment, all adolescent programs should
3 have established relationships with adult programs to support care coordination and effective
4 adolescent–adult care transitions.

5 *Biomedical Support Systems*

6 All clinically managed programs should have formal affiliations* with physicians and/or advanced
7 practice providers who have experience in addiction treatment and controlled substance
8 prescribing authority† to coordinate access to:

- 9 • physical examinations;
- 10 • medical assessments, including assessment of SUD or mental health related
11 medical needs as well as general health needs (eg, wellness exams, strep throat);
- 12 • addiction medications‡;
- 13 • psychiatric medications;
- 14 • contraceptive medication;
- 15 • prescribed medications, including those that are obtained from a specialty
16 pharmacy;
- 17 • medication management services;
- 18 • laboratory testing; and
- 19 • drug testing and toxicology services^s

20 In clinically managed levels of care, the medical director (or a formally affiliated* physician and/or
21 advanced practice provider in a program without a medical director) should regularly review and
22 approve the program’s policies, procedures, and protocols for making admission decisions
23 regarding assessment of Dimension 1, 2, and 3 concerns and related admission policies, including
24 when medical clearance is needed prior to admission.

25 All programs should be able to provide coordinated referrals, as needed, to:

- 26 • primary care providers (eg, pediatricians), and
- 27 • dental care providers.

28 All programs should advocate with external medical providers and services as needed to ensure
29 that significant patient health concerns are addressed in a timely manner.

30 When medical services are required concurrent with treatment in a clinically managed program,
31 care should be coordinated. In programs without medical staff, care coordination may include
32 supporting patients and their families to follow through with medical appointments and other
33 elements of their medical treatment plan (eg, taking medications as directed, performing physical
34 therapy exercises, adopting nutritional changes, monitoring glucose).

35 _____

36 * In Level 1 programs, these may be established relationships.

37 † Including authorization to prescribe buprenorphine.

1 ‡ Including all FDA-approved medications for opioid use disorder (OUD; including methadone, unless unavailable
2 locally), alcohol use disorder (AUD), and tobacco use disorder (TUD); off-label medications for other SUDs, including
3 stimulant use disorder (StUD) and cannabis use disorder (CUD); and medications to manage post-acute withdrawal
4 symptoms.

5 § Please see ASAM's Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.

6 *Psychiatric and Cognitive Support Systems*

7 In all programs, except Level 1, psychiatrists and/or advanced practice providers with specialty
8 certification in psychiatry (eg, psychiatric nurse practitioners [NPs]) should be available in person
9 or via telemedicine to provide psychiatric assessments as needed within a time frame appropriate
10 to the severity and urgency of the mental health signs and/or symptoms.

11 All programs should have established relationships with mental health treatment programs and
12 service providers to support transitions in care and access to crisis services, including:

- 13 • intensive case management services,
- 14 • psychosocial rehabilitation programs,
- 15 • mental health group residential settings, and
- 16 • mental health treatment centers.

17 All programs should have an established relationship with the behavioral health crisis system, if
18 locally available, to respond to urgent mental health needs.

19 All programs should have established relationships with clinicians with the competency and
20 scopes of practice to provide:

- 21 • Learning disorder assessment and management
- 22 • Eating disorder assessment and treatment
- 23 • Neurodevelopmental disorder (eg, autism) assessment and treatment

24 All programs should be able to coordinate access to an assessment for eating disorders and
25 intellectual and developmental concerns as needed, and:

- 26 • Coordinate care as needed
- 27 • Implement accommodations necessary for patient participation in treatment
- 28 • Integrate occupational therapy (OT) as needed

29 *Relationships With Other Levels of Care*

30 To support patient engagement in ongoing addiction treatment, all programs should have
31 established relationships with other levels of addiction treatment—both more and less intensive—
32 to support care coordination and effective transitions in care.

33 *Emergencies*

34 Programs should have established policies and procedures for responding to urgent and emergent
35 medical and psychiatric needs during program hours of operation, including when to engage the
36 on-call physician or advanced practice provider (where applicable) and when to call 911 or 988.

1 *Community and Social Service Support Systems*

2 Programs should have established relationships with community social service providers and other
3 community support systems including:

- 4 • School systems to support coordination of school based clinical services, management of
5 patient educational needs, and transitions back to school.
- 6 • Therapeutic schools and recovery high schools and colleges when available.

7 All programs should have established relationships with local systems of care that serve
8 adolescents, including:

- 9 • Juvenile legal/correctional agencies
- 10 • Child welfare
- 11 • Foster care
- 12 • School systems
- 13 • Housing and homeless services
- 14 • Vocational training programs

15 *Universal Services Standards*

16 All services should be provided in a developmentally responsive manner.

17 In all levels of care except Level 1, case management services should be provided.

- 18 • The staff person with responsibility for providing case management services for a given
19 patient should be clearly documented.

20 Translation and/or interpreter services should be available to make services – including medical,
21 psychotherapeutic, and psychoeducational content – available in the patient or family’s preferred
22 language.

23 *Psychosocial Services*

24 Psychosocial services should be designed with the expectation that most patients will have co-
25 occurring mental health conditions. Individual and group interventions should address concerns
26 related to both SUD and mental health. Psychosocial services should be sensitive and responsive
27 to trauma, designed to prevent re-traumatization, and delivered with gender sensitivity and cultural
28 humility.

29 Psychotherapy, counseling, and psychoeducation should be provided by appropriately trained and
30 supervised professionals acting within their state-regulated scopes of practice for the given service
31 or, when appropriate, via evidence-based digital therapeutics.

32 Psychosocial services should:

- 33 • be evidence-based or evidence-informed,
- 34 • be provided in a developmentally responsive manner and with accommodation for learning
35 disabilities, as needed.

1 Addiction treatment programs should provide individual and group therapy directly or through
2 formally affiliated providers and programs, with individual and group therapy actively addressing
3 and monitoring:

- 4 • SUD
- 5 • the sequelae of SUD,
- 6 • co-occurring mental health concerns,
- 7 • the interaction between SUD and mental health symptoms,
- 8 • management of mental health symptoms and trauma without using substances, and
- 9 • relapse prevention.

10 Appropriately trained and supervised professionals should deliver motivational interviewing and
11 other evidence-based motivational enhancement interventions that are appropriate to patient and
12 family's stage of readiness to change and designed to:

- 13 • facilitate understanding of the relationship between the patient's substance use, mental
14 health conditions, and attendant life challenges;
- 15 • encourage family members to understand their role in creating a healthier environment to
16 support recovery; and
- 17 • increase the patient and family's readiness for change.

18 Programs should also provide occupational and recreational therapies (eg, sports, art, music)
19 adapted to the patient's developmental stage, level of comprehension and understanding, and
20 physical abilities.

21 Programs should provide interventions directly or through formally affiliated providers and
22 programs that are designed to:

- 23 • stabilize and maintain the stability of the patient's SUD and co-occurring mental health
24 symptoms;
- 25 • enhance patients and families' understanding of substance use, and addiction;
- 26 • enhance patients and families' understanding of co-occurring mental health concerns and
27 how they interact with addiction, including:
 - 28 ○ the patient's triggers for substance use;
 - 29 ○ mental health related drivers of substance use;
 - 30 ○ how to discuss mental health disorders, symptoms, and treatments appropriately in
31 the context of recovery programs and mutual support groups; and
 - 32 ○ how to appropriately ask for help for mental health concerns from family, peers,
33 and/or professionals when needed;
 - 34 ○ the importance of adherence to medications prescribed for psychiatric disorders,
35 including:
 - 36 - how to work honestly and effectively with prescribers, and
 - 37 - why it is important to take medications as prescribed;
- 38 • help the patient gain insight into their risk factors for substance use;

- 1 • help the family gain insight into the patient’s risk factors for substance use and SUD
- 2 (including how substance use affects the developing brain and the neurobiology of SUD);
- 3 • educate patients and families on:
- 4 ○ what to expect over the course of treatment,
- 5 ○ the importance of remaining engaged in the continuum of care as they progress
- 6 through treatment,
- 7 ○ signs of SUD recurrence, and
- 8 ○ the patient’s risk for transition to use of other substances;
- 9 • educate patients and families on the role of addiction and psychiatric medications, the
- 10 potential consequences of non-adherence, and the role of the family in supporting
- 11 adherence;
- 12 • enhance patients and families’ understanding of co-occurring mental health concerns and
- 13 how they interact with substance use and addiction, including:
- 14 ○ how to discuss mental health disorders, symptoms, and treatments appropriately in
- 15 the context of recovery programs and mutual support groups; and
- 16 ○ how to appropriately ask for help for mental health concerns from family, peers,
- 17 and/or professionals when needed;
- 18 • support adherence to medications prescribed for addiction and psychiatric disorders,
- 19 including:
- 20 ○ how to work honestly and effectively with prescribers, and
- 21 ○ why it is important to take medications as prescribed;
- 22 • improve the patient and family’s ability to structure and organize tasks of daily living and
- 23 recovery;
- 24 • support successful initial involvement or reinvolvement in regular, productive daily activity
- 25 (eg, school, extracurricular activities, work) and reintegration into family living, as indicated;
- 26 • support patients to develop and apply skills to support long-term remission through:
- 27 ○ substance use or relapse prevention;
- 28 ○ exploration of interpersonal choices;
- 29 ○ development of social networks supportive of recovery;
- 30 ○ educational and skill building groups;
- 31 ○ vocational and jobs training for adolescents;
- 32 ○ occupational and recreational therapies;
- 33 ○ art, music, and/or movement therapies;
- 34 ○ mindfulness interventions; and
- 35 ○ physical therapy;
- 36 • encourage patients and families’ motivation to address their SUD and co-occurring
- 37 conditions; and
- 38 • support integrated treatment for TUD, including:
- 39 ○ benefits of treating TUD at the same time as other SUDs,
- 40 ○ EBIs for TUD (eg, medications, counseling),
- 41 ○ relative risks of nicotine/tobacco products, and
- 42 ○ motivational and harm reduction strategies for patients who are ambivalent about
- 43 stopping use of nicotine/tobacco.

1 The following psychosocial services should be available directly or through established
2 relationships with providers and programs as needed:

- 3 • recovery support group facilitation,
- 4 • contingency management (CM),
- 5 • community reinforcement and family training (CRAFT),
- 6 • family therapy,
- 7 • cognitive behavioral therapy (CBT),
- 8 • eye movement desensitization and reprocessing (EMDR),
- 9 • solution-focused therapy (SFT),
- 10 • multisystemic therapy (MST)
- 11 • dialectical behavioral therapy (DBT), and
- 12 • other EBIs.

13 All programs should have educational materials routinely available (from reputable sources) that
14 address addiction and common comorbid physical and mental health conditions, including
15 trauma.

16 All programs should be able to provide health education for patients and families regarding:

- 17 • the causes of addiction and mental health disorders;
- 18 • the impact of substance use on the developing brain;
- 19 • factors that influence the progression of addiction and mental health disorders;
- 20 • understanding the risks associated with substance use prior to brain maturation;
- 21 • interactions between substance use and mental health symptoms (eg, psychosis, mania,
22 etc.);
- 23 • the importance of taking care of physical and mental health;
- 24 • medications for addiction and psychiatric disorders;
- 25 • understanding the health risks associated with substance use (eg, infectious disease
26 transmission, cannabis hyperemesis syndrome, victimization, etc.);
- 27 • understanding how substance use can increase risks for victimization;
- 28 • harm reduction strategies, including overdose recognition and response training (eg,
29 naloxone training);
- 30 • health-related risk factors associated with SUD (eg, HIV, HCV, STIs, skin and soft tissue
31 infections, unintended pregnancies); and
- 32 • the importance of taking care of physical and mental health.

33 All programs that provide medications should provide psychoeducation to help patients
34 understand medication changes and report medication effects and side effects.

35 In addition to other evidence-based psychoeducation for patients, programs should support
36 psychoeducational services for patients' families and significant others (with appropriate patient
37 consent), including:

- 38 • what to expect during treatment,

- 1 • how to support loved ones during treatment, including:
 - 2 ○ effective communication
 - 3 ○ providing effective monitoring
 - 4 ○ setting appropriate boundaries (eg, access to money, devices, etc.)
- 5 • why self-care is important for caregivers,
- 6 • the role of medications in the management of addiction and psychiatric conditions,
- 7 • safe storage of medication, including both the patient’s and any controlled medications in
- 8 the home.
- 9 • the importance of ongoing engagement in the continuum of care,
- 10 • harm reduction education and training (how to use naloxone, drug checking [eg, fentanyl
- 11 test strips], etc.),
- 12 • how to recognize overdose, and
- 13 • how to respond to overdose.

14 **Family Services**

15 The following family psychosocial services should be available directly or through established
16 relationships with providers and programs as needed:

- 17 • Family assessment²
- 18 • Parental guidance counseling, including skills training related to:
 - 19 ○ parenting skills
 - 20 ○ building healthy family routines
 - 21 ○ self-care while caring for an adolescent with SUD or mental health concerns
 - 22 ○ effectively advocating for your adolescent’s health care needs
- 23 • Family mutual support groups³
- 24 • Social services navigation
- 25 • Individual or group psychoeducation

26 **Therapeutic Milieu**

27 Much of addiction care is provided in a group format that invariably produces group dynamics.
28 Thus, creating and managing a healthy therapeutic milieu is a central aspect of addiction and co-
29 occurring mental health treatment in The ASAM Criteria Levels 2.1Y, 2.5Y, and 3.5Y. A therapeutic
30 milieu is conscious, planned, psychotherapeutically based, and subtly modified for each patient
31 based upon their needs. In a youth treatment program, the milieu should be adjusted to the
32 developmental age of the patient and careful thought should be given to the range of
33 developmental ages that are included in a given group.

34 The therapeutic milieu—which should be clinically managed—is more nuanced and powerful than
35 the rules-based milieu found in recovery residences. Gentle social pressure within the treatment
36 environment, group therapy, and meetings of the entire community are used to affect change.
37 Efficacy is proportional to the number of hours in the day that patients are together and the level of

² [https://www.jaacap.org/article/S0890-8567\(09\)62183-3/pdf](https://www.jaacap.org/article/S0890-8567(09)62183-3/pdf)

³ May be in person or virtual

1 social intimacy; thus, a Level 3.5Y milieu is inherently more potent than a Level 2.1Y milieu when
2 properly constructed and managed. An effective therapeutic milieu:

- 3 • contains the patient during periods of ambivalence about SUD or mental health
4 remission or recovery in a caring environment, moving them along the change
5 continuum;
- 6 • allows the patient to see themselves in others and, in doing so, moves them along the
7 change continuum;
- 8 • encourages medication adherence;
- 9 • engenders bonding in a way that helps the patient realize they are not alone;
- 10 • holds the patient in a safe environment where they learn and practice pro-
11 remission/recovery and behaviors modeled after patients who are further along;
- 12 • helps heal patient’s negative emotions regarding SUD- and mental health related
13 behaviors through open sharing of each other’s past breaches of moral and ethical
14 values—compassion for others in the milieu increases self-compassion;
- 15 • encourages the patient to recognize the negative aspects of addiction in others, which
16 opens a window to reject such aspects in their own addictions;
- 17 • provides a gentle mirror that reflects thoughts, behaviors, and emotional states that
18 either promote remission or recurrence;
- 19 • acknowledges and supports the patient as they grieve aspects of their planned future
20 that are impacted by their SUD, mental health conditions, and/or recovery (eg, expected
21 experiences in college or on their 21st birthday);
- 22 • furnishes a safe therapeutic environment that encourages the exploration of thoughts,
23 behaviors, and emotional states;
- 24 • defines behaviors that promote disease remission through community rules;
- 25 • identifies unconscious and semiconscious substance- and mental health-related
26 thinking and provides a staff-supervised path to remove or repair them; and
- 27 • practices self-driven supportive behaviors, accompanied by therapeutic iterative
28 improvement.

29 *Care Management*

30 All levels of care except Level 1, should provide care management services (eg, services to help
31 patient’s access and coordinate healthcare, social service, and educational needs).

32 Level 1 programs are encouraged to provide care management services.

33 *Recovery Support Services*

34 In all levels except Level 1, peer support specialist services should be available for both
35 adolescents and their families.

36 All programs should provide the following RSS, either directly or through formal affiliations* with
37 external service providers (eg, recovery community organizations [RCOs], recovery high schools
38 [RHSs], collegiate recovery programs [CRPs]), tailored to the needs of each individual and
39 considering their developmental age and stage as determined based on The ASAM Criteria
40 assessment and treatment planning standards† and appropriate to the stage of treatment:

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • assessment of patient and family recovery capital and RSS needs;
- 2 • development of individualized recovery plans for patients and families;
- 3 • certified peer support specialist services, including:
 - 4 ○ strengths-based support and coaching,
 - 5 ○ recovery plan development,
 - 6 ○ recovery resource navigation (ie, supporting connection with other recovery
 - 7 resources), and
 - 8 ○ ally advocacy (ie, advocating for the patient and family as needed with social service
 - 9 organizations and professional services to address SDOH-related needs);
- 10 • support developing and practicing skills of daily living, including:
 - 11 ○ transportation skills,
 - 12 ○ health and healthcare navigation (eg, navigating changes to insurance), and
 - 13 ○ self-care (ie, healthy living and other activities to promote personal well-being);
- 14 • support internalizing and practicing relapse prevention skills, including:
 - 15 ○ learning how to navigate their environments (eg, home, school) that contain
 - 16 substances (or other triggers) without returning to substance use,
 - 17 ○ learning how to interact socially with people outside of the recovery community in a
 - 18 safe and healthy way, and
 - 19 ○ identifying and engaging in prosocial activities outside of the recovery community,
- 20 • support utilizing harm reduction strategies and services;
- 21 • support accessing services to further develop and practice core life skills (eg, educational,
- 22 parenting, financial management, nutrition);
- 23 • patient navigation services** for patients who require concurrent treatment with external
- 24 providers; and
- 25 • transition planning, including warm handoffs.

26 All programs should also provide care coordination and support accessing external RSS in the
27 community, including support with:

- 28 • identifying and/or accessing mutual help programs (eg, assistance finding appropriate
- 29 programs, identifying transportation options);
- 30 • accessing services for domestic violence, intimate partner violence (IPV)[†], or victim
- 31 services;
- 32 • accessing social services (eg, housing, nutritional assistance, health insurance), with ally
- 33 advocacy recommended when feasible;
- 34 • identifying and/or accessing other community activities supportive of recovery (eg, recovery
- 35 high schools and collegiate recovery programs [CRPs], recovery community centers
- 36 [RCCs])[§];
- 37 • accessing transportation to necessary services (eg, community rides to mutual help
- 38 meetings, help identifying public transit options and obtaining passes);
- 39 • coordinating with social service agencies (eg, children, youth, and family services; juvenile
- 40 justice agencies; IPV agencies; foster care; housing and homeless services);

- 1 • identifying and obtaining community services and supports to address potential
- 2 impediments to recovery (eg, legal services, educational services, housing, childcare
- 3 services, vocational training, parenting education, financial training); and
- 4 • identifying and accessing harm reduction services.

5 _____

6 * Formal affiliation is encouraged but not a requirement for Level 1.5Y programs.

7 ** Patient navigation is individualized support to help patients and families overcome barriers to accessing healthcare

8 services, including help communicating with health care providers.

9 † Please see Chapter 8: Assessment, Reassessment, and Measurement-Based Care and Chapter 9: Treatment Planning.

10 ‡ Programs should have established relationships with IPV service providers.

11 § This is not applicable in Level 3.7Y or 4Y programs where patients do not leave the facility for nonmedical reasons.

12

13 *Co-Occurring Capability*

14 All programs should offer services that are designed to provide a welcoming environment for

15 individuals with co-occurring mental health conditions, where patients feel safe addressing their

16 mental health concerns and experiences.

17 All services should be designed with the expectation that many, if not most patients will have co-

18 occurring mental health conditions; for example, individual and group interventions should

19 encourage patients and families to address both SUD- and mental health-related concerns.

20 Programs should provide assessment and treatment services for co-occurring mental health

21 conditions. Patient mental health and SUD related concerns should be treated concurrently. Care

22 should be coordinated with any external mental health treatment providers.

23 Patient mental health concerns should be treated concurrently by the addiction treatment program

24 and/or through coordination with external providers.

25 All programs should provide integrated skilled mental health treatment interventions to address

26 co- occurring mental health conditions in person or via telemedicine.

27 Admission criteria for addiction treatment programs should not exclude patients based on current

28 or past mental health diagnoses alone; the appropriateness of admission should be determined by

29 the severity and acuity of the patient’s psychiatric signs and symptoms as outlined in The ASAM

30 Criteria Dimensional Admission Criteria decision rules.*

31 _____

32 *Please see Chapter 10: Dimensional Admission Criteria and Algorithm.

33 *Biomedical Capabilities*

34 All clinically managed programs should have access to the following biomedical capabilities on-

35 site:

- 36 • basic first aid,
- 37 • overdose reversal medication (eg, naloxone), and

- 1 • point-of-care pregnancy testing.*

2 Clinically managed programs are also encouraged to have an automated external defibrillator
3 (AED) on-site.

4 _____

5 * This is encouraged but not a requirement for Level 1.0Y and 1.5Y programs.

6 *Care Coordination*

7 All programs should support care coordination to manage engagement and track progress when a
8 patient is receiving concurrent services from an external treatment or service provider or program,
9 including:

- 10 • data sharing as needed to support effective coordination of care, and
11 • monitoring of the patient’s adherence in taking prescribed medications and permitted over
12 the counter (OTC) medications or supplements.

13 The staff member responsible for care coordination for a given patient should be clearly
14 documented. In clinically managed levels of care, data sharing should occur monthly, at minimum,
15 to support formal reassessment.

16 Programs should coordinate patient referrals and transitions to other levels of care, including warm
17 handoffs, as needed.

18 All programs should coordinate care with:

- 19 • any external mental health providers involved in the patient’s care (with appropriate patient
20 consent) at admission to and transition from the clinically managed program; at minimum,
21 monthly (when applicable); and as needed to support effective care coordination for the
22 individual patient;
23 • prescribers of addiction and psychiatric medications, including to support rapid referrals for
24 addiction or psychiatric medications as needed;
25 • medical providers concurrently treating issues that may impact the patient’s prognosis or
26 recovery;
27 • Social service providers, including schools; and
28 • The patient’s pediatrician or other primary care provider.

29 **Universal Documentation Standards**

30 *Level of Care and Treatment Planning Assessments*

31 Program documentation of the assessment process, which encompasses The ASAM Criteria Level
32 of Care and Treatment Planning Assessments,* should include:

- 33 • the level of care at which the patient is currently receiving treatment, as well as any levels of
34 care from which the patient has received treatment over the past 12 months;
35 • a summary of the results from the patient’s Level of Care and Treatment Planning
36 Assessments, including:

- 1 ○ an overview and analysis of problems within each of the six dimensions of The
- 2 ASAM Criteria, including:
- 3 ■ prioritization of the problems identified, including Dimensional Drivers,
- 4 ■ the relationship between the problems identified and substance-related and addictive
- 5 disorders, and
- 6 ■ the patient’s current level of functioning (eg, skills of daily living);
- 7 ○ the level of care recommendation(s); and
- 8 ○ the final disposition and reason(s) for any discrepancies (if applicable; eg, barriers
- 9 to care, patient and/or family preferences);
- 10 ● the date of the patient’s most recent physical examination;
- 11 ● dated standardized mental health screening and assessment results with comparison to
- 12 past results (if applicable);
- 13 ● alcohol, nicotine/tobacco, and other drug use status, including:
- 14 ○ duration,
- 15 ○ frequency,
- 16 ○ intensity (eg, pack years,† binge use),
- 17 ○ route(s) of administration, and
- 18 ○ type(s) of products used (eg, prescription medication, high-potency substances,
- 19 oral tobacco); and
- 20 ● problematic behaviors and behavioral addictions;
- 21 ● review of the patient’s admission decision;
- 22 ● the patient’s care team and their contact information, including:
- 23 ○ formal supports, such as healthcare providers and criminal justice officials; and
- 24 ○ informal supports identified by the patient, such as family, chosen family, and
- 25 community-based supports.

26 In all medically managed programs, documentation of the assessment process should additionally
27 include:

- 28 ● results from the nursing assessment, physical examination, and medical assessment;
- 29 ● laboratory and toxicology order sets and results, including documentation on how the
- 30 treatment plan was modified based on results (if applicable); and
- 31 ● scoring for withdrawal rating scale tables and flow sheets, which may include tabulation of
- 32 vital signs.

33 _____

34 * Please see Chapter X: Assessment, Reassessment, and Measurement-Based Care.

35 † That is, the number of packs of cigarettes smoked per day multiplied by the number of years the person has smoked.

36

37 *Treatment Planning*

38 Programs should document the following details regarding each patient’s individualized treatment
39 plan for both SUD and mental health concerns (or remission management plan for Level 1.0Y
40 programs):

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • patient diagnoses, including severity of SUD(s);
- 2 • problem statements and treatment goals;
- 3 • current state of readiness to change for each major concern;
- 4 • measurable treatment objectives;
- 5 • barriers to care;
- 6 • action steps to address identified problems and meet stated objectives;
- 7 • case management services (if applicable);
- 8 • medications and medication management plan (if applicable); and
- 9 • safety plans for after-hours medical advice and emergencies (if applicable).
- 10 • services and/or support to address concerns to be provided by external providers, as
- 11 well as documentation of care coordination as necessary;
- 12 • patient and family strengths that support effective management of SUD and mental
- 13 health symptoms without using substances; and
- 14 • the continuing care plan following transition from the program.

15 Treatment plans for patients with comorbid biomedical conditions should have specific
16 documentation of:

- 17 • patient biomedical concerns (eg, sleep, pain, asthma, diabetes, eating disorder,
- 18 tobacco use/vaping);
- 19 • screening and assessment results (if applicable);
- 20 • relevant patient and family goals;
- 21 • services and/or support, including symptom management strategies (eg, for pain), to
- 22 address biomedical concerns to be provided by the program;
- 23 • services and/or support to address biomedical concerns to be provided by external
- 24 providers, as well as documentation of care coordination as necessary; and
- 25 • the continuing care plan for comorbid biomedical conditions following transition from
- 26 the addiction program.

27 Treatment plans for patients with co- occurring psychiatric conditions should have specific
28 documentation of:

- 29 • patient mental health symptoms and diagnoses;
- 30 • risk of harm to self or others;
- 31 • services and/or support to address mental health concerns to be provided by the program;
- 32 • services and/or support to address mental health concerns to be provided by external
- 33 providers, as well as documentation of care coordination as necessary;
- 34 • individual strengths that support effective management of mental health symptoms without
- 35 using substances; and
- 36 • the continuing care plan for co- occurring psychiatric conditions following transition from
- 37 the addiction program.

38 Treatment plans for patients with co-occurring IDD should have specific documentation of:

- 39 • patient intellectual or developmental concerns and diagnoses;

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • services and/or support to address IDD concerns to be provided by the program;
- 2 • services and/or support to address IDD concerns to be provided by external providers, as
- 3 well as documentation of care coordination as necessary; and
- 4 • the continuing care plan for IDD following transition from the addiction program.

5

6 Treatment plans for patients with social service involvement should have specific documentation
7 of:

- 8 • patient social service needs identified from their biopsychosocial assessment;
- 9 • local agencies that can address social service needs, as well as documentation of care
- 10 coordination as necessary; and
- 11 • the continuing care plan for social service needs following transition from the addiction
- 12 treatment program.

13 *Reassessment*

14 Programs should document individualized progress notes in the patient’s health record that clearly
15 reflect implementation of the treatment plan. These progress notes should capture:

- 16 • the patient’s response to therapeutic interventions for all disorders treated;
- 17 • laboratory and toxicology order sets and results, including documentation on how
- 18 the treatment plan was modified based on results (if applicable);
- 19 • patient and family adherence to the treatment plan;
- 20 • significant events that may alter the course of treatment or recovery;
- 21 • changes in frequency and/or types of services;
- 22 • changes in level of care;
- 23 • subsequent amendments to the treatment plan;
- 24 • the dated signature of the patient’s primary clinician; and
- 25 • the dated signature of a supervisor if the clinician is a trainee.

26 *Care Coordination and Consent*

27 Programs should provide a copy of the treatment plan to the patient and family upon initiation of
28 the plan and subsequently whenever the plan gets updated. Programs should document the
29 patient’s assent/consent—or decline of assent/consent—to involve family members or other
30 support persons. Documentation should also include patient and family assent/consent—or
31 decline of assent/consent—for care coordination and information sharing with external providers
32 and programs.

33 Program documentation should allow each clinician involved in a patient’s care to access relevant
34 medical and psychosocial information for that patient. Documentation of referral to external
35 service providers should include:

- 36 • recommendations for care;
- 37 • reason(s) for departures from clinical recommendations (if applicable);

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • incorporation of externally provided or recommended treatment and/or services in the
- 2 patient’s treatment plan;
- 3 • care coordination; and
- 4 • follow-up plans with external providers to ensure ongoing engagement in care, with
- 5 documentation of each follow-up.

6 In addition, programs should maintain documentation of any memorandums of understanding
7 (MOUs), business associate agreements (BAAs), and qualified service organization agreements
8 with their formally affiliated providers and programs, where applicable.

9 *Transition Planning*

10 Program documentation of transition plans (including adolescent–adult care transition plans)
11 should include:

- 12 • a review of the patient’s six dimensions of The ASAM Criteria;
- 13 • recommendations for follow-up care;
- 14 • reason(s) for any departures from recommendations (if applicable);
- 15 • the service(s) and level(s) of care to which the patient will be transitioning;
- 16 • required medications and how the patient will maintain access to medications during
- 17 the transition;
- 18 • access to overdose reversal medication and patient and family training in its use; and
- 19 • the patient/family follow-up plan to facilitate ongoing engagement in care, with
- 20 documentation of each follow-up that includes dated signatures as appropriate.

21 Transition plans for patients transitioning from adolescent to adult care should also identify
22 trusted, recovery supportive adults who can support the patient in the community, including their
23 contact information with documentation of appropriate release(s) of information;

24 Patients or families sometimes choose to discontinue treatment against the clinical
25 recommendations of their providers. In the event of unplanned discharge, programs should
26 document:

- 27 • the patient’s status at discharge;
- 28 • reason(s) for discharge;
- 29 • care recommendations provided to the patient and family;
- 30 • access to medications after discharge (eg, transfer of prescriptions, bridging prescription),
31 including:
 - 32 ○ access to overdose reversal medication and training in its use,
 - 33 ○ safe discontinuation of psychoactive medication if the patient/family decline
 - 34 continuation of any current medications;
- 35 • notifications made, with dated signatures as appropriate to:
 - 36 ○ The referring provider
 - 37 ○ The receiving provider, and
 - 38 ○ The patient’s primary care provider; and

- 1 • who (eg, the referring provider, the care coordinator with the adult program where the
- 2 patient was supposed to transition) will follow up with the patient and/or family to re-engage
- 3 them in care;
- 4 • follow up attempts, when applicable.

5 *Staffing*

6 Programs should maintain documentation on safe staffing levels that consider:

- 7 • in medically managed levels of care, the number of physicians and advanced practice
- 8 providers that the medical director can safely manage;
- 9 • in programs with a program director, the number of clinical staff and allied health staff that
- 10 the program director can safely manage; and
- 11 • maximum staff-to-patient ratios for each staff type and role.
 - 12 ○ When determining the actual number of patients that an individual staff member
 - 13 can safely manage, responsibilities beyond direct patient care (eg, administration,
 - 14 education) should be considered.

15

16 *Medical Services*

17 Programs that provide integrated* nursing services should carefully document how the appropriate

18 level of nursing care for the severity of patient needs was determined. This encompasses care

19 provided by registered nurses (RNs), licensed practical nurses (LPNs), certified nursing assistants

20 (CNAs), paramedics, and medical technicians under the supervision of an RN.

21 If applicable, documentation should include appropriately maintained records of the program's

22 inventory of essential medicines based on current standards of clinical practice. Programs are

23 responsible for ensuring that these medications are stocked and stored securely and readily

24 accessible as needed, with accompanying careful documentation of dispensing of these

25 medications.

26 _____

27 *Here, integrated refers to medical services provided within the context of addiction treatment.

28

29 *Program Policies and Procedures*

30 In all levels of care, it is important to consider how program policies and procedures align with the

31 principles of The ASAM Criteria and support delivery of high-quality, evidence-based care (EBC) for

32 SUD and co-occurring mental health conditions. Programs should also consider how their policies

33 and procedures help reduce substance-related harms: How can policies and procedures better

34 meet patients and families where they are, promote ongoing engagement in the continuum of care,

35 recognize different pathway to recovery and remission, restore healthy development, and,

36 ultimately, save lives?

37 All programs should have policies and procedures that address:

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • admission, transition, and continued service criteria, in alignment with The ASAM Criteria
2 Dimensional Admission Criteria*;
- 3 • coordination of referrals to alternative levels of care, including preparation of contingencies
4 in the event that a patient requires a more intensive level of care that is not available;
- 5 • coordination of care with external providers and programs;
- 6 • coordination with social services (eg, school, juvenile justice, child protective services),
7 including:
 - 8 ○ clear identification of the responsible staff member;
 - 9 ○ required competencies and training;
- 10 • adolescent–adult care transitions that includes coordination with the adolescent’s support
11 network (eg, family or chosen family, community supports);
- 12 • harm reduction, including:
 - 13 ○ access to overdose reversal medication on-site;
 - 14 ○ access to overdose reversal medication when patients are off-site;
 - 15 ○ overdose reversal training for staff, patients, families, and support persons; and
 - 16 ○ patient and family or support person access to over-dose reversal medication; and
- 17 • confidentiality related to treatment for SUD, mental health conditions, and other relevant
18 conditions commonly experienced by the patient population (eg, sexually transmitted
19 infections, reproductive health), including:
 - 20 ○ informed patient assent or consent,
 - 21 ○ parent or guardian consent,
 - 22 ○ access to health records,
 - 23 ○ storage of health records,
 - 24 ○ patient rights,
 - 25 ○ family/guardian rights, and
 - 26 ○ mandated reporting and communication with juvenile justice entities.
- 27 • safety of patients and staff, including:
 - 28 ○ background checks for all staff and contractors
 - 29 ○ regular monitoring of the sex registry database
 - 30 ○ mechanism to report staff concerns regarding patient care without fear of retaliation

31 Programs should also have policies and procedures regarding the behavior of patients and
32 family/support system, when on-site, formalized in writing with a code of conduct. Patients and
33 families should be presented with the code of conduct at admission and, following their review,
34 asked to sign and date it to indicate that they understand and accept the program’s expectations
35 for safe participation in treatment. The patient code of conduct should clearly outline how the
36 program will respond to conduct that presents risk for harm to self or others.

37 Policies and procedures regarding program staffing should address:

- 38 • staff competency expectations;
- 39 • supervision and monitoring of staff competencies;
- 40 • training of medical and clinical staff, as appropriate to the level of services rendered at the
41 program’s level of care;

- 1 • supervision of peer support specialists and other allied health staff;
- 2 • mental health training and competencies; and
- 3 • determination of appropriate staff-to-patient ratios.

4 Programs that employ peer support specialist should have policies and procedures regarding:

- 5 • the minimum duration of recovery required before an individual is eligible to be a peer;
- 6 • monitoring the individual's risk for relapse; and
- 7 • provision of support for peer staff to process their experiences providing peer support.

8 Considerations for program policies regarding safe staffing levels include strategies for addressing
9 staff shortages and procedures in the event that the program is unable to fill critical positions. This
10 may include designating interim appointments, hiring temporary staff, and/or transitioning patients
11 to other programs if the program cannot provide safe and effective care. Program policies and
12 procedures should ensure that staff know how to:

- 13 • have clear criteria and training regarding when to consult and how to contact a supervisor,
14 including clear identification of the chain of command when urgent and emergent
15 situations arise;
- 16 • respond to urgent questions that arise after-hours;
- 17 • file and handle formal grievance procedures;
- 18 • respond to requests from patients or families to change treating clinicians; and
- 19 • manage violent and threatening behaviors, including when to consider and use restraint and
20 provision of related training.

21 Medically managed (ie, Levels 1.7Y, 2.7Y, 3.7Y, and 4Y) and residential (ie, Level 3.5Y) programs
22 should have policies and procedures on medication reconciliation that address:

- 23 • responsibility for conducting a complete medication reconciliation;
- 24 • oversight of controlled substance prescriptions;
- 25 • verification against the prescription drug management program (PDMP) for each patient
26 upon admission and at appropriate intervals;
- 27 • use of cannabis and cannabinoids for medical purposes;
- 28 • requirements for patients to authorize release of information to coordinate care with
29 external prescribers; and
- 30 • coordination of care with external prescribers upon admission, as needed throughout
31 treatment, and upon transition from the program.

32 Outpatient programs (ie, Levels 1.0Y, 1.5Y, 1.7Y, 2.1Y, 2.5Y, and 2.7Y) should have policies and
33 procedures on:

- 34 • managing access to controlled prescriptions while patients are on-site;
- 35 • educating patients and families on safe storage of medications;
- 36 • collaborating with the family on strategies for securing medications and monitoring
37 medication adherence.

1 All addiction treatment programs should maintain policies and procedures concerning the
2 treatment of TUD, including:

- 3 • screening patients for nicotine/tobacco use;
- 4 • providing barrier-free access to EBIs for TUD, including medications and behavioral therapy;
- 5 • supporting integrated treatment for TUD;
- 6 • restricting staff, patient, family and visitor use of nicotine/tobacco products and
7 nonmedical nicotine products (eg, combustible cigarettes, smokeless tobacco, e-
8 cigarettes) while on-site, including program and facility smoke-free policies; and
- 9 • providing organizational support for staff to access treatment for TUD.

10 Programs across all levels of care should have policies and procedures that clearly outline
11 program response to public health alerts and emergency preparedness, including:

- 12 • planning for emergency evacuation, including considerations for:
 - 13 ○ relocating patients in residential and inpatient programs,
 - 14 ○ transitioning patients during both pre- and post-disaster evacuation. and
 - 15 ○ communicating with family members during an emergency;
- 16 • ensuring continued access to critical medications;
- 17 • identifying staff leads and emergency points of contact;
- 18 • communicating and coordinating in an emergency; and
- 19 • utilizing backup communication strategies (eg, cell, radio, internet) if telephone and/or
20 electrical power become inoperable.

21 In addition, programs should have established procedures for training staff and educating patients
22 and families on the program’s response in the event of a public health alert or emergency. Program
23 policies should also include standards on reporting patient safety events, as well as how the
24 program will access local, state, and/or federal services and support before, during, and after a
25 disaster.

26 _____

27 * Please see Chapter X: Dimensional Admission Criteria and Algorithm.

28 Residential Programs

29 Residential programs should have policies and procedures that address:

- 30 • activities to be performed during the night shift (eg, hourly monitoring and documentation
31 of patient whereabouts, coordinating response to urgent patient issues);
- 32 • the safety of patients and staff, including searches of patients and their belongings that are
33 conducted in a trauma-sensitive manner and preserve privacy and dignity;
- 34 • the handling of items brought into the program (eg, addictive substances, nicotine/tobacco
35 products, prescription medications, OTC products, weapons, paraphernalia related to
36 addiction, pornography); and
- 37 • medication reconciliation, including when to assume management of all controlled
38 substance prescriptions.

1 Residential programs that house multiple levels of care should consider delineating which beds
2 may be filled by patients at Level 3.7Y to ensure that staffing is sufficient to meet the needs of
3 patients placed at this level of care. If beds are used flexibly, the program must be able to expand
4 staffing to meet the needs of all patients admitted to Level 3.7Y. Competency-based training
5 should be provided for all staff directly involved in patient care as appropriate to their disciplines
6 and scopes of practice.

7 Residential programs should have policies and procedures that address screening, control, and
8 mitigation of infectious disease (eg, HIV, HCV, tuberculosis [TB], COVID-19), including
9 identification of an infection control officer and the responsibilities of this role.

10

11 **Dimension 1 and 2 Considerations**

12 Policies and procedures related to Dimensions 1 and 2 concerns should be reviewed and approved
13 by the medical director or, for programs without a medical director, physicians or advanced
14 practice providers with demonstrated competency in specialty addiction treatment. Program
15 policies and procedures include:

- 16 • admission, transition, and continued service criteria related to intoxication, withdrawal, and
17 biomedical concerns and in alignment with The ASAM Criteria Dimensional Admission
18 Criteria;
- 19 • determination of when medical evaluations are needed for intoxication, withdrawal, and
20 other biomedical concerns;
- 21 • response to medical emergencies, including those that occur on-site;
- 22 • drug testing and toxicology services,[†] including:
 - 23 ○ when to use point-of-care tests,
 - 24 ○ when to use confirmatory tests,
 - 25 ○ when to conduct alcohol testing,
 - 26 ○ which staff have the scopes of practice to order and interpret test results,
 - 27 ○ timely communication of drug test results to patients and families (with appropriate
28 patient assent/consent), and
 - 29 ○ how to address unanticipated drug test results;
- 30 • access to all addiction medications[†];
- 31 • management of patients with chronic biomedical comorbidities (eg, diabetes, asthma,
32 seizures); and
- 33 • management of patients with co-morbid pain, including:
 - 34 ○ recognizing when to refer patients to a pain specialist or a pain psychologist,
 - 35 ○ understanding how to modify the current treatment regimen to accommodate pain
36 as a significant trigger for recurrence, and
 - 37 ○ related staff training.

38 _____

39 † Please see ASAM's Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.

1 ‡ Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
2 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal
3 symptoms.

4 **Dimension 3 Considerations**

5 Policies and procedures related to Dimension 3 concerns should be reviewed and approved by a
6 psychiatrist, psychiatric specialist advanced practice provider, or qualified master's level mental
7 health professional as appropriate for their scope of practice. In all levels of care except Level 1,
8 policies and procedures related to management of risk of harm to self or others should be
9 approved by a psychiatrist. Program policies and procedures include:

- 10 • screening for mental health, developmental, and trauma concerns;
- 11 • admission, transition, and continued service criteria related to psychiatric and cognitive
12 concerns and in alignment with The ASAM Criteria Dimensional Admission Criteria;
- 13 • determination of when mental health assessments are needed for psychiatric, intellectual
14 or developmental concerns, including ascertaining the level of assessment needed (eg, by a
15 master's level clinical staff versus a psychiatrist or psychiatric NP);
- 16 • accommodations for patients affected by changes in mental health or cognitive status that
17 interfere with their treatment participation, including:
 - 18 ○ educating patients and families on how to ask for accommodation when needed,
19 and
 - 20 ○ providing accommodations appropriate to the given level of care in a way that is
21 transparent and fair for all patients
 - 22 ○ facilitating transfer to appropriate level of care when needed accommodations
23 cannot be provided in the current level of care;
- 24 • access to medications for psychiatric disorders, including oversight and monitoring of
25 controlled medications; and
- 26 • management of mental health advanced directives.

27 **Secondary Prevention and Early Intervention Standards**

28 **Staff Competencies**

- 29 • All staff who provide secondary prevention services should have competency in:
 - 30 ○ Applying the principles of secondary and tertiary prevention
 - 31 ○ Assessing a patient's risks associated with substance use and their risk for
32 developing SUD
 - 33 ○ Motivational interviewing
 - 34 ○ How to support the patient to make developmentally appropriate behavioral
35 changes
 - 36 ○ How to communicate effectively with adolescents and their families regarding
37 substance use and prevention of SUD
 - 38 ○ How to effectively engage adolescent patients, including through use of technology
 - 39 ○ State and federal requirements related to adolescent confidentiality and consent
- 40 • All clinical staff should understand:

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 ○ The unique vulnerabilities of the adolescent brain to substance exposure
- 2 ○ The disease model of addiction and how substance use progresses to SUD
- 3 ○ The importance of early intervention to prevent escalation from substance use to
- 4 SUD
- 5 ○ The importance of avoiding normalization of substance use
- 6 ○ The importance of avoiding stigmatizing language

7 Support systems

- 8 ● All programs should establish relationships with the schools that are serving their
- 9 adolescent patients, with appropriate assent/consent
- 10 ● Level 1.5Y programs should have an established relationship with more intensive levels of
- 11 care that serve adolescent patients to facilitate referral when needed.
- 12 ● All programs should maintain a list of community resources to address common ancillary
- 13 needs, for example:
 - 14 ○ Mutual support groups for families (eg, Alanon, NAMI)
 - 15 ○ Recovery schools, when available
 - 16 ○ Supportive housing options
 - 17 ○ Individuals with Disabilities Education Act (IDEA) support services
 - 18 ○ Mentoring programs
- 19 ● All programs should have established relationships with local crisis services

20 Assessment and treatment planning

- 21 ● The Treatment Planning Assessment for patients who are using substances but do not
- 22 currently meet criteria for an SUD should:
 - 23 ○ Assess both risk and protective factors, including:
 - 24 ■ Home environment
 - 25 ■ Parental or primary caregiver support and attachment
 - 26 ■ Relationships with other recovery supportive trusted adults
 - 27 ■ Parental health, including substance use and mental health conditions
 - 28 ■ Adverse childhood experiences
 - 29 ■ Developmental concerns, including unmet milestones
 - 30 ■ Behavioral concerns including impulsivity, aggression, criminal justice
 - 31 involvement, risky behaviors, behavioral addictions
 - 32 ■ Academic or occupational successes, challenges, supports and aspirations
 - 33 ■ Community connections
 - 34 ■ Peer affiliations
 - 35 ■ Emotional regulation/coping skills
 - 36 ■ Family and community norms and perceptions related to substance use,
 - 37 addiction, and mental health
 - 38 ○ Assess all dimensions and subdimensions of The ASAM Criteria
 - 39 ○ Assess the patient's strengths (developmentally appropriate social skills,
 - 40 communication skills, resilience, empathy, goals and aspirations)
 - 41 ○ Motivation for behavior change

- 1 • Treatment plans for patients who are using substances but do not currently meet criteria for
2 an SUD should be:
 - 3 ○ Tailored to the patient’s needs and strengths.
 - 4 ○ Focused on preventing escalation to SUD through strengthening the patient’s
5 protective factors and mitigating their risk factors.
- 6 • Patients who do not currently meet the criteria for SUD but are receiving specialty care (as
7 recommended per the Dimensional Admission Criteria) should be reassessed at least
8 monthly for SUD.

9 Services

- 10 • Level 1.5Y and 2.1Y programs should provide secondary prevention services for patients
11 who do not currently meet the criteria for SUD but are recommended specialty care per the
12 Dimensional Admission Criteria.
- 13 • All levels of care should provide family therapy services directly or through formally
14 affiliated providers
- 15 • Level 2.1Y programs should provide family focused recovery support services (eg,
16 parent/family peer support) to support prevention of the escalation of risky substance use
17 to SUD
- 18 • Level 1.5Y programs are encouraged to provide family focused recovery support services
19

20 Documentation

- 21 • Level 1.5Y and 2.1Y programs should have policies and procedures that address:
 - 22 ○ Admission criteria for patients who are using substances but do not currently meet
23 criteria for SUD, in alignment with the Dimensional Admission Criteria
 - 24 ○ Provision of secondary prevention services
 - 25 ○ Monitoring patients who do not currently meet criteria for SUD for escalation to SUD

26 Co-occurring Enhanced (COE) Standards

27 Universal expectations

- 28 • Direct psychiatric management of patients
 - 29 ○ A psychiatrist or psychiatric advanced practice provider is the medical director or
30 co-director
 - 31 ○ Nurse availability for medications (except at Level 1)
- 32 • Increased staff to patient ratio to manage instability and disability

33 Setting

- 34 • All COE programs should provide a welcoming and supportive environment for individuals
35 with serious mental health conditions, including those who may experience significant
36 active or unstable symptoms and/or significant functional impairment and/or disability.
- 37 • Level 1 COE programs should seek to provide a calm therapeutic environment.
- 38 • Level 2 and above COE programs should provide a quiet space for de-escalation.

- 1 • Level 2 and above COE programs should provide a sensory supportive therapeutic space.

2 Staff

- 3 • All clinical and allied health staff in COE programs should have competency to care for
4 individuals who have active co-occurring psychiatric symptoms and/or related functional
5 deficits.
- 6 • COE programs should generally have a higher staff-to-patient ratio than standard (ie,
7 cooccurring capable) programs to provide additional flexibility and support.
- 8 • Medically managed COE programs should have a psychiatrist or psychiatric NP available
9 on-site or on-call during program hours of operation (ie, 24/7 in residential and inpatient
10 programs).

11 Support Systems

- 12 • The universal standards include established relationships with clinicians with the scopes of
13 practice to provide IDD assessment and management, eating disorder assessment and
14 management
- 15 • The universal standards include established relationships with school systems, therapeutic
16 school and recovery schools, as available.

17 Assessment and Treatment Planning

- 18 • All COE programs should admit individuals with any type of co-occurring mental health
19 disorder, diagnosis, or symptoms provided they meet program admission criteria based on
20 their level of acuity or disability per The ASAM Criteria Dimensional Admission Criteria.
- 21 • An integrated Treatment Planning Assessment should be conducted that addresses:
- 22 ○ response to prior treatment,
 - 23 ○ baseline acuity of psychiatric conditions and related disabilities based on history
24 and current presentation,
 - 25 ○ intellectual and developmental concerns,
 - 26 ○ symptom management and disability support needs,
 - 27 ○ family services involvement and needs,
 - 28 ○ other youth-service systems of care considerations (eg, juvenile justice, child
29 protective service mandates, etc.),
 - 30 ○ educational needs,
 - 31 ○ medical management of psychiatric conditions,
 - 32 ○ adherence to mental health treatment, including medications, and
 - 33 ○ psychosocial treatment services for psychiatric conditions and IDD.

34 Clinical Services

- 35 • All COE programs should provide skilled mental health treatment interventions to address
36 co- occurring mental health conditions and have the flexibility to provide individual support
37 to patients who require:
- 38 ○ de-escalation or reduction of stimulation (eg, due to panic attacks or feeling
39 overwhelmed) during program hours of operation, and

- 1 ○ additional assistance due to IDD or other functional impairment.
- 2 • COE programs should also have educational materials available that address common
- 3 serious mental health concerns that are youth specific/developmentally appropriate.
- 4 • COE programs should provide psychoeducation to help patients report symptoms and
- 5 disabilities.
- 6 • Compared to standard (ie, co- occurring capable) programs, COE programs should provide
- 7 more guidance for managing significant acute symptoms (eg, panic attacks, psychosis),
- 8 IDD, cognitive impairment, and functional disabilities. Educational content should:
- 9 ○ provide guidance on the identification and management of severe mental health
- 10 symptoms (eg, psychosis, developmental trauma);
- 11 ○ be accessible for individuals with severe cognitive impairment due to IDD or
- 12 psychiatric disabilities; and
- 13 ○ address how to discuss severe mental health disorders, symptoms, and treatments
- 14 appropriately in the context of mutual support and other RSS.
- 15 • In COE programs, any group programming offered should:
- 16 ○ be flexibly designed to accommodate those who have symptoms, functional
- 17 impairment, and/or disabilities that preclude full attendance and participation,
- 18 ○ be able to accommodate smaller group sizes compared to groups in standard (ie,
- 19 co- occurring capable) programs, and
- 20 ○ deliver content in a format appropriate for individuals who experience challenges
- 21 due to IDD or psychiatric disabilities.
- 22 ○

23 Level 1.0Y Standards

24 Level 1.0Y Description

25 Level 1.0Y programs provide remission monitoring and early reintervention services for patients
26 who are in sustained remission.

27 Level 1.0Y Setting

28 Level 1.0Y services may be offered in any appropriate outpatient or telemedicine- based treatment
29 setting that meets state licensure or certification criteria.

30 Level 1.0Y Staff

31 Level 1.0Y programs are staffed by appropriately trained addiction and mental health treatment
32 professionals acting within their state-regulated scopes of practice.*

33 Level 1.0Y programs may also be staffed by allied health staff, such as certified peer support
34 specialists, patient and family navigators**, health educators, certified recovery coaches, and
35 counselor aides who support ongoing engagement in addiction treatment, deliver recovery support
36 services (RSS), and provide warm handoffs to more intensive levels of care when needed.

37 —

1 * Please see **Appendix D** for additional information on recommended staff competencies.

2 ** A patient and family navigator is a person who helps the patient and/or their family navigate healthcare and social
3 service systems. They help patients and families identify and access appropriate resources in the community and
4 communicate effectively with service providers.

5 *Medical Staff*

6 Level 1.0Y programs might not provide medical services and, therefore, might not have a medical
7 director, physicians and advanced practice providers, addiction specialist physicians, nor nursing
8 and medical support staff.

9 *Clinical Staff*

10 If the Level 1.0Y program is clinically managed, it should have a program director (or responsible
11 clinician in an independent practice) who, at minimum, has a master's degree in a field related to
12 clinical behavioral health.

13 **Level 1.0Y Support Systems**

14 If Level 1.0Y programs do not provide psychotherapeutic services (eg, counseling, therapy) directly,
15 they should be made available through coordinated referral.

16 Level 1.0Y programs should have, at minimum, established relationships with psychiatric and
17 addiction specialists.

18 **Level 1.0Y Assessment and Treatment Planning**

19 *Assessment*

20 *Level of Care Assessment*

21 The initial assessment should include an up-to-date addiction and mental health focused history (if
22 the program does not already have this information documented).

23 *Treatment Planning Assessment*

24 The Treatment Planning Assessment in Level 1.0Y programs involves:

- 25 • a recovery management checkup (RMC), which should include sufficient recovery- and
26 remission- focused biopsychosocial screening and assessments to identify:
 - 27 ○ any current or emerging SUD-related treatment needs;
 - 28 ○ any biomedical health needs that may impact the patient's recovery;
 - 29 ○ any mental health needs that may impact the patient's recovery, using validated
30 tools when available (eg, Patient Health Questionnaire- 9 [PHQ- 9], Generalized
31 Anxiety Disorder- 7 [GAD- 7], Columbia- Suicide Severity Rating Scale [C- SSRS]);
32 and
 - 33 ○ any RSS needs; and
- 34 • verification that the patient has had a physical examination conducted by a physician or
35 advanced practice provider within the past year, with the program either:
 - 36 ○ referring the patient for a physical examination if they have not had one in the past
37 year, or

- 1 ○ identifying any care coordination needs based on the most recent physical exam.

2 **Psychiatric Assessment**

3 Level 1.0Y programs should be able to provide referral for a psychiatric assessment as needed.

4 *Treatment Planning*

5 In Level 1.0Y programs, treatment plans should be individualized recovery management plans
6 developed at initiation of treatment that include:

- 7 • identification of any concerns that may impact the patient’s recovery,
8 • problem identification in each applicable dimension,
9 • defined recovery goals and measurable recovery objectives, and
10 • activities designed to meet those objectives (eg, adherence to addiction or psychiatric
11 medications, participation in mutual support, mental health counseling).

12 The recovery management plan should be developed in collaboration with the patient and family,
13 reflect the patient and family’s goals, and incorporate the patient and family’s strengths.*

14 The recovery management plan should include a plan for the patient and family to contact the
15 program between appointments if new concerns emerge that may compromise the patient’s
16 recovery.

17 *Reassessment*

18 Level 1.0Y programs should conduct RMCs, including recovery capital assessments, at least
19 quarterly. Check-ins should occur more frequently in response to life events that could lead to
20 instability (eg, end of a relationship, loss of a loved one).

21 Formal reassessment of the recovery management plan should occur at least yearly, with
22 remission and recovery management plan updates incorporated as needed.

23 **Level 1.0Y Services**

24 *Medical Services*

25 Level 1.0Y programs that do not directly provide medical services should have established
26 relationships with physicians and/or advanced practice providers to coordinate access to:

- 27 • medication management services,
28 • medication adherence monitoring,
29 • infectious disease screening and referral for care as needed, and
30 • drug testing and toxicology services.*

31 —

32 * Please see ASAM’s Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.

33 *Clinical Services*

34 Level 1.0Y programs should provide:

- 1 • RMCs, including recovery capital assessments, either in-person or via telemedicine;
- 2 • mental health screening; and
- 3 • patient and family healthcare navigation services, including the ability to:
 - 4 ○ rapidly reengage the patient in the appropriate level of addiction or mental health
 - 5 treatment as needed, including providing warm handoffs; and
 - 6 ○ rapidly refer the patient for assessment for addiction or psychiatric medications* if
 - 7 not directly provided by the program.

8 Level 1.0Y programs should provide regular follow- ups until the patient is engaged in treatment.
9 The frequency of follow- ups should be determined by the acuity of individual patient needs.

10 —

11 * Including all FDA- approved medications for opioid use disorder (OUD; including methadone, unless unavailable
12 locally), alcohol use disorder (AUD), and tobacco use disorder (TUD); off- label medications for other SUDs, including
13 stimulant use disorder (StUD) and cannabis use disorder (CUD); and medications to manage post- acute withdrawal
14 symptoms.

15 *Psychosocial Services*

16 Level 1.0Y programs should provide psychosocial services either directly or through formally
17 affiliated providers and programs to address emerging concerns that may undermine the patient's
18 recovery.

19 Level 1.0Y programs should provide patient and family education, including education on when to
20 seek a reassessment prior to the next scheduled RMC.

21 Level 1.0Y programs that do not directly provide psychosocial services should have formal
22 affiliations with external providers to coordinate access to:

- 23 • psychosocial services, including motivational interviewing and solution-focused therapy
- 24 (SFT) to support reengagement in treatment as needed;
- 25 • health education for medical concerns associated with the course of SUD and other
- 26 potential health- related risk factors as appropriate (eg, HIV, hepatitis C virus [HCV], STIs,
- 27 unintended pregnancies, risk of exacerbating other conditions); and

28 *Recovery Support Services*

29 Level 1.0Y programs should provide the following RSS either directly or through formal affiliations
30 with external service providers (eg, recovery community organizations [RCOs]):

- 31 • assessment of RSS needs, and
- 32 • development of individualized recovery and remission management plans.

33 *Level 1.0Y Documentation*

34 Core documentation in Level 1.0Y includes:

- 35 • results from RMCs, and
- 36 • individualized remission management plans.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Level 1.5Y Standards

Level 1.5Y Description

Level 1.5Y programs provide outpatient psychosocial services for patients with SUD. These programs provide less than 6 hours (typically 1-2 hours) of structured clinical services per week consisting primarily of psychotherapy, counseling, and psychoeducation to address addiction and co-occurring mental health conditions.

Level 1.5Y Setting

Level 1.5Y services may be offered in any appropriate outpatient setting where psychosocial services are provided that meets state licensure or certification criteria, such as:

- office-based practices,
- health clinics,
- outpatient addiction programs, and
- behavioral health clinics.

Level 1.5Y services may also be provided in home and community settings including schools, community-based organizations, social service settings, group homes or shelters, and via telemedicine.

Level 1.5Y Staff

Level 1.5Y programs are staffed by appropriately trained addiction treatment professionals acting within their state-regulated scopes of practice, including:

- A program director (who may be the responsible clinician in an independent practice), and
- Clinical staff, such as psychologists, clinical social workers, SUD and mental health counselors, and others trained to assess and treat SUD and/or co-occurring mental health conditions with the necessary scopes of practice to support the delivery of services provided in Level 1.5Y.*

Level 1.5Y programs may be supported by allied health staff, such as certified peer support specialists, patient and family navigators**, health educators, and certified recovery coaches, counselor aides who support ongoing engagement in addiction treatment, deliver RSS, and provide warm handoffs to other levels of care.

—

* Please see Appendix D for additional information on recommended staff competencies.

** A patient and family navigator is a person who helps the patient and/or their family navigate healthcare and social service systems. They help patients and families identify and access appropriate resources in the community and communicate effectively with service providers.

1 *Medical Staff*

2 Level 1.5Y programs do not typically provide medical services and, therefore, do not typically have
3 a medical director, physicians and advanced practice providers, nursing or medical support staff.
4 However, programs are encouraged to have, at minimum, formal affiliations with physicians or
5 advanced practice providers to support access to physical examinations, medical assessments,
6 and addiction and psychiatric medications.

7 Program policies and procedures should define when and how to consult with and refer to
8 psychiatric and addiction specialist physicians as needed.

9 *Clinical Staff*

10 Level 1.5Y programs should have a program director (who may be the responsible clinician in an
11 independent practice) who has, at minimum, a master's degree in a field related to clinical
12 behavioral health and at least one year of experience working with adolescents.

13 **Level 1.5Y Support Systems**

14 Level 1.5Y programs should ideally have formal affiliations, but at minimum established
15 relationships, with addiction medication providers (eg, methadone treatment providers, physicians
16 and advanced practice providers with controlled substance prescribing authority[†]) to support
17 access to addiction medications.[‡]

18 Level 1.5Y programs should have established relationships with mental health treatment providers
19 and programs to support access to routine psychiatric consultation, and facilitate access to more
20 intensive mental health treatment as needed.

21 —

22 ‡ Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
23 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal
24 symptoms.

25 † Including authorization to prescribe buprenorphine.

26 **Level 1.5Y Assessment and Treatment Planning**

27 *Assessment*

28 **Physical Examination**

29 In Level 1.5Y programs, the patient should be referred to a physician or advanced practice provider
30 for a physical examination, which should ideally be conducted within one month of admission – or
31 sooner based on the patient's medical presentation – if they have not had a recent physical
32 examination.*

33 The physical examination should include assessment for addiction and psychiatric medication
34 needs.

35 —

1 *Per program protocol – which should be regularly reviewed and approved by a qualified physician or advanced practice
2 provider – and in coordination with the patient’s personal physician whenever possible

3 *Treatment Planning*

4 In Level 1.5Y programs, a comprehensive individualized treatment plan should be developed within
5 3 visits.

6 The patient- and family-facing treatment plan should include a plan for accessing emergency care
7 24/7, including when to call 911 or 988.

8 *Reassessment*

9 Formal reassessment and treatment plan updates [with signatures from key clinical staff] should
10 occur at least quarterly and include determination of whether the patient is progressing
11 appropriately and if treatment at a different level of care may be needed.

12 **Level 1.5Y Services**

13 *Clinical Services*

14 Level 1.5Y programs provide less than 6 hours of structured clinical services per week.

15 Services should be provided in an amount, frequency, and intensity appropriate to individual
16 patient and family needs and level of function as determined by The ASAM Criteria
17 multidimensional assessment.

18 Level 1.5Y services may be provided via telehealth when appropriate for the patient as determined
19 by the treating clinician.

20 *Psychiatric Services*

21 Level 1.5Y programs should have an established relationship at minimum with a psychiatrist or
22 advanced practice provider with specialty certification in psychiatry (eg, psychiatric NP).

23 Level 1.5Y programs should be able to refer for a psychiatric assessment as needed. The physical
24 exam should assess need for a psychiatric assessment.

25 *Care Coordination*

26 Level 1.5Y programs should coordinate care with prescribers of addiction and psychiatric
27 medications, and support rapid referrals for addiction or psychiatric medications as needed.

28 **Level 2.1Y Standards**

29 **Level 2.1Y Description**

30 Level 2.1Y programs provide intensive outpatient services for patients with SUDs and their families.
31 These programs provide 6 to 19 hours of structured clinical services per week consisting primarily
32 of counseling, psychoeducation, and psychotherapy to address addiction and co-occurring mental
33 health conditions. Level 2.1Y programs also provide a clinically planned and managed therapeutic

1 milieu facilitated by trained clinical staff that imparts peer support, builds pro-recovery attitudes,
2 and improves coping strategies and behaviors.

3 **Level 2.1Y Setting**

4 Level 2.1Y services may be offered in any appropriate outpatient setting where psychosocial
5 services are provided that meets state licensure or certification criteria, such as:

- 6 • outpatient treatment programs
- 7 • behavioral health clinics

8 Level 2.1Y services may also be provided in home (eg, intensive in-home services) and community
9 settings including schools, community-based organizations, social service settings, informal
10 supports, and via telemedicine.

11 **Level 2.1Y Staff**

12 Level 2.1Y programs are staffed by an interdisciplinary team of appropriately trained and
13 supervised addiction treatment professionals acting within their state-regulated scopes of
14 practice*, including:

- 15 • A medical director
- 16 • A program director
- 17 • Clinical staff, such as psychologists, clinical social workers, SUD and mental health
18 counselors, and others trained to assess and treat SUD and/or co-occurring mental health
19 conditions with the necessary scopes of practice to support the delivery of services
20 provided in Level 2.1Y.
- 21 • Allied health staff, such as certified peer support specialists, patient and family
22 navigators**, health educators, certified recovery coaches, and counselor aides who
23 support ongoing engagement in addiction treatment, deliver recovery support services
24 (RSS), and provide warm handoffs to other levels of care.†

25 _____

26 * Please see Appendix D for additional information on recommended staff competencies.

27 ** A patient and family navigator is a person who helps the patient and/or their family navigate healthcare and social
28 service systems. They help patients and families identify and access appropriate resources in the community and
29 communicate effectively with service providers.

30 † In low resources areas these services may be provided by clinical staff or through established relationships with
31 external organizations.

32 *Medical Staff*

33 **Physicians and Advanced Practice Providers**

34 Level 2.1Y programs should have at minimum a formal affiliation with a physician or advanced
35 practice provider who has competency in adolescent psychiatry and/or addiction medicine with at
36 least 2 years of documented experience treating adolescents.

1 A physician or advanced practice provider with the experience noted above should regularly review
2 the program’s policies, procedures, and protocols for making admission decisions.

3 A qualified physician or advanced practice provider should be available to review admission
4 decisions as needed (eg, when a patient presents with concerns in Dimensions 1, 2, or 3 that may
5 require medical evaluation or management).

6 *Specialty Physicians*

7 In Level 2.1Y programs, the medical director does not need to be a psychiatrist or addiction
8 specialist physician. However, programs should have formal affiliations with psychiatric and
9 addiction specialist(s) with adolescent treatment experience and the program’s policies and
10 procedures should define when and how to consult with and refer to them when needed.

11 *Nursing, and Medical Support Staff*

12 Level 2.1Y programs should have established relationships with registered nurses, other
13 appropriately licensed and credentialed nurses (eg, LPNs), or other medical support staff with the
14 scope of practice to collect vitals, administer medications (including injectable medications), and
15 provide medical monitoring as needed.

16 *Clinical Staff*

17 Level 2.1Y programs should have appropriately trained clinical staff available during program hours
18 of operation and on-call 24/7.

19 Level 2.1Y programs should have a program director who has, at minimum, a master’s degree in a
20 field related to clinical behavioral health, and at least 5 years of documented experience in
21 addiction and/or mental health treatment with at least 2 years of experience treating adolescents.*

22 ____

23 * If a program is unable to identify a program director who meets these qualifications after reasonable efforts, a clinician
24 with at least five years of documented clinical and supervisory experience in addiction treatment who meets the
25 competencies described in Appendix D may serve as the program director. In these instances, this program director
26 should have an established mentor and a written plan to obtain a terminal degree within five years.

27 *Allied Health Staff*

28 In Level 2.1Y programs, allied health staff, either directly or through formal affiliation, should be
29 available to provide RSS during program hours.†

30 ---

31 † In low resources areas RSS may be provided by clinical staff or through established relationships with external
32 organizations.

33

1 Level 2.1Y Support Systems

2 Level 2.1Y programs a should also have formal affiliations with addiction medication providers (eg,
3 methadone treatment providers, physicians and advanced practice providers with controlled
4 substance prescribing authority[†]) to support access to addiction medications.[‡]

5 ---

6 ‡ Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
7 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal
8 symptoms.

9 † Including authorization to prescribe buprenorphine.

10

11 Level 2.1Y Assessment and Treatment Planning

12 *Assessment*

13 *Psychiatric Assessment*

14 In Level 2.1Y programs, a psychiatric assessment should occur within 14 calendar days.

15 The psychiatric assessment should:

- 16 • Assess the patient’s need for addiction and psychiatric medications.[†]
- 17 • Determine the patient’s need for a physical examination based on the timing of their most
18 recent wellness exam and medical presentation.*

19 _____

20 † Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
21 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal
22 symptoms.

23 * Per program protocol – which should be regularly reviewed and approved by a qualified physician or advanced practice
24 provider – and in coordination with the patient’s primary care provider whenever possible

25

26 *Physical Examination*

27 In Level 2.1Y programs, when needed, a physical examination should be conducted or reviewed by
28 a physician or advanced practice provider within a reasonable timeframe.

- 29 • The timeframe for completing the physical exam, if needed, should be determined by a
30 physician or advanced practice provider based on findings during:
 - 31 ○ The Level of Care Assessment*, and/or
 - 32 ○ The psychiatric assessment

33 _____

34 * During the Level of Care Assessment, the Dimensional Admission Criteria may flag the need for a “prompt evaluation”
35 or “prompt medical management”. A patient who needs “prompt medical management” should have a medical
36 evaluation as soon as possible, within 24 hours at most. A patient who needs a “prompt evaluation” should have a
37 medical evaluation within 72 hours.

1 *Treatment Planning*

2 In Level 2.1Y programs:

- 3 • an initial individualized treatment plan should be developed at the time of admission.
4 • a comprehensive individualized treatment plan should be developed within 5 business
5 days of admission.

6 The patient- and family-facing treatment plan should include a plan for accessing emergency care
7 24/7, including when to call 911 or 988.

8 *Reassessment*

9 The interdisciplinary treatment team in Level 2.1Y programs should meet at least weekly to discuss
10 patient progress and adjust the treatment plan as needed. All treatment team members do not
11 need to be present at each meeting; the patient’s primary clinician is responsible for obtaining
12 relevant information from others who provide treatment services to the patient. A weekly progress
13 note should be added to the clinical record that outlines progress, concerns, and any planned
14 changes to clinical care.

15 Formal reassessment and treatment plan updates [with signatures from key clinical staff] should
16 occur at least monthly and include determination of whether the patient is progressing
17 appropriately and if treatment at a different level of care may be needed.

18 **Level 2.1Y Services**

19 *Medical Services*

20 A nursing assessment should be conducted as needed that includes:

- 21 • Vitals, including pulse oximetry;
22 • History of present illness;
23 • Assessment of withdrawal signs and symptoms;
24 • Medical history, including assessment of current biomedical, psychiatric, and cognitive
25 concerns and medication review;
26 • psychiatric needs assessment; and
27 • Weight and BMI.

28 *Psychiatric Services*

29 Level 2.1Y programs provide psychiatric services, directly or through formal affiliation.

30 *Clinical Services*

31 Level 2.1Y programs provide 6 to 19 hours per week of structured clinical services.

32 Structured services selected by master’s level clinical staff should be provided at least two days
33 per week.

1 Services should be provided in an amount, frequency, and intensity appropriate to the individual
2 patient and family's needs and level of function as determined by The ASAM Criteria
3 multidimensional assessment.

4 Clinical services provided by formally affiliated external addiction treatment providers and
5 programs (eg, OTPs) may count toward the total hours of weekly clinical services if care and billing
6 are coordinated and documented.

7 Level 2.1Y services may be provided via telehealth when appropriate for the patient as determined
8 by the treating clinician.

9 *Recovery Support Services*

10 Level 2.1Y programs should directly provide a therapeutic milieu that includes consistency in
11 support and structure

12 **Level 2.5Y Standards**

13 **Level 2.5Y Description**

14 Level 2.5Y programs (previously referred to as partial hospitalization programs [PHPs] in the Third
15 Edition) provide high-intensity outpatient services for patients with SUDs and their families. These
16 programs provide at least 20 hours of structured clinical services per week consisting primarily of
17 psychotherapy, counseling, and psychoeducation to address addiction and co-occurring mental
18 health conditions. Level 2.5Y programs also provide a clinically planned and managed therapeutic
19 milieu facilitated by trained clinical staff that imparts peer support, builds pro-recovery attitudes,
20 and improves coping strategies and behaviors.

21 **Level 2.5Y Setting**

22 Level 2.5Y services may be offered in any appropriate outpatient setting where psychosocial
23 services are provided that meets state licensure or certification criteria, such as:

- 24 • outpatient day treatment programs,
- 25 • behavioral health clinics, and
- 26 • PHPs.

27 Level 2.5Y services may also be provided in home (eg, intensive in-home services) and community
28 settings including schools, community-based organizations, social service settings, informal
29 supports, and, via telemedicine.

30 **Level 2.5Y Staff**

31 Level 2.5Y programs are staffed by an interdisciplinary team of appropriately trained and
32 supervised addiction treatment professionals acting within their state-regulated scopes of
33 practice*, including:

- 34 • A medical director,

- 1 • A program director,
- 2 • Clinical staff, such as psychologists, clinical social workers, SUD and mental health
- 3 counselors, and others trained to assess and treat SUD and/or co-occurring mental health
- 4 conditions with the necessary scopes of practice to support the delivery of services
- 5 provided in Level 2.5Y, and
- 6 • Allied health staff, such as certified peer support specialists, patient and family
- 7 navigators**, health educators, certified recovery coaches, and counselor aides who
- 8 support ongoing engagement in addiction treatment, deliver RSS for patients and families,
- 9 and provide warm handoffs to other levels of care. †

10 _____

11 * Please see Appendix D for additional information on recommended staff competencies.

12 ** A patient and family navigator is a person who helps the patient and/or their family navigate healthcare and social
13 service systems. They help patients and families identify and access appropriate resources in the community and
14 communicate effectively with service providers.

15 † In low resources areas these services may be provided by clinical staff or through established relationships with
16 external organizations.

17 *Medical Staff*

18 *Medical Director*

19 Level 2.5Y programs should have a medical director who has competency in adolescent psychiatry
20 and/or addiction medicine.

- 21 • Competency in both adolescent psychiatry and addiction medicine should be represented
- 22 on the program's medical team, which may include both staff and formally affiliated
- 23 providers.
- 24 • The medical director should be board certified or board eligible in adolescent psychiatry,
- 25 addiction psychiatry, or addiction medicine with at least 2 years of documented experience
- 26 working with adolescents.

27 The medical director in Level 2.5Y programs should regularly review and approve the program's
28 policies, procedures, and protocols for making admission decisions.

29 The medical director, or another qualified physician or advanced practice provider, should be
30 available to review admission decisions as needed (eg, when a patient presents with concerns in
31 Dimensions 1, 2, or 3 that may require medical evaluation or management).

32 *Specialty Physicians*

33 In Level 2.5Y, program leadership should include both psychiatric and addiction specialty
34 expertise.

- 35 • Psychiatric specialty expertise includes psychiatrists and advanced practice providers with
- 36 specialty psychiatric certification (eg, psychiatric NP).
- 37 • Addiction specialty expertise includes physicians who are board certified or board eligible
- 38 in addiction medicine or addiction psychiatry.

1 In Level 2.5Y programs, a psychiatrist or advanced practice provider with specialty certification in
2 psychiatry (eg, psychiatric nurse practitioner [NP]) should be available on-site or via telemedicine
3 daily during program days of operation to assess patients and make medication adjustments as
4 needed.

5 **Physicians and Advanced Practice Providers**

6 In Level 2.5Y programs, physicians and advanced practice providers with controlled substance
7 prescribing authority† should be active members of the care team.

8 A physician or advanced practice provider should be available in-person or via telemedicine during
9 program hours of operation to initiate or adjust medications as needed.

- 10 • Medications may be provided by medical support staff based on a patient-specific verbal
11 order from the physician or advanced practice provider.*
12 • In Level 2.5Y programs, a physician or advanced practice provider should be on-call 24/7
13 directly or through formal affiliation.

14 ____

15 * Per program protocol, which should be developed, approved, and regularly reviewed by the medical director.

16 † Including authorization to prescribe buprenorphine.

17

18 **Nursing, and Medical Support Staff**

19 Level 2.5Y programs should have formal affiliations with registered nurses (RNs), other
20 appropriately licensed and credentialed nurses (eg, LPNs), or other medical support staff with the
21 scope of practice to collect vitals, administer medications (including injectable medications), and
22 provide medical monitoring as needed.

23 *Clinical Staff*

24 Level 2.5Y programs should have appropriately trained clinical staff available during program hours
25 of operation and on-call 24/7.

26 Level 2.5Y programs should have a program director who has, at minimum, a master's degree in a
27 field related to clinical behavioral health and at least 5 years of documented experience in
28 addiction and/or mental health treatment with at least 2 years of experience treating adolescents.*

29 ____

30 * If a program is unable to identify a program director who meets these qualifications after reasonable efforts, a clinician
31 with at least five years of documented clinical and supervisory experience in addiction treatment who meets the
32 competencies described in Appendix D may serve as the program director. In these instances, this program director
33 should have an established mentor and a written plan to obtain a terminal degree within five years.

34 *Allied Health Staff*

35 Level 2.5Y programs should have allied health staff available during program hours of operation.

36

1 Level 2.5Y Assessment and Treatment Planning

2 *Assessment*

3 *Psychiatric Assessment*

4 In Level 2.5Y programs, a psychiatric assessment should occur within 5 calendar days.

5 Level 2.5Y programs should be able to provide a psychiatric assessment within 24 hours, when
6 needed (as determined during the Level of Care Assessment).

- 7 • The psychiatric assessment should:
 - 8 ○ Assess the patient’s need for addiction and psychiatric medications. †
 - 9 ○ Determine the patient’s need for a physical examination based on the timing of their
10 most recent wellness exam and medical presentation.*

11 _____

12 † Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
13 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal
14 symptoms.

15 *Per program protocol – which should be regularly reviewed and approved by a qualified physician or advanced practice
16 provider – and in coordination with the patient’s primary care provider whenever possible

17

18 *Physical Examination*

19 In Level 2.5Y programs, when needed, a physical examination should be conducted or reviewed by
20 a physician or advanced practice provider within a reasonable timeframe.

- 21 • The timeframe for completing the physical exam, if needed, should be determined by a
22 physician or advanced practice provider based on findings during:
 - 23 ○ The Level of Care Assessment*, and/or
 - 24 ○ The psychiatric assessment

25 _____

26 * During the Level of Care Assessment, the Dimensional Admission Criteria may flag the need for a “prompt evaluation”
27 or “prompt medical management”. A patient who needs “prompt medical management” should have a medical
28 evaluation as soon as possible, within 24 hours at most. A patient who needs a “prompt evaluation” should have a
29 medical evaluation within 72 hours.

30 *Per program protocol – which should be regularly reviewed and approved by a qualified physician or advanced practice
31 provider – and in coordination with the patient’s primary care provider whenever possible

32 † Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
33 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal
34 symptoms.

35 *Treatment Planning*

36 In Level 2.5Y programs, an initial individualized treatment plan should be developed at the time of
37 admission.

1 In Level 2.5Y programs, a comprehensive individualized treatment plan should be developed within
2 5 business days of admission.

3 The patient- and family-facing treatment plan should include a plan for accessing emergency care
4 24/7, including when to call 911 or 988.

5 *Reassessment*

6 The interdisciplinary treatment team in Level 2.5Y programs should meet at least weekly to discuss
7 patient progress and adjust the treatment plan as needed. All treatment team members do not
8 need to be present at each meeting; the patient’s primary clinician is responsible for obtaining
9 relevant information from others who provide treatment services to the patient. A weekly progress
10 note should be added to the clinical record that outlines progress, concerns, and any planned
11 changes to clinical care.

12 Formal reassessment and treatment plan updates [with signatures from key clinical staff] should
13 occur at least monthly and include determination of whether the patient is progressing
14 appropriately and if treatment at a different level of care may be needed.

15 **Level 2.5Y Services**

16 *Medical Services*

17 Level 2.5Y programs should be able to provide nursing assessments as needed, that include:

- 18 • Vitals, including pulse oximetry;
- 19 • History of present illness;
- 20 • Assessment of withdrawal signs and symptoms;
- 21 • Medical history, including assessment of current biomedical, psychiatric, and cognitive
22 concerns and medication review;
- 23 • psychiatric needs assessment; and
- 24 • Weight and BMI.

25 Level 2.5Y programs should be able to initiate and titrate addiction and psychiatric medications
26 and provide medication management, including regular monitoring of the patient’s adherence to
27 prescribed medications.

28 Level 2.5Y programs should be able to provide medical monitoring and management of common
29 low complexity biomedical conditions when needed, including:

- 30 • basic management of hyperglycemia and hypoglycemia;
- 31 • basic wound care;
- 32 • infectious disease management, including:
 - 33 ○ screening and assessment for STIs and bloodborne infections (eg, HIV, hepatitis B
34 virus [HBV], HCV);
 - 35 ○ initiation of treatment and/or coordinated referral to treatment with coordination of
36 care with infectious disease specialists as needed; and

- 1 ○ initiation of treatment and/or coordinated referral for preexposure prophylaxis (PrEP)
- 2 and postexposure prophylaxis (PEP) and provision of patient education regarding
- 3 PrEP and PEP*;
- 4 ● coordination of care for pregnancy and postpartum needs;
- 5 ● coordination of care for biomedical conditions, including pain, for which the patient is
- 6 receiving treatment from an external provider;
- 7 ● direct management or coordination of controlled medications;
- 8 ● supporting pharmacy access.

9 —

10 * Please see the US Public Health Service’s Preexposure Prophylaxis for the Prevention of HIV Infection in the United

11 States— 2021 Update: A Clinical Practice Guideline for guidance.

12 ** Per program protocol, which should be developed, approved, and regularly reviewed by the medical director

13 Biomedical Capabilities

14 Level 2.5Y programs should have access to the following biomedical capabilities on-site:

- 15 ● vitals measurement and monitoring, including pulse oximetry and blood pressure;
- 16 ● glucose monitoring;
- 17 ● basic first aid;
- 18 ● an AED;
- 19 ● ECG with a 3-lead rhythm strip at minimum*;
- 20 ● basic wound care;
- 21 ● injectable epinephrine;
- 22 ● overdose reversal medication (eg, naloxone,);
- 23 ● point- of- care pregnancy testing; and
- 24 ● drug testing and toxicology services.

25 Level 2.5Y program should have established relationships to coordinate access to laboratory and

26 phlebotomy services.

27 Level 2.5Y programs should provide coordinated access to vaccines (eg, hepatitis A and B viruses,

28 influenza, COVID- 19) either on-site or through facilitated access to a community partner. †

29 —

30 * The rationale for ECG capacity is to determine the level of risk and need for Level 4Y care, *not* for diagnosis or disease

31 management. It is also important for monitoring for QTc prolongation in patients on methadone.

32 † Vaccines may be provided through established relationships with external partners.

33 Psychiatric Services

34 Level 2.5Y programs directly provide psychiatric services.

35 Clinical Services

36 Level 2.5Y programs provide at least 20 hours of structured clinical services per week. Structured

37 services selected by master’s level staff should be available 5 days per week.

1 Services should be provided in an amount, frequency, and intensity appropriate to individual
2 patient and family's needs and level of function as determined by *The ASAM Criteria*
3 multidimensional assessment.

4 Clinical services provided by formally affiliated external addiction treatment providers and
5 programs (eg, OTPs) may count toward the total hours of weekly clinical services if care and billing
6 are coordinated and documented.

7 **Clinically Managed Withdrawal Management**

8 Level 2.5Y programs should be able to provide clinical monitoring of intoxication and withdrawal
9 symptoms, including:

- 10 • Supervision, observation, and support during program hours of operations for patients who
11 are intoxicated or experiencing withdrawal but do not require medically monitored or
12 managed care as determined by medical evaluation;
- 13 • Support for adherence to medications for withdrawal management in accordance with a
14 prescription from a physician or advanced practice provider;
- 15 • Clinical monitoring of intoxication and withdrawal, including use of physician-established
16 protocols to monitor for changes in status that may require medical consultation and/or
17 transition to a medically managed level of care; and
- 18 • Psychosocial services designed to support completion of the withdrawal management
19 process.

20 **Recovery Support Services**

21 Level 2.5Y programs should directly provide a therapeutic milieu that includes consistency in
22 support and structure.

23 **Level 3.5Y Standards**

24 **Level 3.5Y Description**

25 Level 3.5Y programs provide clinically managed high-intensity residential services for youth with
26 SUD who require a safe and stable living environment to develop and practice their recovery skills
27 to avoid experiencing immediate recurrence or continuing to use in a manner that poses significant
28 risk for serious harm or destabilizing loss. These programs provide at least 20 hours of structured
29 clinical services per week consisting primarily of psychotherapy, counseling, psychoeducation,
30 and family services to address youth addiction and co-occurring mental health conditions. Level
31 3.5Y programs also provide a high-intensity clinically planned and managed therapeutic milieu that
32 encourages development and internalization of prosocial attitudes and behaviors using community
33 support to reinforce recovery skills.

34 Level 3.5Y aligns with the adolescent mental health treatment system's CALOCUS-CASII Level 5.
35 However, one major difference is that the CALOCUS-CASII Level 5 can be delivered in a therapeutic
36 foster home or another home setting with sufficient intensity of home and community-based
37 support. *The ASAM Criteria* Level 3.5Y will be a residential level of care, however, the Dimensional

1 Admission Criteria may separately recommend intensive or high intensity outpatient care (Level
2 2.1Y or 2.5Y) plus an alternative recovery supportive home (eg, respite, therapeutic foster home).
3 The need for residential care will be differentiated from the need for a recovery supportive home
4 based on Dimension 4 and 5, including risks related to substance use and SUD-related behaviors
5 and level of afterhours support needed.

6 **Level 3.5Y Setting**

7 Services may be offered in any appropriate residential treatment setting with 24-hour staff and
8 integrated clinical services that meets state licensure or certification criteria. The facility should
9 incorporate space for:

- 10 • Individual and family counseling services,
- 11 • Group counseling and psychoeducation services,
- 12 • Other clinical activities,
- 13 • Academic activities,
- 14 • Recreational and group activities (eg, sports, music, art),
- 15 • Patient rest and privacy,
- 16 • Visiting space
- 17 • Meals, and
- 18 • Hygiene.

19 The layout of the facility should enable adequate supervision and management of patients at all
20 times, ensuring that staff can respond to instability in a safe and timely manner. Patients should be
21 able to alert staff to an issue immediately, and staff should be able to respond immediately (ie,
22 within minutes) to assess patients' needs.

23 The living space should be within reasonable proximity of the space for clinical services, allowing
24 staff to maintain adequate supervision of patients to rapidly address emerging clinical issues.

25 If the facility also admits adult patients, it should be designed such that adolescent patients can
26 maintain separation from adult patients and any interactions can be closely monitored.

27 *Living Environment*

28 The facility should maintain a supportive living environment that provides:

- 29 • The needs of daily living;
- 30 • Safety from substances, paraphernalia, and weapons, with any searches of patients,
31 visitors, and their belongings using trauma-sensitive practices (TSP), focused on preserving
32 the dignity and privacy of the individual whose person or belongings are being searched;
33 and
- 34 • Privacy and a secure place to store personal belongings

35 *Patient Supervision*

36 Level 3.5Y should provide 24-hour supervision of patients. Staff should verify and document the
37 whereabouts and wellness of each patient who is on-site at least once every hour. Note that this is

1 separate from clinical monitoring, the frequency of which should be determined based on the
2 individual clinical needs of each patient.

3 At the start of treatment in Level 3.5Y, patients should not leave program premises except under
4 limited circumstances, such as for specialty medical or diagnostic appointments or medical or
5 psychiatric emergencies.

- 6 • Program staff (or staff of external providers or programs delivering services to the patient)
7 should provide continuous supervision of patients when they are off-site to prevent risky
8 behaviors and address any instability or other issues that may arise in a safe and timely
9 manner.
- 10 • Programs should have policies and procedures in place for providing direct supervision
11 when patients are off-site.

12 As the patient progresses clinically in treatment at Level 3.5Y (as determined by a supervisory
13 clinician), they may be given opportunities to visit family and/or to practice skills for community
14 reintegration in preparation for transition to a less intensive level of care.

- 15 • Patients may leave program premises with appropriate staff supervision to participate in
16 appropriate services in the community, such as mutual support meetings or school
17 reintegration services.
 - 18 ○ The degree of staff supervision provided should be determined based on
19 established policies and procedures, and documented in the patient's record.
 - 20 ○ The degree of supervision when patients participate in services in the community
21 may vary from continuous observation then they are off-site to a lesser amount of
22 staff supervision (eg, one staff member supervising a group of patients at an off-site
23 mutual support meeting, school-based supervision for a patient preparing for
24 school reintegration) based on the patients' readiness and progress in treatment as
25 determined by a supervisory clinician.
- 26 • Patients may leave program premises with appropriate parent/guardian supervision for
27 family visits, with supervisory staff approval.
 - 28 ○ Programs should have policies and procedures in place that govern family visits,
29 that addresses:
 - 30 ▪ family assessment and preparation,
 - 31 ▪ the process for approval by supervisory staff,
 - 32 ▪ documentation requirements, and
 - 33 ▪ patient searches and drug testing upon return to the facility.
 - 34 ○ A family assessment should be conducted to determine that the patient can be
35 safely and effectively supervised during the visit, and documented in the patient
36 record.
 - 37 ○ Program clinicians should prepare the family to provide appropriate oversight and
38 safety.

39

1 Level 3.5Y Staff

2 Level 3.5Y programs are staffed by an interdisciplinary team of appropriately trained and
3 supervised addiction treatment professionals acting within their state-regulated scopes of
4 practice, including:

- 5 • A medical director;
- 6 • A program director;
- 7 • Clinical staff, such as psychologists, clinical social workers, SUD and mental health
8 counselors, and other trained to assess and treat SUD and/or co-occurring mental health
9 conditions with the necessary scopes of practice to support the delivery of services
10 provided in Level 3.5Y; and
- 11 • Allied health staff, such as certified peer support specialists, patient and family navigators*,
12 health educators, counselor aides, certified recovery coaches, and group living workers
13 who support ongoing engagement in SUD treatment, deliver RSS, and provide warm
14 handoffs to other levels of care.

15 _____

16 * A patient and family navigator is a person who helps the patient and/or their family navigate healthcare and social
17 service systems. They help patients and families identify and access appropriate resources in the community and
18 communicate effectively with service providers.

19 *Medical Staff*

20 Medical Director

- 21 • Level 3.5Y programs should have a medical director who:
 - 22 ○ is board certified or board eligible in adolescent psychiatry, addiction psychiatry
23 or addiction medicine, and
 - 24 ○ has at least 2 years of documented experience working with adolescents.
- 25 • Competency in both adolescent psychiatry and addiction medicine should be represented
26 on the leadership team, which may include both staff and formally affiliated providers.
- 27 • The medical director in Level 3.5Y programs should develop (in partnership with other
28 program staff), approve, and regularly review the program's policies, procedures, and
29 protocols for making admission decisions.
- 30 • The medical director, or another qualified physician should be available to review
31 admission decisions within 24 hours as needed (eg, when a patient presents with concerns
32 in Dimension 1, 2, or 3 that may require medical evaluation or management).

33 Physicians and Advanced Practice Providers

- 34 • In Level 3.5Y programs, physicians and/or advanced practice providers with controlled
35 substance prescribing authority† should be available daily on-site or via telemedicine as
36 active members of the care team.

37 _____

38 † Including authorization to prescribe buprenorphine.

39

1 Specialty Physicians

- 2 • In Level 3.5Y, program leadership should include both psychiatric and addiction specialty
3 expertise.
 - 4 ○ Psychiatric specialty expertise includes psychiatrists and advanced practice providers
5 with specialty psychiatric certification.
 - 6 ○ Addiction specialty expertise includes physicians who are board certified or board
7 eligible in addiction medicine or addiction psychiatry.
- 8 • A psychiatrist or advanced practice provider with specialty certification in psychiatry (eg,
9 psychiatric nurse practitioner [NP]) should be available on site or via telemedicine 24/7 to
10 assess patients and make medication adjustments as needed.

11 Nursing, and Medical Support Staff

- 12 • Registered nurses (RNs), other appropriately licensed and credentialed nurses (eg, LPNs)
13 with the scope of practice to conduct nursing assessments should be available as needed.
- 14 • Medical support staff with the scope of practice to take vitals, administer medications
15 (including injectable medications), and provide medical monitoring should be available on-
16 site 24/7.
- 17 • A nursing supervisor should be available 24/7 to respond to urgent situations.

18 *Clinical Staff*

19 Level 3.5Y programs should have appropriately trained clinical staff available on-site 24/7.

- 20 • Level 3.5Y programs should have a program director who has, at minimum, a master's
21 degree in a field related to clinical behavioral health and at least 5 years of documented
22 experience in adolescent addiction and/or mental health treatment with at least 2 years of
23 experience treating adolescents.*

24 —

25 * If a program is unable to identify a program director who meets these qualifications after reasonable efforts, a clinician
26 with at least five years of documented clinical and supervisory experience in addiction treatment who meets the
27 competencies described in Appendix D may serve as the program director. In these instances, this program director
28 should have an established mentor and a written plan to obtain a terminal degree within five years.

29 *Allied Health Staff*

30 Level 3.5Y programs should have allied health staff who are on-site and alert 24/7.

31 Level 3.5Y programs should have policies and procedures that define activities to be performed
32 during the night shift (eg, hourly monitoring and documentation of patient whereabouts, response
33 coordination to urgent patient issues).

34 Level 3.5Y Support Systems

- 35 • Level 3.5Y programs should have a physician or advanced practice provider available on-
36 call 24/7 to respond to urgent situations, including determining if this level of care is
37 appropriate for management of patients who are intoxicated or experiencing mild
38 withdrawal.

- 1 • Level 3.5Y programs are encouraged to establish relationships (eg, memorandum of
2 understanding [MOU] or less formal connection) with nearby hospitals, local urgent care
3 providers, and emergency departments to support coordination of biomedical care as
4 needed.
- 5 • Level 3.5Y programs should have established policies and procedures for responding to
6 urgent medical and psychiatric needs 24/7, including:
 - 7 ○ When to engage the on-call physician or advanced practice provider,
 - 8 ○ When to call 911, and
 - 9 ○ When to call 988.

10 Level 3.5Y Assessment and Treatment Planning

11 *Assessment*

12 *Psychiatric Assessment*

- 13 • In Level 3.5Y programs, a psychiatric assessment should occur within 48-72 hours. The
14 assessment should generally occur within 48 hours, but may occur within 72 hours to
15 accommodate for weekends.
 - 16 ○ The psychiatric assessment should:
 - 17 ▪ Assess the patient’s need for addiction and psychiatric medications.
 - 18 ▪ Determine the patient’s need for a physical examination.
- 19 • Level 3.5Y programs should be able to provide a psychiatric assessment within 24 hours,
20 when needed.

21 *Physical Examination*

- 22 • In Level 3.5Y programs, a physical examination should be conducted or reviewed by a
23 physician or advanced practice provider within a reasonable timeframe, as determined
24 during the psychiatric assessment based on the timing of their most recent wellness exam
25 and medical presentation.*

26 —

27 * Per program protocol – which should be regularly reviewed and approved by a qualified physician or advanced practice
28 provider – and in coordination with the patient’s primary care provider whenever possible

29 *Treatment Planning*

- 30 • In Level 3.5Y programs, an initial individualized treatment plan should be developed at the
31 time of admission.
- 32 • A comprehensive individualized treatment plan should be developed within 72 hours of
33 admission.

34 *Reassessment*

- 35 • The interdisciplinary treatment team in Level 3.5Y programs should meet at least weekly to
36 discuss patient progress and adjust the treatment plan as needed. All treatment team
37 members do not need to be present at each meeting; the patient’s primary clinician is
38 responsible for obtaining relevant information from others who provide treatment services

1 to the patient. A weekly progress note should be added to the clinical record that outlines
2 progress, concerns, and any planned changes to clinical care.

- 3 • Formal reassessment and treatment plan updates [with signatures from key clinical staff]
4 should occur at least monthly and include determination of whether the patient is
5 progressing appropriately and if treatment at a different level of care may be needed.

6 Level 3.5Y Services

7 *Medical Services*

- 8 • A nursing assessment should be conducted at admission that includes:
 - 9 ○ Vitals, including pulse oximetry;
10 ○ History of present illness;
11 ○ Evaluation of withdrawal risks;12 ○ Medical history, including assessment of current biomedical, psychiatric, and
13 cognitive concerns and medication review;14 ○ psychiatric needs assessment; and15 ○ Weight and BMI.
- 16 • Level 3.5Y programs should be able to initiate and titrate addiction and psychiatric
17 medications and provide medication management, including regular monitoring of the
18 patient's adherence to prescribed medications.
- 19 • A physician or advanced practice provider should be available in-person or via telemedicine
20 daily to initiate or adjust medications.
- 21 • Medications may be provided based on a patient-specific verbal order from the physician or
22 advanced practice provider.*
- 23 • Level 3.5Y programs should be able to provide medical monitoring and management of
24 common low complexity biomedical conditions, including:
 - 25 ○ basic management of hyperglycemia and hypoglycemia;
26 ○ basic wound care;
- 27 ○ infectious disease management, including:
- 28 ■ screening and assessment for STIs and bloodborne infections (eg, HIV,
29 hepatitis B virus [HBV], HCV);
30 ■ initiation of treatment and/or coordinated referral to treatment with
31 coordination of care with infectious disease specialists as needed; and32 ■ initiation of treatment and/or coordinated referral for preexposure
33 prophylaxis (PrEP) and postexposure prophylaxis (PEP) and provision of
34 patient education regarding PrEP and PEP**;
- 35 ○ coordination of care for pregnancy and postpartum needs;36 ○ coordination of care for biomedical conditions, including pain, for which the patient
-
- 37 is receiving treatment from an external provider;38 ○ direct management or coordination of controlled medications;39 ○ supporting pharmacy access.

40 _____
41 * Per program protocol, which should be developed, approved, and regularly reviewed by the medical director

1 ** Please see the US Public Health Service’s Preexposure Prophylaxis for the Prevention of HIV Infection in the United
2 States— 2021 Update: A Clinical Practice Guideline for guidance.

4 **Biomedical Capabilities**

5 Level 3.5Y programs should have access to the following biomedical capabilities on-site:

- 6 • Vitals measurement and monitoring, including pulse oximetry and blood pressure;
- 7 • Glucose monitoring;
- 8 • Basic first aid;
- 9 • An automated external defibrillator (AED);
- 10 • Basic wound care;
- 11 • Injectable epinephrine;
- 12 • Overdose reversal medication (eg, naloxone,);
- 13 • Point-of-care pregnancy testing; and
- 14 • Drug testing and toxicology services.

15 Level 3.5Y program should have established relationships to coordinate access to laboratory and
16 phlebotomy services.

17 Level 3.5Y programs should provide coordinated access to vaccines (eg, hepatitis A and B viruses,
18 influenza, COVID- 19) either on-site or through facilitated access to a community partner.

19 —

20 * The rationale for ECG capacity is to determine the level of risk and need for Level 4Y care, *not* for diagnosis or disease
21 management. It is also important for monitoring for QTc prolongation in patients on methadone.

22 † Vaccines may be provided through established relationships with external partners.

24 **Psychiatric Services**

- 25 • Level 3.5Y programs directly provide psychiatric services.

26 **Clinical Services**

- 27 • Level 3.5Y programs provide ≥ 20 hours of structured clinical services per week, including
28 family systems therapy when possible.
- 29 • Structured services selected by master’s level clinical staff should be available 7 days per
30 week.
 - 31 ○ These services should be designed to support recovery from SUD and co-occurring
32 conditions and include daily activities that allow patients to learn and practice
33 healthy social behaviors.
 - 34 ○ Services should be provided in an amount, frequency, and intensity appropriate to
35 individual patient and family’s needs and level of function as determined by *The*
36 *ASAM Criteria* multidimensional assessment.
- 37 • Clinical services provided by formally affiliated external addiction treatment providers and
38 programs (eg, OTPs) may count toward the total hours of weekly clinical services if care and
39 billing are coordinated and documented.

1 **Clinically Managed Withdrawal Management**

- 2 • Level 3.5Y programs should be able to provide clinically managed residential intoxication
3 and withdrawal management, including:
- 4 ○ Twenty-four-hour supervision, observation, and support for patients who are
5 intoxicated or experiencing withdrawal but do not require medically monitored or
6 managed care as determined by medical evaluation;
 - 7 ○ Dispensing of medications for withdrawal management in accordance with a
8 prescription from a physician or advanced practice provider;
 - 9 ○ Clinical monitoring of intoxication and withdrawal, including use of physician-
10 established protocols to monitor for changes in status that may require medical
11 consultation and/or transition to a medically managed level of care; and
 - 12 ○ Psychosocial services designed to support completion of the withdrawal
13 management process.

14 *Recovery Support Services*

- 15 • Level 3.5Y programs should directly provide:
- 16 ○ Planned community reinforcement designed to foster healthy social values and
17 community living skills; and
 - 18 ○ A therapeutic milieu that includes consistency in support and structure.

19

20 **Universal MM Standards**

21 These standards apply to all specialty medically managed settings, including Levels 1.7Y, 2.7Y,
22 3.7Y, and Level 4Y specialty addiction units.

23 **Universal MM Setting**

24 The layout of the facility should enable adequate supervision and management of patients during
25 program hours of operation (ie, 24/7 in residential and inpatient programs), ensuring that staff can
26 respond to instability in a safe and timely manner. Patients should be able to alert staff to an issue
27 immediately, and staff should be able to respond immediately (ie, within minutes) to assess
28 patients' needs.

29 Staff supervision should be provided whenever adult and adolescent patients may be in the same
30 space.

- 31 • Interactions between adult and adolescent patients should be minimized and should
32 primarily occur when patients are transitioning between spaces or waiting for
33 appointments/sessions to begin.
- 34 • Staff should be able to see and hear any interactions between adult and adolescent
35 patients at all times.

36 When applicable, the nursing station should be in close proximity to the patient area to allow
37 nursing staff to respond to medical needs and instability in a safe and timely manner.

1 Universal MM Staff

2 *Medical Staff*

3 Medical Director

4 The medical director is ultimately responsible for the care delivered. The medical director:

- 5 • develops,⁴ approves, and regularly reviews the program's admission and discharge criteria
- 6 and medical policies, procedures, and protocols;
- 7 • directs patient care;
- 8 • ensures the adequacy of individual treatment plans;
- 9 • ensures daily medical coverage to meet patient needs;
- 10 • determines the credentials required of other physicians and advanced practice providers
- 11 who serve the program;
- 12 • monitors the care delivered by other physicians and advanced practice providers who serve
- 13 the program; and
- 14 • oversees the quality of treatment delivered by the program.

15 Written protocols related to the treatment of intoxication; withdrawal; SUD; co-occurring
16 biomedical, psychiatric, and cognitive conditions; and addiction medications should be reviewed
17 and approved by the medical director and a physician with adolescent treatment expertise.

18 Physicians and Advanced Practice Providers

19 In medically managed youth programs, there should be a physician leader who has at least 2 years
20 of experience in adolescent treatment who provides oversight of the adolescent unit.

21 Physicians and/or advanced practice providers should be readily available to:

- 22 • review admission decisions within 24 hours of admission to confirm the appropriateness of
- 23 the patient's level of care recommendation, including that withdrawal management in this
- 24 setting is safe;
- 25 • perform medical histories and physical examinations;
- 26 • assess and treat substance withdrawal and active comorbid biomedical conditions;
- 27 • manage medications and other treatment modalities for acute withdrawal management
- 28 and other biomedical needs;
- 29 • monitor patient response to treatment;
- 30 • coordinating parent or guardian, educating on medical care options and needs, including
- 31 medications, and obtaining consent for treatment when needed; and
- 32 • provide clinical consultation and supervision for co-occurring biomedical, psychiatric, and
- 33 cognitive conditions.

34 Physicians and advanced practice providers are responsible for managing medical care and
35 assuring quality of care, which includes:

⁴ In partnership with other program staff

- 1 • diagnosis, treatment, and treatment plan decisions⁵ for acute intoxication, withdrawal,
- 2 SUD, and co-occurring biomedical, psychiatric, and cognitive conditions;
- 3 • determination of if and when to admit the patient;
- 4 • determination of if and when a patient should be transitioned to a more intensive level of
- 5 care;
- 6 • determination of when to transition the patient to a less intensive level of care;
- 7 • coordination with families and other trusted adults in the patient’s life to support effective
- 8 care; and
- 9 • coordination of care with prescribers of controlled substances.

10 Physicians, other than the medical director when applicable, do not need to be certified as
11 addiction specialist physicians, but training and experience in assessing and managing intoxication
12 and withdrawal syndromes and using addiction medications in adolescents are necessary.
13 Advanced practice providers should have ready access to physician(s) with expertise in addiction
14 medicine and adolescent treatment at all times.

15 **Nursing and Medical Support Staff**

16 When nurses are on staff, they should meet the core competencies outlined in *Addiction Nursing*
17 *Competencies: A Comprehensive Toolkit for the Addictions Nurse*. Nurses do not need to be
18 certified as addiction nurses, but training and experience in assessing and managing intoxication
19 and withdrawal syndromes are necessary.

20 The level of nursing care provided (when applicable) should be appropriate to the severity of patient
21 needs. Registered nurses (RNs) or other appropriately licensed and credentialed nurses (eg,
22 licensed practical nurses [LPNs]) should be available during program hours of operation to:

- 23 • conduct nursing assessments on admission;
- 24 • provide primary nursing care and observation;
- 25 • monitor patient progress;
- 26 • provide medication management services;
- 27 • administer medications and nonpharmacological interventions in accordance with
- 28 physician and advanced practice provider orders;
- 29 • administer standardized withdrawal severity assessments;
- 30 • conduct routine daily nursing assessments of withdrawal and co-occurring biomedical,
- 31 psychiatric, and cognitive conditions; and
- 32 • provide patient and family education.

33 **Clinical Staff**

34 Medically managed levels of care should have appropriately trained clinical staff (eg, SUD and
35 mental health counselors, psychologists, social workers) available directly or through formally

⁵ In collaboration with the patient

1 affiliated providers or programs. Clinical staff should have appropriate training and scopes of
2 practice to treat adolescent patients and should:

- 3 • deliver planned regimens of professionally directed psychosocial services, including
- 4 counseling, psychoeducation, and psychotherapy;
- 5 • assess and treat substance use and other addictive disorders;
- 6 • assess and treat co-occurring mental health conditions;
- 7 • provide family services;
- 8 • support care coordination and coordinated treatment planning; and
- 9 • coordinate the delivery of recovery support services (RSS).

10 In medically managed youth programs, a clinical staff member who has at least 2 years of
11 experience in adolescent treatment should provide oversight of youth treatment plans.

12 *Allied Health Staff*

13 Medically managed levels of care may have allied health staff (eg, certified peer support
14 specialists, patient navigators, health educators, counselor aides, group living workers) who
15 support the delivery of RSS, including:

- 16 • peer support services for patients and families;
- 17 • health education services, such as prevention of infectious diseases (eg, HIV, HCV), safe
- 18 sex practices, and overdose prevention and reversal training;
- 19 • healthcare and social service navigation services for patients and families; and
- 20 • transition support.

21 **Universal MM Support Systems**

22 Medically managed programs should have formal relationships with a psychiatric specialist with
23 training and experience treating adolescent patients.

24 Medically managed programs are encouraged to establish relationships with nearby hospitals,
25 local urgent care providers, and emergency departments to support effective coordination of care.

26 All medically managed programs should have the ability to:

- 27 • coordinate care with methadone treatment providers (eg, OTPs), unless methadone access
- 28 is not locally available;
- 29 • refer for specialized clinical consultation for biomedical, psychiatric, and cognitive
- 30 problems as needed, including:
 - 31 ○ establishing relationships with infectious disease specialists,
 - 32 ○ establishing relationships with obstetricians to support coordination of care for
 - 33 patients who are pregnant and postpartum, and
 - 34 ○ considering local and treatment community needs when determining the need for
 - 35 other relationships⁶;

⁶ For example, if renal failure is common in the program's patient population, consider establishing a relationship with a nearby dialysis center to support effective coordination of care.

- 1 • support access to prescribed medications, including those that are obtained from a
- 2 specialty pharmacy;
- 3 • provide or refer for primary care services;
- 4 • conduct or refer for appropriate laboratory testing services (eg, infectious disease
- 5 screening) as needed; and
- 6 • conduct or refer for appropriate drug testing and toxicology services as needed.⁷

7 Universal MM Assessment and Treatment Planning

8 *Assessment*

9 The Level of Care and Treatment Planning Assessments in all medically managed programs
10 involve:

- 11 • a comprehensive nursing assessment performed at admission⁸;
- 12 • a history and physical examination conducted by a physician or advanced practice provider;
- 13 • review and approval of the admission by a physician or advanced practice provider (if the
- 14 history was conducted by other medical staff);
- 15 • appropriate laboratory, drug testing, and toxicology services as needed⁸; and
- 16 • sufficient biopsychosocial screening and assessments conducted to determine the
- 17 appropriate level of care and develop individualized care and transition plans that address
- 18 treatment priorities identified in each dimension.

19 Program policies and procedures should define when a physician or advanced practice provider
20 needs to be consulted prior to admission (eg, medically complex cases).

21 *Treatment Planning*

22 In medically managed levels of care, a preliminary treatment plan should be developed within 24
23 hours of admission.

24 The treatment plan should reflect coordination of addiction treatment, biomedical health care,
25 mental health care, and RSS needs to address problems identified through the comprehensive
26 biopsychosocial assessment as needed and reflect coordination of care with external biomedical
27 and psychiatric providers.

28 The treatment plan should also reflect coordination with the family, including the family's role in
29 supporting the treatment plan.

30 *Reassessment*

31 Programs should perform regular reassessments at a frequency appropriate to the patient's level
32 of stability and severity of illness to determine if the patient is progressing appropriately. Medical
33 staff should assess patients and review patient progress daily, at minimum; in Level 3.7Y, a

⁷ Please see ASAM's Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.

⁸ This does not apply in Level 1.7Y programs, which may not have nursing staff.

1 physician or advanced practice provider should conduct the assessment. Daily assessments may
2 occur in-person or, when appropriate, via video-based telemedicine check-ins during the acute
3 phase of withdrawal management and biomedical treatment. Telephone check-ins may be
4 appropriate alternatives to in-person or video-based telemedicine check-ins depending on the
5 acuity of the patient’s signs and symptoms and concerns regarding adherence to prescribed
6 medications. Progress notes and treatment changes should be recorded in the patient’s health
7 record.

8 Serial medical assessments, including appropriate measures of withdrawal, should be conducted
9 as needed.

10 Universal MM Services

11 *Withdrawal Management*

12 Medically managed programs provide intoxication and withdrawal management services,
13 including:

- 14 • medical monitoring and management of signs and symptoms of intoxication and
15 withdrawal;
- 16 • assessment with standardized scales (eg, Clinical Institute Withdrawal Assessment for
17 Alcohol, revised [CIWA-Ar], Clinical Opiate Withdrawal Scale [COWS]) to determine the
18 severity of withdrawal as appropriate;
- 19 • pharmacological methods of withdrawal management that are appropriate for the severity
20 of withdrawal or anticipated withdrawal syndrome^{9*}; and
- 21 • nonpharmacological clinical support, including but not limited to:
 - 22 ○ informing patients and families of what to expect over the course of treatment;
 - 23 ○ offering reassurance;
 - 24 ○ providing a quiet environment;
 - 25 ○ educating patients and families on the importance of adequate hydration and
26 nutrition; and
 - 27 ○ for patients treated in outpatient settings (ie, Levels 1.7 and 2.7), educating family
28 members, caregivers, and other support persons (with patient assent or consent as
29 appropriate) on how to support the patient during withdrawal management,
30 including:
 - 31 ■ monitoring for withdrawal signs and symptoms,
 - 32 ■ what situations require urgent or emergent medical or clinical services (ie,
33 when to call the program, 911, or 988),
 - 34 ■ supporting medication adherence,
 - 35 ■ supporting adequate hydration and nutrition,
 - 36 ■ creating a low stimulation environment, and
 - 37 ■ offering encouragement and reassurance.

⁹ Please see The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management for guidance

1 *Addiction Medications*

2 Medically managed programs should be able to support initiation, titration, and continuation of
3 addiction medications¹⁰ in alignment with current best practices, such as those established in:

- 4 • The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020
5 Focused Update,
- 6 • The APA Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use
7 Disorder,
- 8 • The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder,
9 and
- 10 • ASAM’s Integrating Tobacco Use Disorder Interventions in Addiction Treatment: A Guide for
11 Addiction Treatment Clinicians and Programs.

12 Injectable medications may be provided through an appropriate provider of injection medication
13 services but should be available on-site.

14 Patient and family education should be provided regarding available addiction medications,
15 including those currently available to treat opioid use disorder (OUD), alcohol use disorder (AUD),
16 and tobacco use disorder (TUD).

17 *Management of Co-occurring Biomedical and Psychiatric Conditions*

18 All medically managed programs should provide medical monitoring and management of
19 biomedical and psychiatric conditions, including:

- 20 • basic management of hyperglycemia and hypoglycemia;
- 21 • basic wound care;
- 22 • infectious disease management, including:
 - 23 ○ screening and assessment for STIs and bloodborne infections (eg, HIV, hepatitis B
24 virus [HBV], HCV);
 - 25 ○ initiation of treatment and/or coordinated referral to treatment with coordination of
26 care with infectious disease specialists as needed; and
 - 27 ○ initiation of treatment and/or coordinated referral for preexposure prophylaxis (PrEP)
28 and postexposure prophylaxis (PEP) and provision of patient education regarding
29 PrEP and PEP*¹¹;
- 30 • coordination of care for pregnancy and postpartum needs;
- 31 • coordination of care for biomedical conditions, including pain, for which the patient is
32 receiving treatment from an external provider;

¹⁰ Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD (some of which are approved for use in adolescents); off-label medications for other SUDs, including stimulant use disorder (StUD) and cannabis use disorder (CUD); and medications to manage post-acute withdrawal symptoms.

¹¹ Please see the US Public Health Service’s Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update: A Clinical Practice Guideline for guidance

- 1 • psychiatric medication initiation or titration and management of common, low-moderate
- 2 complexity psychiatric conditions;
- 3 • direct management or coordination of controlled medications; and
- 4 • prescription services with essential medications on-site.^{12†}

5 *Toxicology Services*

6 Medically managed programs should provide drug testing to support the patient’s individual
7 treatment plan as needed, following standards such as those defined in ASAM’s current guideline
8 on the use of drug testing in clinical addiction medicine.

9 Drug testing should be conducted based on patient- specific orders from their responsible
10 physician or advanced practice provider. Drug testing and toxicology results should be reviewed
11 and interpreted by a physician or advanced practice provider for whom interpretation of drug
12 testing and toxicology results is in their scope of practice.

13 Programs should have written policies that outline how to respond to unexpected drug test and
14 toxicology results, including modification of the treatment plan.

15

16 **Level 1.7Y Standards**

17 **Level 1.7Y Description**

18 Level 1.7Y programs provide medically managed outpatient services for patients with SUD who can
19 be treated safely and effectively with low-intensity outpatient services. These programs also
20 provide outpatient psychosocial services consisting primarily of psychotherapy, counseling, and
21 psychoeducation to address addiction and co-occurring mental health conditions.

22 Level 1.7Y programs should provide all the services of Level 1.5Y programs either directly or
23 through formal affiliations with other providers or programs.

24 **Level 1.7Y Setting**

25 Level 1.7Y services may be offered in any appropriate outpatient treatment setting with physician
26 oversight that meets state licensure or certification criteria, such as:

- 27 • physicians’ offices,
- 28 • health clinics,
- 29 • behavioral health clinics,
- 30 • primary care settings,
- 31 • outpatient addiction programs,
- 32 • OTPs,
- 33 • office-based addiction treatment programs,

¹² This is encouraged but not required in Level 1.7Y.

- 1 • mobile addiction treatment programs (eg, street medicine), and
- 2 • school-based health clinics.

3 **Level 1.7Y Staff**

4 Level 1.7Y programs are staffed by appropriately trained addiction treatment professionals acting
5 within their state-regulated scopes of practice,* including physicians with controlled substance
6 prescribing authority.†

7 Level 1.7Y programs may also be staffed by:

- 8 • advanced practice providers with controlled substance prescribing authority† who
9 collaborate with program physicians, and
- 10 • nurses with the necessary scope of practice to support the delivery of services provided in
11 Level 1.7Y.

12 Level 1.7Y programs are also staffed, directly or through formally affiliated providers or programs,
13 by clinical staff, such as psychologists, clinical social workers, SUD and mental health counselors,
14 and others trained to assess and treat SUD and/or co- occurring mental health conditions with the
15 necessary scopes of practice to support the delivery of psychosocial services provided in Level
16 1.7Y.

17 ---

18 * Please see Appendix D for additional information on recommended staff competencies.

19 † Including authorization to prescribe buprenorphine.

20 *Medical Staff*

21 **Medical Director**

22 Level 1.7Y programs should have a medical director (or responsible physician in an independent
23 practice) who is a physician with at least two years of documented experience delivering specialty
24 addiction treatment. The medical director may be supported by advanced practice providers and
25 nursing staff.

26 **Physicians and Advanced Practice Providers**

27 In Level 1.7Y programs, physicians and advanced practice providers with controlled substance
28 prescribing authority* should be active members of the care team during program hours of
29 operation. Physicians and advanced practice providers should have consistent, direct
30 interactions— either in-person or via video-based telemedicine— with patients in the acute phase
31 of withdrawal.

32 In Level 1.7Y programs, the medical director or another physician in the program should have at
33 least 2 years of experience in adolescent SUD treatment. This physician should provide supervision
34 of patient treatment plans.

35 ---

1 * Including authorization to prescribe buprenorphine.

2 **Addiction/Psychiatric Specialist Physicians**

3 Level 1.7Y programs may not have addiction specialist physicians on staff. However, programs
4 should have policies and procedures that define when and how to consult with or refer to addiction
5 specialist physicians as needed.

6 Level 1.7Y programs should have established relationships with psychiatrists or advanced practice
7 providers with specialty certification in psychiatry (eg, psychiatric NP) and experience treating
8 adolescent patients to support effective referrals when needed.

9 *Clinical Staff*

10 Level 1.7Y programs should have appropriately trained clinical staff available on-site or via
11 telemedicine during program hours of operation, directly or through formally affiliated providers or
12 programs. At this level of care, treatment planning should be led by medical staff.

13 Level 1.7Y programs may have a program director.

14 **Level 1.7Y Support Systems**

15 Level 1.7Y programs are encouraged to provide afterhours telephonic availability through direct
16 connection to on-call services, such as nurse triage lines. At intake, programs should educate
17 patients and families on what to do if urgent or emergent issues arise after- hours (eg, community
18 resources, help lines, 911, 988).

19 **Level 1.7Y Assessment and Treatment Planning**

20 A physical examination should be conducted by a physician or advanced practice provider within a
21 reasonable time frame of treatment initiation.

22 In Level 1.7Y programs, the patient-facing treatment plan should include a plan for accessing
23 emergency care 24/7, including when to call 911 or 988.

24 A psychiatric assessment should be coordinated within 7 days when needed.

25 A Treatment Planning Assessment should be conducted or reviewed within the first three visits.

26 **Level 1.7Y Services**

27 *Medical Services*

28 Level 1.7Y programs provide outpatient medical management of acute withdrawal and biomedical
29 and psychiatric conditions including:

- 30 • a medical or nursing assessment upon admission that includes:
 - 31 ○ vitals, including pulse oximetry;
 - 32 ○ history of present illness;
 - 33 ○ baseline evaluation of withdrawal severity and risks; and
 - 34 ○ medical history, including assessment of current

- 1 • biomedical, psychiatric, and cognitive concerns and medication review;
- 2 • a physical examination or psychiatric assessment, typically at initial visit.
- 3 ○ If a psychiatric assessment is conducted the provider should determine whether a
- 4 physical examination is needed and, if so, provide a coordinated referral in a
- 5 timeframe appropriate to the need; and
- 6 • medication initiation and management for common low complexity psychiatric conditions.

7 Programs should consider providing daily walk-in slots to ensure availability of services.

8 Level 1.7Y programs should support outpatient medical monitoring and management of common
9 comorbid biomedical and psychiatric conditions.

10 Note that the draft standards require programs to be capable of conducting a hands-on
11 assessment (eg, collection of vital signs). This may limit the ability of telehealth only programs from
12 meeting the standards for Level 1.7Y. When assessing Dimension 1 and 2 needs and providing
13 related medical care, in-person assessments are a best practice. However, this may present
14 access issues in some areas of the country. We are seeking public comment on whether to leave
15 the standards as written or to add flexibility in the standards such that the medical director may
16 determine the appropriateness of virtual assessment for a given patient.

17 **Biomedical Capabilities**

18 Level 1.7Y programs should have access to the following biomedical capabilities on-site:

- 19 • vitals measurement and monitoring, including pulse oximetry and blood pressure;
- 20 • glucose monitoring;
- 21 • basic first aid;
- 22 • an automated external defibrillator (AED);
- 23 • basic wound care;
- 24 • injectable epinephrine;
- 25 • overdose reversal medication (eg, naloxone);
- 26 • point-of-care pregnancy testing;
- 27 • laboratory services; and
- 28 • drug testing and toxicology services.

29 **Clinical Services**

30 Level 1.7Y programs provide clinical services in an amount, frequency, and intensity appropriate to
31 individual patient and family needs and level of function as determined by *The ASAM Criteria*
32 multidimensional assessment.

33 **Psychosocial Services**

34 The psychosocial services delivered should be individualized based on the patient and family's
35 assessment. Patients should be excused from participating in psychosocial services and RSS if
36 acute withdrawal or biomedical, psychiatric, or cognitive conditions prevent effective participation.

1 If psychosocial services are provided through formally affiliated providers and programs, regular
2 check-ins should occur regarding the care of each patient.

3 **Level 2.7Y Standards**

4 **Level 2.7Y Description**

5 Level 2.7Y programs provide medically managed intensive outpatient services for patients who
6 require access to medical management with extended nurse monitoring but not 24-hour nursing
7 support, overnight medical monitoring, nor residential structure and support.

8 These programs provide coordinated management of withdrawal and biomedical and psychiatric
9 comorbidities delivered by medical and clinical staff in an intensive outpatient setting. They
10 provide at least 20 hours of clinical services per week comprised of medical care and psychosocial
11 services to address addiction and cooccurring mental health conditions.

12 Level 2.7Y programs should provide all the services of Level 2.5Y programs either directly or
13 through formal affiliations with other providers or programs.

14 **Level 2.7Y Setting**

15 Level 2.7Y services may be offered in any appropriate outpatient treatment setting with physician
16 oversight that meets state licensure or certification criteria, such as:

- 17 • IOP program settings,
- 18 • partial hospitalization program (PHP) settings,
- 19 • OTPs, and
- 20 • office- based specialty addiction treatment practices.

21 **Level 2.7Y Staff**

22 Level 2.7Y programs are staffed by an interdisciplinary team of appropriately trained and
23 supervised addiction treatment professionals acting within their state-regulated scopes of
24 practice,* including:

- 25 • a medical director;
- 26 • physicians and advanced practice providers with controlled substance prescribing
27 authority†; and
- 28 • nurses with the necessary scope of practice to support the delivery of services provided in
29 Level 2.7Y.

30 Level 2.7Y programs are also staffed, directly or through formally affiliated providers or programs,
31 by:

- 32 • a program director; and
- 33 • clinical staff, such as psychologists, clinical social workers, SUD and mental health
34 counselors, and others trained to assess and treat SUD and/or co- occurring mental health

1 conditions with the necessary scopes of practice to support the delivery of services
2 provided in Level 2.7Y.

3 Level 2.7Y programs are typically supported by allied health staff, such as certified peer support
4 specialists, patient navigators, health educators, and counselor aides who support ongoing
5 engagement in addiction treatment, deliver RSS, and provide warm handoffs to other levels of care.

6 ---

7 * Please see Appendix D for additional information on recommended staff competencies

8 † Including authorization to prescribe buprenorphine.

9

10 *Medical Staff*

11 *Medical Director*

12 Level 2.7Y programs should have a medical director who is an addiction specialist physician or a
13 physician with at least five years of documented experience in specialty addiction treatment.*

14 ---

15 * If a program is unable to identify a medical director who meets these qualifications after reasonable efforts, a physician
16 with at least two years of documented experience in specialty addiction treatment who meets the competencies
17 described in Appendix D may serve as the medical director. In these instances, this medical director should have an
18 established mentor who is board certified in addiction medicine or addiction psychiatry.

19 *Physicians and Advanced Practice Providers*

20 In Level 2.7Y programs, physicians and advanced practice providers with controlled substance
21 prescribing authority* should be available on- site or via telemedicine as active members of the
22 care team during program hours of operation. Medical staff should be on call 24 hours a day to
23 address urgent issues that arise after- hours, though qualified clinical staff may serve as first- line
24 triage.

25 Level 2.7Y programs should be supported by physicians with at least 2 years of experience in
26 adolescent SUD treatment, either on staff or through formal affiliations, who provide supervision of
27 treatment plans.

28 Physicians and advanced practice providers should have consistent, direct interactions— either in-
29 person or via video- based telemedicine— with patients in the acute phase of withdrawal.

30 Advanced practice providers should have ready access to the medical director or another
31 equivalently qualified physician at all times.

32 ---

33 * Including authorization to prescribe buprenorphine.

1 **Addiction/Psychiatric Specialist Physicians**

2 In Level 2.7Y programs, an addiction specialist physician should ideally serve as the medical
3 director. However, if addiction specialist physicians are not on staff, programs should have
4 policies and procedures that define when and how to consult with or refer to addiction specialist
5 physicians as needed.

6 Level 2.7Y programs should have formal affiliations with psychiatrists or advanced practice
7 providers with specialty certification in psychiatry (eg, psychiatric NPs) and experience treating
8 adolescent patients who are available on-site or via telemedicine within 24 hours. [Note: In acute
9 situations where more rapid psychiatric services are needed, the patient should be transitioned to
10 a more intensive level of care or crisis services should be engaged.]

11 **Nursing and Medical Support Staff**

12 RNs or other appropriately licensed and credentialed nurses (eg, LPNs) should be available during
13 program hours of operation.

14 *Clinical Staff*

15 Level 2.7Y programs should have appropriately trained clinical staff available on-site or via
16 telemedicine during program hours of operation, directly or through formally affiliated providers or
17 programs. At this level of care, treatment planning should be led by medical staff.

18 The program director in a Level 2.7Y program (or formally affiliated program that provides
19 psychosocial services) should, at minimum, have a master's degree in a field related to adolescent
20 clinical behavioral health and at least five years of documented experience in addiction
21 treatment.*

22 ---

23 * If a program is unable to identify a program director who meets these qualifications after reasonable efforts, a clinician
24 with at least five years of documented clinical and supervisory experience in addiction treatment who meets the
25 competencies described in Appendix D may serve as the program director. In these instances, this program director
26 should have an established mentor and a written plan to obtain a terminal degree within five years.

27 **Level 2.7Y Support Systems**

28 Level 2.7Y programs are encouraged to provide afterhours telephonic availability through direct
29 connection to on- call services, such as nurse triage lines. At intake, programs should educate
30 patients and families on what to do if urgent or emergent issues arise after- hours (eg, community
31 resources, help lines, 911, 988).

32 **Level 2.7Y Assessment and Treatment Planning**

33 Within 24 to 48 hours of admission, a physician or advanced practice provider should conduct a
34 history and physical examination on-site and review and approve the admission decision.*

35 In Level 2.7Y programs, the patient-facing treatment plan should include a plan for contacting the
36 program afterhours and accessing emergency care 24/7, including when to call 911 or 988.

1 A psychiatric assessment should be conducted within 72 hours of admission.

2 A Treatment Planning Assessment should be conducted or reviewed within 48 hours of admission
3 or initial stabilization.

4 ---

5 * The physical exam and review and approval of admission should typically be completed within 24 hours of admission,
6 but flexibility is included to account for programs that operate six days per week.

7 **Level 2.7Y Services**

8 *Medical Services*

9 Level 2.7Y programs provide intensive outpatient medical management and extended nurse
10 monitoring for stabilization of acute withdrawal and biomedical and psychiatric conditions
11 including:

- 12 • a comprehensive medical history and physical examination;
 - 13 ○ collateral information should be obtained from family members, if available.
- 14 • a nursing assessment upon admission that includes:
 - 15 ○ vitals, including pulse oximetry;
 - 16 ○ history of present illness;
 - 17 ○ baseline evaluation of withdrawal severity and risks; and
 - 18 ○ medical history, including assessment of current biomedical, psychiatric, and
19 cognitive concerns and medication review;
- 20 • nurse monitoring;
- 21 • medication management, including regular monitoring of the patient's adherence to
22 prescribed medications; and
- 23 • prescription services with essential medications on-site.

24 A physician or advanced practice provider should be available in-person or via telemedicine during
25 program hours of operation to initiate or adjust medications based on the results of nursing
26 assessments. Medications may be provided based on a patient-specific verbal order from the
27 physician or advanced practice provider.*

28 Withdrawal management and medication initiation services should be available within 1 hour of
29 initial assessment. Programs should consider providing daily walk-in slots to ensure availability of
30 services.

31 Level 2.7Y programs provide outpatient medical monitoring and management of common
32 comorbid biomedical and psychiatric conditions.

33 Programs should have policies and procedures that define essential medicines based on current
34 standards of clinical practice. Programs are responsible for ensuring that these medications are
35 stocked and stored securely.

1 In Level 2.7Y programs, a psychiatrist or advanced practice provider with specialty certification in
2 psychiatry (eg, psychiatric NP) and experience treating adolescent patients should be available on-
3 site or via telemedicine within 24 hours to provide medical management of psychiatric conditions
4 and titrate psychiatric medications when needed.

5 ---

6 * Per program protocol, which should be developed, approved, and regularly reviewed by the medical director.

7 Biomedical Capabilities

8 Level 2.7Y programs should have access to the following biomedical capabilities on-site:

- 9 • vitals measurement and monitoring, including pulse oximetry and blood pressure;
- 10 • glucose monitoring;
- 11 • basic first aid;
- 12 • an AED;
- 13 • ECG with a 3- lead rhythm strip at minimum*;
- 14 • basic wound care;
- 15 • injectable epinephrine;
- 16 • overdose reversal medication (eg, naloxone);
- 17 • vaccine administration† (eg, hepatitis A and B viruses, influenza, COVID- 19, HPV);
- 18 • point- of- care pregnancy testing;
- 19 • laboratory and phlebotomy services; and
- 20 • drug testing and toxicology services.

21 ---

22 * The rationale for ECG capacity is to determine the level of risk and need for Level 4Y care, not for diagnosis or disease
23 management. It is also important for monitoring for QTc prolongation in patients on methadone.

24 † Vaccines should be available on-site in Level 2.7Y programs but may be provided through established relationships with
25 external partners.

26 Clinical Services

27 Level 2.7Y programs provide at least 20 hours of clinical services per week comprised of both
28 medical and psychosocial services.

29 Services should be provided in an amount, frequency, and intensity appropriate to individual
30 patient and family needs and level of function as determined by *The ASAM Criteria*
31 multidimensional assessment.

32 Psychosocial Services

33 The psychosocial services delivered should be individualized based on the patient and family's
34 assessment. Structured psychosocial services selected by master's level clinical staff should be
35 available at least five days per week either directly or through formal affiliation.

36 Patients should be excused from participating in psychoeducation, psychotherapy, and RSS if
37 acute withdrawal or biomedical, psychiatric, or cognitive conditions prevent effective participation.

1 If psychosocial services are provided through formally affiliated providers and programs, frequent
2 (ie, daily or near-daily) check-ins should occur regarding the care of each patient.

3

4 Level 3.7Y Standards

5 Level 3.7Y Description

6 Level 3.7Y programs provide medically managed residential services for patients who require 24-
7 hour observation, monitoring, and treatment but not the full resources of a hospital. These
8 programs provide coordinated management of withdrawal and biomedical and psychiatric
9 comorbidities delivered by medical and clinical staff in a permanent residential facility. They
10 provide at least 20 hours of clinical services per week comprised of medical care and psychosocial
11 services to address addiction and co-occurring mental health conditions.

12 Level 3.7Y programs should provide all the services of Level 3.5Y programs either directly or
13 through formal affiliations with other providers or programs.

14 Level 3.7Y Setting

15 Level 3.7Y services may be offered in any appropriate residential treatment setting with 24-hour
16 nursing staff and physician oversight that meets state licensure or certification criteria. The facility
17 should incorporate space for:

- 18 • medical and nursing services, and
- 19 • all services and activities outlined in the Universal Residential Setting Standards (p x).

20

21 *Patient Supervision*

22 Level 3.7Y programs should provide 24-hour supervision of patients. Staff should verify and
23 document the whereabouts and wellness of each patient who is on-site at least once every hour.
24 Note that this is separate from clinical monitoring, the frequency of which should be determined
25 based on the individual clinical needs of each patient.

26 At this level of care, patients should not leave program premises except under limited
27 circumstances, such as for specialty medical or diagnostic appointments or medical or psychiatric
28 emergencies.

29 Program staff (or staff of external providers or programs providing services to the patient) should
30 provide continuous supervision of patients when they are off-site to prevent risky behaviors and
31 address any instability or other issues that may arise in a safe and timely manner.

32 Programs should have policies and procedures in place for providing continuous supervision when
33 patients are off-site.

1 Level 3.7Y Staff

2 Level 3.7Y programs are staffed by an interdisciplinary team of appropriately trained and
3 supervised addiction treatment professionals acting within their state-regulated scopes of
4 practice,* including:

- 5 • a medical director,
- 6 • physicians and advanced practice providers with controlled substance prescribing
7 authority,† and
- 8 • nurses with the necessary scope of practice to support the delivery of services provided in
9 Level 3.7Y.

10 Level 3.7Y programs are also staffed, directly or through formally affiliated providers or programs,
11 by:

- 12 • a program director;
- 13 • clinical staff, such as psychologists, clinical social workers, SUD and mental health
14 counselors, and others trained to assess and treat SUD and/or co- occurring mental health
15 conditions with the necessary scopes of practice to support the delivery of services
16 provided in Level 3.7Y; and
- 17 • allied health staff, such as certified peer support specialists, patient navigators, health
18 educators, counselor aides, and group living workers who support ongoing engagement in
19 addiction treatment, deliver RSS, and support warm handoffs to other levels of care.

20 ---

21 * Please see Appendix D for additional information on recommended staff competencies.

22 † Including authorization to prescribe buprenorphine.

23 *Medical Staff*

24 **Medical Director**

25 Level 3.7Y programs should have a medical director who is an addiction specialist physician with
26 board certification in addiction medicine or addiction psychiatry.*

27 ---

28 *If a program is unable to identify a medical director who meets these qualifications after reasonable efforts, a physician
29 with at least five years of documented experience in specialty addiction treatment who meets the competencies
30 described in Appendix D may serve as the medical director. In these instances, this medical director should have an
31 established mentor who is board certified in addiction medicine or addiction psychiatry.

32 **Physicians and Advanced Practice Providers**

33 In Level 3.7Y programs, physicians and advanced practice providers with adolescent treatment
34 experience and controlled substance prescribing authority* should be available on- site or via
35 telemedicine as active members of the care team 24 hours a day.

1 Level 3.7Y programs should have access to physicians with 2 or more years of experience in
2 adolescent SUD treatment, either on staff or through formal affiliations, who provide supervision of
3 treatment plans.

4 Physicians and advanced practice providers should have consistent, direct interactions— either in-
5 person or via video-based telemedicine— with patients in the acute phase of withdrawal.

6 Physicians and advanced practice providers should generally assume management of all
7 controlled substance prescriptions from external prescribers and make final determinations
8 regarding the medication treatment plan, including when to taper or discontinue medications
9 prescribed prior to admission.

10 Advanced practice providers should have ready access to the medical director or another
11 equivalently qualified physician at all times.

12 ---

13 * Including authorization to prescribe buprenorphine.

14 **Addiction/Psychiatric Specialist Physicians**

15 In Level 3.7Y programs, the medical director should be an addiction specialist physician except
16 under limited circumstances. Other physicians and advanced practice providers can support and
17 extend the capabilities of addiction specialist physicians; however, they should not replace the
18 role of the addiction specialist physician in direct patient care.

19 In the limited instances where addiction specialist physicians are not on staff, programs should
20 have policies and procedures that define when and how to consult with or refer to addiction
21 specialist physicians as needed.

22 Level 3.7Y programs should have formal affiliations with psychiatrists or advanced practice
23 providers with specialty certification in psychiatry (eg, psychiatric NPs) experienced in adolescent
24 treatment who are available onsite or via telemedicine within 24 hours. [Note: In acute situations
25 where more rapid psychiatric services are needed the patient should be transitioned to a more
26 intensive level of care or crisis services should be engaged.]

27 **Nursing and Medical Support Staff**

28 RNs or other appropriately licensed and credentialed nurses (eg, LPNs) should be available 24
29 hours a day. A nursing supervisor should be available 24/7 to respond to urgent situations.

30 **Clinical Staff**

31 Level 3.7Y programs should have appropriately trained clinical staff available on-site or on-call 24
32 hours a day, directly or through formally affiliated providers or programs.

33 At this level of care, treatment planning should be led by medical staff.

34 Mental health treatment providers with adolescent treatment experience should be part of the
35 interdisciplinary team. Clinical staff members on the interdisciplinary team who have more training

1 and experience with mental health care should support their team members to deliver effective,
2 integrated* co-occurring capable care.

3 The program director in a Level 3.7Y program (or formally affiliated program that provides
4 psychosocial services) should, at minimum, have a master's degree in a field related to adolescent
5 clinical behavioral health and at least five years of documented experience in addiction
6 treatment.†

7 ---

8 *Here, integrated refers to mental health services provided within the context of addiction treatment.

9 † If a program is unable to identify a program director who meets these qualifications after reasonable efforts, a clinician
10 with at least five years of documented clinical and supervisory experience in addiction treatment who meets the
11 competencies described in Appendix D may serve as the program director. In these instances, this program director
12 should have an established mentor and a written plan to obtain a terminal degree within five years.

13 **Level 3.7Y Assessment and Treatment Planning**

14 Within 24 hours of admission, a physician or advanced practice provider should conduct a history
15 and physical examination on-site and review and approve the admission. When Level 3.7Y is a
16 step- down service from Level 4, records of physical examination within the preceding seven days
17 should be reviewed by a physician or advanced practice provider within 24 hours of admission.

18 A psychiatric assessment should be conducted within 72 hours of admission.

19 A Treatment Planning Assessment should be conducted or reviewed within 48 hours of admission
20 or initial stabilization.

21 **Level 3.7Y Services**

22 *Medical Services*

23 Level 3.7Y programs provide residential medical management and 24-hour nurse monitoring for
24 stabilization of acute withdrawal and biomedical and psychiatric conditions including:

- 25 • a comprehensive medical history and physical examination performed within 24 hours of
26 admission;
- 27 • a nursing assessment conducted at admission that includes:
 - 28 ○ vitals, including pulse oximetry;
 - 29 ○ history of present illness;
 - 30 ○ baseline evaluation of withdrawal severity and risks; and
 - 31 ○ medical history, including assessment of current biomedical, psychiatric, and
32 cognitive concerns and medication review;
- 33 • hourly nurse monitoring of the patient's progress and medication administration as needed;
- 34 • medication management, including regular monitoring of the patient's adherence to
35 prescribed medications, which may include self- administered injections or infusions; and
- 36 • prescription services with essential medications on- site.

1 A physician or advanced practice provider should be available in-person or via telemedicine 24/7 to
2 initiate or adjust medications based on the results of nursing assessments. Medications may be
3 provided based on a patient-specific verbal order from the physician or advanced practice
4 provider.*

5 Level 3.7Y programs should provide residential medical monitoring and management of common
6 comorbid biomedical and psychiatric conditions.

7 Level 3.7Y programs are encouraged to provide at least 3.5 hours of nursing care per patient per
8 day, encompassing care provided by RNs, LPNs, CNAs, paramedics, and medical technicians
9 under the supervision of an RN.

10 Programs should have policies and procedures that define essential medicines based on current
11 standards of clinical practice. Programs are responsible for ensuring that these medications are
12 stocked and stored securely.

13 In Level 3.7Y programs, a psychiatrist or advanced practice provider with specialty certification in
14 psychiatry (eg, psychiatric NP) and adolescent treatment experience should be available on- site or
15 via telemedicine within 24 hours to provide medical management of psychiatric conditions,
16 respond to psychiatric emergencies, and titrate psychiatric medications as needed.

17 ---

18 * Per program protocol, which should be developed, approved, and regularly reviewed by the medical director.

19 Biomedical Capabilities

20 Level 3.7Y programs should have access to the following biomedical capabilities on- site:

- 21 • vitals measurement and monitoring, including pulse oximetry and blood pressure;
- 22 • glucose monitoring;
- 23 • basic first aid;
- 24 • bottle oxygen;
- 25 • an AED;
- 26 • ECG with a 3- lead rhythm strip at minimum*;
- 27 • basic wound care;
- 28 • mobility assistance;
- 29 • injectable epinephrine;
- 30 • overdose reversal medication (eg, naloxone);
- 31 • injectable medications (eg, injectable buprenorphine, extended- release naltrexone);
- 32 • vaccine administration† (eg, hepatitis A and B viruses, influenza, COVID- 19, HPV);
- 33 • point-of-care pregnancy testing;
- 34 • laboratory and phlebotomy services, including:
 - 35 ○ access to laboratory services five days per week, and
 - 36 ○ access to blood culture services; and
 - 37 ○ drug testing and toxicology services.‡

1 ---

2 *The rationale for ECG capacity is to determine the level of risk and need for Level 4Y care, not for diagnosis or disease
3 management. It is also important for monitoring for QTc prolongation in patients on methadone.

4 † Vaccines should be available on- site in Level 3.7Y programs but may be provided through established relationships
5 with external partners.

6 ‡ Please see ASAM's Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.

7 *Clinical Services*

8 Level 3.7Y programs provide at least 20 hours of clinical services per week comprised of both
9 medical and psychosocial services. Structured psychosocial services selected by master's level
10 clinical staff should be available seven days per week either directly or through formal affiliation.

11 Services should be provided in an amount, frequency, and intensity appropriate to individual
12 patient and family needs and level of function as determined by The ASAM Criteria
13 multidimensional assessment. Level 3.7Y programs should be able to provide transportation as
14 needed for clinical services (eg, specialty healthcare services) that are not available on-site.

15 *Psychosocial Services*

16 The psychosocial and family services delivered should be individualized based on the patient and
17 family's assessment. Patients should be excused from participating in psychoeducation,
18 psychotherapy, and RSS if acute withdrawal or biomedical, psychiatric, or cognitive conditions
19 prevent effective participation.

20 If psychosocial services are provided through formally affiliated providers and programs, daily
21 check-ins should occur regarding the care of each patient.

22 **Level 4Y Standards**

23 **Level 4Y Description**

24 Level 4Y programs provide medically managed inpatient services for patients whose acute
25 intoxication; withdrawal; and biomedical, psychiatric, and/or cognitive conditions are so severe
26 that they require 24-hour medically directed evaluation and treatment in an acute care hospital.
27 Because Level 4Y programs provide the most intensive services in the continuum of care, its
28 principal focus is stabilization of the patient and preparation for their transition to a less intensive
29 setting for continuing care.

30 **Level 4Y Setting**

31 Level 4Y services may be offered in any appropriate acute care treatment setting with 24-hour
32 nursing staff and physician oversight that meets state licensure or certification criteria. Level 4Y
33 treatment typically occurs in two types of settings:

- 34 • acute care general hospitals (Level 4Y General Hospital), or
- 35 • addiction treatment units within acute care general hospitals with critical care services
36 available on premises (Level 4Y Addiction Specialty Unit).

1 Level 4Y General Hospital

2 Level 4Y Staff

3 Level 4Y General Hospitals are staffed by an interdisciplinary team of appropriately trained and
4 supervised professionals acting within their state-regulated scopes of practice,* including:

- 5 • physicians with controlled substance prescribing authority†;
- 6 • nurses with the necessary scope of practice to support the delivery of services provided in
7 Level 4Y General Hospitals; and
- 8 • clinical staff, such as psychologists, clinical social workers, SUD and mental health
9 counselors, and others trained to assess and treat SUD and/or co-occurring mental health
10 conditions with the necessary scopes of practice to support the delivery of services
11 provided in Level 4Y General Hospitals.

12 Level 4Y General Hospitals are encouraged to employ allied health staff, such as certified peer
13 support specialists, patient navigators, health educators, and counselor aides who support
14 ongoing engagement in addiction treatment, deliver RSS, and provide warm handoffs to less
15 intensive levels of care.

16 Advanced practice providers may collaborate with physicians at this level of care. At least one
17 prescriber authorized to prescribe buprenorphine should be available on-site or via telemedicine
18 24 hours a day.

19 ---

20 * Please see Appendix D for additional information on recommended staff competencies.

21 † Including authorization to prescribe buprenorphine.

22 *Medical Staff*

23 Physicians and Advanced Practice Providers

24 In Level 4Y General Hospitals, physicians and advanced practice providers with controlled
25 substance prescribing authority† should be available on- site or via telemedicine as active
26 members of the care team 24 hours a day.

27 Physicians and advanced practice providers should determine if and when a patient should be
28 transitioned to an intensive care unit (ICU) or relevant specialty unit.

29 ____

30 † Including authorization to prescribe buprenorphine.

31

32 Addiction Specialist Physicians

33 Level 4Y General Hospitals are encouraged to establish evidence- based addiction medicine
34 consultation teams that have expertise in addiction medicine to address complex addiction
35 treatment needs and facilitate appropriate referrals when transitioning patients from hospital care.

1 Written protocols related to the treatment of intoxication, withdrawal, and SUD should be reviewed
2 by a physician who is board certified in addiction medicine or addiction psychiatry and has at least
3 2 years of experience treating adolescent patients.

4 **Nursing and Medical Support Staff**

5 RNs or other appropriately licensed and credentialed nurses (eg, LPNs) should be available 24
6 hours a day. A nursing supervisor should be available 24/7 to respond to urgent situations.

7 *Clinical Staff*

8 Level 4Y General Hospitals should have appropriately trained clinical staff available daily. Clinical
9 staff with the appropriate training and scopes of practice should provide case management
10 services according to the assessed needs of the patient and family.

11 Level 4Y General Hospitals do not typically have a program director.

12 *Allied Health Staff*

13 Level 4Y General Hospitals may have allied health staff and are encouraged to provide the following
14 services for patients and families:

- 15 • peer support services;
- 16 • health education services, such as overdose prevention and reversal training;
- 17 • family education services;
- 18 • patient navigation services; and
- 19 • transition support.

20 **Level 4Y Support Systems**

21 Support systems in Level 4Y General Hospitals include a full range of acute care services, specialty
22 consultation, and ICU services. Support system requirements are established by hospital
23 accreditation organizations and typically include the following of relevance to the management of
24 SUD and co-occurring conditions:

- 25 • psychiatric assessment available within a time frame appropriate to the severity and
26 urgency of the need;
- 27 • laboratory and phlebotomy services available on- site; and
- 28 • drug testing and toxicology services,* including the ability to conduct:
 - 29 ○ laboratory-based immunoassay testing for common substances and substance
 - 30 metabolites available onsite, and
 - 31 ○ confirmatory testing for specialty metabolites available on-site or through
 - 32 established relationship with an external laboratory.

33 To support patient engagement in ongoing addiction treatment, Level 4Y General Hospitals are
34 encouraged to have established relationships with less intensive levels of adolescent addiction
35 and psychiatric treatment to support care coordination and effective transitions in care. Important
36 examples include but are not limited to:

- 1 • addiction medication providers (eg, methadone treatment programs, physicians and
2 advanced practice providers with controlled substance prescribing authority†) to confirm
3 doses and support effective engagement in ongoing addiction treatment upon transition
4 from the Level 4Y program,
- 5 • Level 3.7Y programs to support step-down to medically managed residential treatment, and
6 • Level 2.5Y and 3.5Y programs to support step- down to clinically managed high-intensity
7 addiction treatment.
- 8 • CALOCUS-CASII Levels 4 (Medically Monitored Community Based Services) and 5
9 (Medically Monitored Intensive Integrated Services to support step- down to clinically
10 managed high-intensity mental health treatment.

11 ---

12 * Please see ASAM's Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.
13 † Including authorization to prescribe buprenorphine.

14 Level 4Y Assessment and Treatment Planning

15 The Treatment Planning Assessment in Level 4Y General Hospitals involves a history and physical
16 examination performed within 24 hours of admission.

17 Although Level 4Y is specifically designed for acute issues in Dimensions 1, 2, and 3, it is also
18 important to assess any treatment priorities in Dimensions 4 through 6. The results of all
19 biopsychosocial screening and assessments should be clearly communicated to the patient's next
20 level of care, ideally through a direct conversation between clinicians and written documentation
21 of assessment results and treatment plans (with appropriate patient and family assent/consent as
22 required).

23 In Level 4Y General Hospitals, the treatment plan should reflect:

- 24 • case management conducted by on- site staff;
- 25 • coordination with the family; and
- 26 • coordination of addiction treatment, biomedical care (eg, obstetrics and gynecology,
27 infectious diseases), and mental health care.

28 Level 4Y Services

29 *Medical Services*

30 Level 4Y General Hospitals should have the following medical services available:

- 31 • full medical acute care services, including:
 - 32 ○ medical histories and physical examinations,
 - 33 ○ prescribing and medication management, and
 - 34 ○ diagnostic assessments;
- 35 • ICU services as needed;
- 36 • psychiatric services;

- 1 • nursing assessments conducted at admission and regular intervals throughout the episode
- 2 of care; and hourly or more frequent nurse monitoring of patient progress and medication
- 3 administration as needed; and
- 4 • laboratory, drug testing, and toxicology services, with medical staff with the training and
- 5 experience to appropriately interpret the results.

6 Level 4Y General Hospitals should be able to support initiation, titration, and continuation of
7 addiction medications* in alignment with current best practices.

8 Level 4Y pharmacy services should include all FDA approved treatments for SUDs on their
9 formularies, including methadone, buprenorphine, and naltrexone, as well as medications for AUD
10 and TUD. Programs should have protocols that address care coordination with prescribers in the
11 community.

12 Level 4Y General Hospitals should deliver individualized management of all acute biomedical,
13 psychiatric, and cognitive conditions with an interdisciplinary treatment team.

14 ---

15 * Including all FDA- approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
16 label medications for other SUDs, including StUD and CUD; and medications to manage post- acute withdrawal
17 symptoms.

18 **Biomedical Capabilities**

19 Level 4Y General Hospitals should have access to the full biomedical capabilities available in an
20 acute care hospital setting.

21 **Clinical Services**

22 Level 4Y General Hospitals directly provide:

- 23 • daily clinical services delivered by an interdisciplinary treatment team to assess and
- 24 address each patient's individual needs, including:
 - 25 ○ nursing services;
 - 26 ○ medical services, including access to critical care services as needed;
 - 27 ○ psychiatric services; and
 - 28 ○ social work and/or case management services;
- 29 • integrated care delivery, including:
 - 30 ○ coordination between relevant specialty units within the hospital, and
 - 31 ○ care coordination with external providers involved in the patient's care; and
- 32 • management of transition to other levels of care.

33 **Care Coordination**

34 Level 4Y General Hospitals should ideally coordinate care with any external addiction or mental
35 health care providers involved in the patient's care (with appropriate patient and family
36 assent/consent) at admission to and transition from the Level 4Y General Hospital and as needed
37 to support effective care coordination for the individual patient.

1 For patients with severe comorbid biomedical and/ or psychiatric disorders, biomedical and/or
2 psychiatric interventions, respectively, should ideally be coordinated with intoxication, withdrawal,
3 and/or addiction treatment services.

4 Level 4Y General Hospitals should coordinate patient referrals and transitions to other levels of
5 care, including warm handoffs, through care coordination and data sharing as appropriate.

6 **Psychosocial Services**

7 Level 4Y General Hospitals should provide basic psychosocial services including:

- 8 • interventions designed to enhance the patient and family’s understanding of addiction and
9 co-occurring mental health concerns, completion of treatment at Level 4Y, and
10 engagement in appropriate levels of care for continuing treatment; and
- 11 • patient and family education on withdrawal management, harm reduction (eg, opioid
12 overdose reversal training), and addiction treatment.

13 *Recovery Support Services*

14 Level 4Y General Hospitals should ideally provide peer support services for patients and families to
15 facilitate engagement in ongoing care including:

- 16 • support for engagement in a less intensive level of care;
- 17 • transition planning, including warm handoffs;
- 18 • harm reduction (eg, naloxone training and access);
- 19 • connection to appropriate community resources; and
- 20 • support accessing services for domestic violence or (DV) intimate partner violence (IPV)
21 through established relationships with DV and IPV violence service providers.

22 **Level 4Y Documentation**

23 Core documentation in Level 4Y General Hospitals should include:

- 24 • scoring for withdrawal rating scale tables and flow sheets (which may include tabulation of
25 vital signs) as needed;
- 26 • standardized addiction screening and assessment results;
- 27 • standardized mental health screening and assessment results; and
- 28 • a transition plan that ideally addresses:
 - 29 ○ a review of the six dimensions of The ASAM Criteria,
 - 30 ○ recommendations for follow-up care,
 - 31 ○ reason(s) for departures from recommendations (if applicable),
 - 32 ○ program and level of care that the patient will transition to,
 - 33 ○ required medications and how patients will maintain access to medications during
34 the transition, and
 - 35 ○ a follow-up plan to support ongoing engagement in care and documentation of
36 follow- ups.

1 Level 4Y Addiction Specialty Unit

2 Level 4Y Specialty Staff

3 Level 4Y Addiction Specialty Unit programs are staffed by an interdisciplinary team of appropriately
4 trained and supervised professionals acting within their state-regulated scopes of practice,*
5 including:

- 6 • a medical director;
- 7 • physicians with controlled substance prescribing authority†;
- 8 • nurses with the necessary scope of practice to support the delivery of services provided in
9 Level 4Y Addiction Specialty Unit programs;
- 10 • clinical staff, such as psychologists, clinical social workers, SUD and mental health
11 counselors, and others trained to assess and treat adolescent SUD and/or co-occurring
12 mental health conditions with the necessary scopes of practice to support the delivery of
13 services provided in Level 4Y Addiction Specialty Unit programs; and
- 14 • allied health staff, such as certified peer support specialists, patient navigators, health
15 educators, counselor aides, and group living workers who support ongoing engagement in
16 addiction treatment, deliver RSS, and provide warm handoffs to less intensive levels of
17 care.

18 Advanced practice providers may support physicians at this level of care. At least one prescriber
19 authorized to prescribe buprenorphine should be available on-site or via telemedicine 24 hours a
20 day.

21 ---

22 * Please see Appendix D for additional information on recommended staff competencies.

23 † Including authorization to prescribe buprenorphine.

24 Level 4Y Specialty Support Systems

25 Support systems in Level 4Y Addiction Specialty Unit programs include a full range of acute care
26 services, specialty consultation, and ICU services. Support system requirements are established
27 by hospital accreditation organizations and typically include the following of relevance to the
28 management of SUD and co-occurring conditions:

- 29 • psychiatric assessment available within a time frame appropriate to the severity and
30 urgency of the need;
- 31 • laboratory and phlebotomy services available on-site; and
- 32 • drug testing and toxicology services,* including the ability to conduct:
 - 33 ○ laboratory-based immunoassay testing for common substances and substance
34 metabolites available onsite, and
 - 35 ○ confirmatory testing for specialty metabolites available on-site or through
36 established relationship with an external laboratory.

1 To support patient engagement in ongoing addiction treatment, Level 4Y Addiction Specialty Unit
2 programs should have formal affiliations with less intensive levels of addiction treatment to
3 support care coordination and effective transitions in care. Important examples include but are not
4 limited to:

- 5 • addiction medication providers (eg, methadone treatment programs, physicians and
6 advanced practice providers with controlled substance prescribing authority†) to confirm
7 doses and support effective engagement in ongoing addiction treatment upon transition
8 from the Level 4Y program,
- 9 • Level 3.7Y and 3.7 BIO programs to support step-down to medically managed residential
10 treatment, and
- 11 • Level 2.5Y and 3.5Y programs to support step-down to clinically managed high-intensity
12 addiction treatment.
- 13 • CALOCUS-CASII Levels 4 (Medically Monitored Community Based Services) and 5
14 (Medically Monitored Intensive Integrated Services to support step- down to clinically
15 managed high-intensity mental health treatment.

16 ---

17 * Please see ASAM's Appropriate Use of Drug Testing in Clinical Addiction Medicine consensus statement for guidance.

18 † Including authorization to prescribe buprenorphine.

19 Level 4Y Specialty Assessment and Treatment Planning

20 The Treatment Planning Assessment in Level 4Y Addiction Specialty Unit programs involves a
21 history and physical examination performed within 24 hours of admission.

22 Although Level 4Y is specifically designed for acute issues in Dimensions 1, 2, and 3, it is also
23 important to assess any treatment priorities identified in Dimensions 4 through 6. The results of all
24 biopsychosocial screening and assessments should be clearly communicated to the patient's next
25 level of care, ideally through a direct conversation between clinicians and written documentation
26 of assessment results and treatment plans (with appropriate patient consent as required).

27 In Level 4Y Addiction Specialty Unit programs, individualized treatment plans should include:

- 28 • problem identification in each applicable dimension,
- 29 • defined treatment goals and measurable treatment objectives related to the Dimensional
30 Drivers of admission to Level 4Y Addiction Specialty Unit care, and
- 31 • activities designed to meet those objectives.

32 The treatment plan should be developed in collaboration with the patient and their family, reflect
33 the patient and family goals, and incorporate the patient and family's strengths. The treatment plan
34 should also:

- 35 • reflect case management conducted by on-site staff;

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • reflect coordination of addiction treatment, biomedical care (eg, obstetrics and gynecology,
- 2 infectious diseases), psychiatric care, and RSS needs to address problems identified
- 3 through the comprehensive biopsychosocial assessment as needed;
- 4 • reflect coordination of care with external treatment and service providers;
- 5 • incorporate family services;
- 6 • reflect coordination with the family; and
- 7 • address any mental health treatment needs identified, including:
- 8 ○ services delivered by the program’s treatment team, and
- 9 ○ services delivered by external providers.

10 For patients who are from another region or state, transitions should be coordinated to appropriate

11 care in their local communities.

12 Level 4Y Specialty Services

13 *Medical Services*

14 Level 4Y Addiction Specialty Unit programs should have the following medical and nursing services

15 available:

- 16 • full medical acute care services, including:
- 17 ○ medical histories and physical examinations,
- 18 ○ prescribing and medication management, and
- 19 ○ diagnostic assessments;
- 20 • ICU services as needed;
- 21 • psychiatric services;
- 22 • nursing assessments conducted at admission and regular intervals throughout the episode
- 23 of care; and
- 24 • hourly or more frequent nurse monitoring of patient progress and medication administration
- 25 as needed.

26 Level 4Y Addiction Specialty Unit programs should be able to support initiation, titration, and

27 continuation of addiction and psychiatric medications* in alignment with current best practices.

28 Level 4Y pharmacy services should include all FDA-approved treatments for SUDs on their

29 formularies, including methadone, buprenorphine, and naltrexone, as well as medications for AUD

30 and TUD. Programs should have protocols that address care coordination with prescribers in the

31 community.

32 Level 4Y Addiction Specialty Unit programs should deliver individualized management of all acute

33 biomedical, psychiatric, and cognitive conditions with an interdisciplinary treatment team.

34 ---

35 * Including all FDA-approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-

36 label medications for other SUDs, including StUD and CUD; and medications to manage post-acute withdrawal

37 symptoms.

1 **Biomedical Capabilities**

2 Level 4Y Addiction Specialty Unit programs should have access to the full biomedical capabilities
3 available in an acute care hospital setting.

4 *Clinical Services*

5 Level 4Y Addiction Specialty Unit programs directly provide:

- 6 • daily clinical services delivered by an interdisciplinary treatment team to assess and
7 address each patient and family’s needs, including:
 - 8 ○ nursing services;
 - 9 ○ medical services, including access to critical care services as needed;
 - 10 ○ psychiatric services;
 - 11 ○ social work and/or case management services;
 - 12 ○ psychosocial services, including family services;
 - 13 ○ health education; and
 - 14 ○ services integrating family and significant others;
- 15 • integrated care delivery, including:
 - 16 ○ coordination between relevant specialty units within the hospital, and
 - 17 ○ care coordination with external providers involved in the patient’s care; and
- 18 • management of transition to other levels of care.

19 *Care Coordination*

20 Level 4Y Addiction Specialty Unit programs should coordinate care with any external mental health
21 care providers and any other external providers involved in the patient’s care (with appropriate
22 patient and family assent/consent) at admission to and transition from the Level 4Y Addiction
23 Specialty Unit program and as needed to support effective care coordination for the individual
24 patient.

25 For patients with severe comorbid biomedical and/ or psychiatric disorders, biomedical and/or
26 psychiatric interventions, respectively, should be coordinated with intoxication, withdrawal, and/or
27 addiction treatment services.

28 Programs should coordinate patient referrals and transitions to other levels of care, including warm
29 handoffs, through care coordination and data sharing as appropriate.

30 *Psychosocial Services*

31 Level 4Y Addiction Specialty Unit programs should have psychosocial services available at least 8
32 hours per day, with services including:

- 33 • interventions designed to enhance the patient and family’s understanding of addiction,
34 completion of treatment at Level 4Y, and engagement in appropriate levels of care for
35 continuing treatment;
- 36 • patient and family education on withdrawal management, addiction treatment, and the role
37 of family-systems in adolescent recovery; and
- 38 • coordination of engagement in psychosocial and recovery support services.

1 Many patients in Level 4Y programs may not be ready to fully engage in psychosocial support
2 services while acute problems in Dimensions 1, 2, or 3 are being stabilized. However, once
3 stabilized, patients should be engaged in psychosocial treatment services.

4 **Level 4Y Psychiatric**

5 **Level 4Y Psych Setting**

6 The program's services should be designed to provide a welcoming environment for individuals
7 with mental health disorders co- occurring SUDs, where patients feel safe addressing their SUD-
8 related concerns and experiences along with their mental health-related concerns.

9 **Level 4Y Psych Staff**

10 All clinical and allied health staff in Level 4Y Psychiatric programs should be trained to support
11 individuals with SUDs and their families. At least one clinical staff member who is qualified by
12 training and licensure to assess and treat SUDs should be available on-site or via telemedicine.

13 Level 4Y Psychiatric programs should also have physicians or advanced practice providers with
14 controlled substance prescribing authority.*

15 ---

16 * Including authorization to prescribe buprenorphine.

17 **Level 4Y Psych Support Systems**

18 Level 4Y Psychiatric programs should have established relationships with more and less intensive
19 levels of care, including both COE and standard (ie, co-occurring capable) addiction treatment
20 providers and programs, to:

- 21 • support access to specialty addiction assessment and consultation, and
- 22 • facilitate coordinated transitions in care.

23 Programs should also have established relationships with community physicians and/or advanced
24 practice providers who prescribe addiction medications* and have controlled substance
25 prescribing authority.†

26 ---

27 * Including all FDA- approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
28 label medications for other SUDs, including StUD and CUD; and medications to manage post- acute withdrawal
29 symptoms.

30 † Including authorization to prescribe buprenorphine.

31 **Level 4Y Psych Assessment and Treatment Planning**

32 Initial assessment in Level 4Y Psychiatric programs includes:

- 1 • an integrated mental health and addiction history conducted or reviewed by a physician or
- 2 advanced practice provider,
- 3 • a nursing assessment screening for and assessing intoxication and withdrawal risks and
- 4 addiction treatment needs, and
- 5 • a physical examination conducted by a physician or advanced practice provider within 24
- 6 hours of admission.

7 Treatment plans should address any addiction treatment needs identified, including:

- 8 • services delivered by the program’s treatment team, and
- 9 • services delivered by external providers.

10 Transition plans should address continuity of care for both SUDs and co- occurring mental health

11 conditions.

12 Level 4Y Psych Services

13 *Medical Services*

14 Level 4Y Psychiatric programs should be able to provide the equivalent of Level 3.7Y intoxication,

15 withdrawal management, and addiction treatment services, including:

- 16 • nursing and medical monitoring for stabilization of acute withdrawal and biomedical and
- 17 psychiatric conditions;
- 18 • psychosocial services for patients and families to encourage engagement in ongoing
- 19 treatment;
- 20 • hourly nurse monitoring of the patient’s progress and medication administration;
- 21 • medical monitoring and management of signs and symptoms of intoxication and
- 22 withdrawal;
- 23 • assessment with standardized scales (eg, CIWA-Ar, COWS, Richmond Agitation- Sedation
- 24 Scale [RASS]) to determine the severity of withdrawal when appropriate;
- 25 • pharmacological methods of withdrawal management that are appropriate for the severity
- 26 of withdrawal or anticipated withdrawal;
- 27 • nonpharmacological methods of withdrawal management when indicated, including but
- 28 not limited to:
 - 29 ○ informing patients and families of what to expect over the course of treatment,
 - 30 ○ offering reassurance,
 - 31 ○ providing a quiet environment, and
 - 32 ○ educating patients and families on the importance of adequate hydration and
 - 33 nutrition; and
- 34 • biomedical capabilities equivalent to a Level 3.7Y program.

35 Level 4 Psychiatric programs should be able to support initiation, titration, and continuation of

36 addiction medications* in alignment with current best practices.

37 Patient education should be provided regarding available FDA- approved medications, including

38 those currently available to treat OUD, AUD, and TUD.

1 ---

2 * Including all FDA- approved medications for OUD (including methadone, unless unavailable locally), AUD, and TUD; off-
3 label medications for other SUDs, including StUD and CUD; and medications to manage post- acute withdrawal
4 symptoms.

5 *Clinical Services*

6 Level 4Y Psychiatric services should be designed with the expectation that many patients will have
7 co-occurring substance use- related problems; individual and group interventions should
8 encourage patients and families to address both mental health- related concerns and SUD- related
9 concerns. Programs should support patients and families with the management of SUD- related
10 symptoms, and patients' SUDs should be addressed concurrently by the program or through
11 coordination with external providers as needed.

12 Programs should coordinate care with any external addiction and mental health care providers
13 involved in the patient's care (with appropriate patient and family assent/ consent) at admission,
14 discharge, and as needed to support effective care coordination for the individual patient and
15 family.

16 The clinical services provided by Level 4Y Psychiatric programs should include individual and group
17 interventions for SUD and mental health and family therapy, with interventions designed to
18 address:

- 19
- 20 • how to manage mental health symptoms and trauma without using substances;
 - 21 • how to discuss SUD, SUD symptoms, and addiction treatments— including medications—
22 appropriately in the context of mental health treatment and RSS;
 - 23 • motivation for change related to mental health and SUD concerns; and
 - 24 • how to discuss improve interpersonal communications related to SUD and mental health
concerns and ask for support when needed.

25 Patients should be excused from participating in psychotherapy, psychoeducation, and RSS if
26 acute psychiatric, withdrawal, or biomedical conditions prevent effective participation.

27 Level 4Y Psychiatric programs should be able to admit individuals currently receiving opioid agonist
28 medications for OUD (eg, methadone, buprenorphine) who require psychiatric inpatient care.

29

30

31

32

33

34

35

1 Appendix A. Adolescent and Transition Aged Youth

2 Volume Draft Outline

3 Front Matter

4 Section I: Introduction

- 5 1. Introduction
- 6 2. Methodology
- 7 3. How to Use The ASAM Criteria

8 Section II: Continuum of Care

- 9 4. Continuum Overview Chapter
- 10 5. Outpatient
- 11 6. Residential
- 12 7. Medically Managed Care

13 Section III: Assessment and Treatment Planning

- 14 8. Assessment
- 15 9. Treatment Planning
- 16 10. Dimensional Admission Criteria and Algorithm

17 Section IV: Implementation Considerations and Comprehensive Care

- 18 11. Prevention and Early Intervention
- 19 12. Co-Occurring Care
- 20 13. Coordination Across Systems of Care
- 21 14. Utilization Management
- 22 15. Recovery Support Services
- 23 16. Trauma/Culture/SDOH

24 Section V: Population Considerations

- 25 17. Transition-aged Youth
- 26 18. Pregnancy & Parenting

27 Appendices

28 Back Matter

29

30

1 **Appendix B. ASAM Criteria/CALOCUS-CASII Levels of**
 2 **Care Crosswalk**

ASAM Level of Care	CALOCUS-CASII	Comments
Prevention Services, previous ASAM Criteria Level 0.5.	Level 0: Basic Services: Prevention and Health Maintenance	Treatment as prevention is now incorporated into <i>The ASAM Criteria</i> Level 1.5Y and 2.1Y.
Level 1.0Y Long term remission monitoring	Level 1: Recovery Maintenance and Health Management	<i>The ASAM Criteria</i> Level 1.0Y is a new level that was introduced in the Fourth Edition; includes a minimum of quarterly recovery management check-ups to support rapid reengagement in care when needed.
Level 1.5Y: Outpatient	Level 2: Low Intensity Community-based services	Less than 6 hours per week of clinical services
Level 2.1Y: Intensive Outpatient and Home-based	Level 3: High Intensity Community-based services	Clinical services at least 3 days per week
Level 2.5Y: Intensive Outpatient and Home-based	Level 4: Medically Monitored Community Based Services: Intensive Integrated Services without 24 hr Psychiatric Monitoring	Daily or near daily clinical services.
Level 3.5Y: Residential	Level 5: Medically Monitored Intensive Integrated Services: Non-secure, 24-hour service with psychiatric monitoring	CALOCUS-CASII Level 5 does not need to be delivered in a residential setting. It provides 24-hour services, including mobile crisis response. <i>The ASAM Criteria</i> Level 3 is a residential level of care.
Level 4Y Psych: Inpatient Psychiatric	Level 6: Medically Managed Secure, Integrated Intensive Services: Secure, 24-hour Services with Psychiatric Management	Psychiatric hospital or secure psychiatric unit within a general hospital.

3

4

1 **Appendix C. ASAM Criteria/CALOCUS-CASII Assessment**
 2 **Dimensions Crosswalk**

<i>The ASAM Criteria</i> Dimensions and Subdimensions	CALOCUS-CASII Dimensions
ASAM Criteria Dimension 1 - Intoxication, Withdrawal, and Addiction Medications	
Intoxication and related risks	CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
Withdrawal and related risks	CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
Addiction medication needs	CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
ASAM Criteria Dimension 2 - Biomedical Conditions	
Physical health concerns	CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
Pregnancy-related concerns	CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
Sleep problems	CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
<i>The ASAM Criteria</i> Dimension 3 - Psychiatric and Cognitive Conditions	
Active psychiatric symptoms	CALOCUS-CASII Dimension 1 – Risk of Harm CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
Intellectual and Developmental Concerns	CALOCUS-CASII Dimension 2 - Functional Status CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions
Trauma-related needs	CALOCUS-CASII Dimension 1 – Risk of Harm CALOCUS-CASII Dimension 3 – Co-occurrence of Conditions

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

	CALOCUS-CASII Dimension 4 – Recovery Environment (environmental stress sub-scale)
Psychiatric and Cognitive History	CALOCUS-CASII Dimension 5 – Resiliency and Response to Services
<i>The ASAM Criteria</i> Dimension 4 - Substance-Use Related Risks	
Likelihood of engaging in risky substance use	CALOCUS-CASII Dimension 1 – Risk of Harm CALOCUS-CASII Dimension 5 – Resiliency and Response to Services
Likelihood of engaging in risky SUD- related behaviors	CALOCUS-CASII Dimension 1 – Risk of Harm CALOCUS-CASII Dimension 5 – Resiliency and Response to Services
<i>The ASAM Criteria</i> Dimension 5 - Recovery Environment Interactions	
Ability to function effectively in current environment	CALOCUS-CASII Dimension 2 – Functional Status CALOCUS-CASII Dimension 5 – Resiliency and Response to Services
Safety in current environment	CALOCUS-CASII Dimension 1 – Risk of Harm CALOCUS-CASII Dimension 4 – Recovery Environment (environmental stress sub-scale)
Support in current environment	CALOCUS-CASII Dimension 4 – Recovery Environment (environmental support sub-scale) CALOCUS-CASII Dimension 6 – Engagement in Services (parental engagement)
Cultural perceptions of substance use and addiction	CALOCUS-CASII Dimension 4 – Recovery Environment CALOCUS-CASII Dimension 6 – Engagement in Services
Educational Needs	CALOCUS-CASII Dimension 2 – Functional Status CALOCUS-CASII Dimension 4 – Recovery Environment (environmental stress sub-scale)
<i>The ASAM Criteria</i> Dimension 6 - Person-Centered Considerations	

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

Barriers to care	CALOCUS-CASII Dimension 6 – Engagement in Services (Child or Adolescent Engagement and Parental and/or Primary Caretaker Engagement sub-scales)
Patient needs and preferences	CALOCUS-CASII Dimension 6 – Engagement in Services (Child or Adolescent Engagement and Parental and/or Primary Caretaker Engagement sub-scales)
Family and support system preferences	CALOCUS-CASII Dimension 6 – Engagement in Services (Child or Adolescent Engagement and Parental and/or Primary Caretaker Engagement sub-scales)
Need for motivational enhancement services	CALOCUS-CASII Dimension 6 – Engagement in Services (Child or Adolescent Engagement and Parental and/or Primary Caretaker Engagement sub-scales)

- 1
- 2
- 3
- 4
- 5

Appendix D. Recommended Staff Competencies

The following represent recommended staff competencies to support delivery of care in alignment with *The ASAM Criteria* standards. In developing these competencies, the Editorial Team sought to align with the following existing national competencies:

- American Board of Psychiatry and Neurology Child and Adolescent Psychiatry Core Competencies Outline. American Board of Psychiatry and Neurology Child and Adolescent Psychiatry, 2011. Accessed September 4, 2024. https://www.abpn.org/wp-content/uploads/2015/02/2011_core_CAP_MREE.pdf
- Mental Health Competencies for Pediatric Practice. American Academy of Pediatrics. 2019. Accessed September 4, 2024. *Pediatrics* (2019) 144 (5): e20192757.
- American Board of Addiction Medicine. Core Competencies for Addiction Medicine, Version 2. The American Board of Addiction Medicine Foundation, Inc; 2012. Accessed April 22, 2023. <https://acaam.memberclicks.net/assets/docs/Core-Competencies-for-Addiction-Medicine.pdf>
- Center for Substance Abuse Treatment. Addiction Counseling Competencies: The Knowledge, Skills, and Attitudes of Professional Practice. Technical Assistance Publication (TAP) Series 21. HHS Publication No. (SMA) 15-4171. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006. Accessed January 27, 2021. <https://store.samhsa.gov/sites/default/files/d7/priv/sma12-4171.pdf>
- Hoge MA, Morris JA, Laraia M, Pomerantz A, Farley T. Core Competencies for Integrated Behavioral Health and Primary Care. Washington, DC: SAMHSA-HRSA Center for Integrated Health Solutions; 2014. Accessed January 27, 2021. <http://womenshealthcouncil.org/wp-content/uploads/2016/11/WF-Core-Competencies-for-Integrated-Behavioral-Health-and-Primary-Care.pdf>
- Substance Abuse and Mental Health Services Administration. Core Competencies for Peer Workers in Behavioral Health Services. Bringing Recovery Supports to Scale Technical Assistance Center Strategy (BRSS TACS). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015. Accessed January 27, 2021. https://www.samhsa.gov/sites/default/files/programs_campaigns/brss_tacs/core-competencies_508_12_13_18.pdf
- Wason, K, Potter, A, Alves, J, et al. Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse. *J Nurs Adm.* 2021;51(9):424-429.
doi:10.1097/NNA.0000000000001041

These recommendations are not meant to replace existing competency frameworks but to highlight areas of importance for implementing The ASAM Criteria standards.

1 **Professional and Allied Health Staff**

2 All professional (ie, medical and clinical staff) and allied health staff should have a basic
3 understanding of *The ASAM Criteria*, including:

- 4 • Multidimensional factors that contribute to *The ASAM Criteria* level of care
- 5 recommendations and treatment needs
- 6 • The continuum of care
- 7 • Principles of The ASAM Criteria

8 All professional and allied health staff should also have a basic understanding of addiction, SUD,
9 and related health conditions in adolescents and transition age youth that includes:

- 10 • The prevalence and demography of SUD in these populations
- 11 • The genetic and biological basis of addiction
- 12 • The principles of early intervention and prevention
- 13 • Developmental considerations that interact with adolescent substance use
- 14 • Signs and symptoms of intoxication, withdrawal, and SUDs
- 15 • Common biomedical and psychiatric comorbidities in these populations
- 16 • Addiction treatment options and their efficacies in adolescents and transition age youth,
17 including:
 - 18 ○ Addiction medications, including medications* for opioid use disorder (OUD),
19 alcohol use disorder (AUD), and tobacco use disorder (TUD); off-label
20 medications for other SUDs, including stimulant use disorder (StUD) and
21 cannabis use disorder (CUD); medications to manage post-acute withdrawal
22 symptoms
 - 23 ○ Psychosocial interventions
- 24 • Evidence supporting concurrent treatment for TUD and other SUDs
- 25 • The importance of recovery support services (RSS)
- 26 • The importance of diverse systems of care, including educational and other social service
27 systems that can help support full wraparound services for adolescents
- 28 • Harm reduction approaches

29
30 ---

31 * Including FDA-approved medications and off-label use of evidence-based medications that have not been FDA-
32 approved for use in adolescents and competency discussing boxed label warnings.

33 All professional and allied health staff should have the competency to:

- 34 • Provide patient-centered, whole-person care

- 1 • Facilitate shared decision-making with the patient and family
- 2 • Listen to and communicate effectively with adolescents and transition age youth
- 3 • Incorporate developmental considerations in the care provided to adolescents and
- 4 transition-aged youth
- 5 • Engage the patient’s family in their treatment, including providing family with education
- 6 on addiction, SUD, and evidence-based treatments
- 7 • Communicate in a developmentally appropriate manner with patients and their families
- 8 and support persons (with appropriate patient consent), as well as other professionals
- 9 and staff with empathy, respect, compassion, and understanding, including awareness of
- 10 stigmatizing language
- 11 • Be aware of available treatment and RSS resources for the patient and family
- 12 • Collaborate effectively with multidisciplinary and interdisciplinary care teams
- 13 • Advocate for patient and family needs across diverse systems of care as appropriate to
- 14 scope of practice
- 15 • Apply behavior management techniques appropriately, including de-escalation and
- 16 conflict resolution
- 17 • Manage violent and threatening behaviors
- 18 • Respond to urgent biomedical and psychiatric situations, including those that occur on-
- 19 site
- 20 • Administer overdose medications (eg, naloxone) and basic life support (BLS), including
- 21 CPR
- 22 • Recognize when to consult the chain of command and know how to contact supervisors
- 23 • Respond to requests from patients or families to change treating providers
- 24 • Document services provided consistent with clinical and regulatory standards, relevant
- 25 medical necessity requirements, and awareness of utilization management (UM) needs
- 26 • Use electronic health records (EHRs) and other health technologies used by the program
- 27 • Understand and follow state and federal privacy and confidentiality laws and regulations
- 28 • Be aware of ethical considerations for providing addiction treatment and related services

29 As part of the provision of patient-centered, whole-person care, all professional and allied health
30 staff should be able to:

- 31 • Contribute to a welcoming, respectful, and nonjudgmental culture in all aspects of their
- 32 work
- 33 • Recognize developmental considerations specific to adolescence and transition age
- 34 youth, including understanding of the signs and symptoms of neurocognitive and
- 35 neurodevelopmental disorders and when to refer for a neurocognitive assessment

- 1 • Recognize the social, economic, and cultural contexts within which addiction exists,
2 including:
 - 3 ○ SDOH
 - 4 ○ The effects of stigma and discrimination
 - 5 ○ The effects of racism, including structural issues at the intersection of racism,
6 substance use, and addiction
 - 7 ○ Risk and resiliency factors of individuals, families, and groups
- 8 • Provide services appropriate to each patient’s and family’s personal and cultural
9 identities, including:
 - 10 ○ Delivering services with trauma-sensitive practices (TSP)
 - 11 ○ Demonstrating cultural humility and openness to understand and respond to
12 patient and family needs related to their individual culture, including race and
13 ethnicity, sex and gender, sexual orientation, socioeconomic status, and religion
14 and spirituality, among others
 - 15 ○ Understanding the core concepts of gender-sensitive and gender-responsive care,
16 including how gender can influence addiction and mental health treatment needs
17 and preferences
 - 18 ○ Working effectively with a translator as needed
- 19 • Understand the principles of harm reduction, including but not limited to:
 - 20 ○ The importance of educating patients and their families and support persons
21 about harm reduction techniques
 - 22 ○ Overdose prevention and reversal
- 23 • Understand the unique needs and barriers faced by people experiencing dating violence,
24 domestic violence, interpersonal violence, and intimate partner violence (IPV), including
25 substance use coercion, and sex trafficking
- 26 • Identify resources in the community that can support common patient and family needs
27 (eg, housing, food, transportation, parenting programs, recovery support services, legal
28 services.)
- 29 • Understand the role of different systems of care that may impact adolescent and family
30 service needs (eg, schools, healthcare, child welfare, juvenile legal, housing and other
31 social services)

32 ***Professional Staff***

33 All professional staff who provide care to adolescents should understand the following within
34 the limits of and at a level appropriate to their scope of practice:

- 35 • Human development including neurodevelopment, typical developmental trajectories,
36 and developmental disorders
- 37 • Family systems and dynamics

- 1 • The importance of attachment in healthy development
- 2 • Risk and protective factors for SUD and other mental health disorders
- 3 • Signs and symptoms associated with substance toxicity and withdrawal
- 4 • The continuum of care for adolescents for both addiction and mental health
- 5 • How to access specialty care for common comorbidities (eg, eating disorders)
- 6 • The impact of adverse childhood experiences (ACEs) on SUD and mental health
- 7 • The impact of neurodiversity on adolescent treatment needs
- 8 • Biological and psychological effects of commonly used substances
- 9 • Biological and psychological effects of chronic substance use and SUDs

10 All professional staff who provide care to adolescents should have competency in:

- 11 • Effectively communicating considerations related to privacy and confidentiality,
12 including when protected health information may be disclosed and when reporting may
13 be required
- 14 • Building therapeutic alliances with patients and family members
- 15 • Conveying information at a developmentally appropriate level and tailored
16 communication to the patient and family's level of comprehension
- 17 • Conducting assessments of adolescents in alignment with their scope of practice,
18 including:
 - 19 ○ Administering standardized screening and assessment tools
 - 20 ○ Collecting information from collateral sources (with appropriate consent or
21 assent) including family members, teachers, coaches, other systems of care
 - 22 ○ Applying knowledge of risk and protective factors to identify patients at risk for
23 SUD
 - 24 ○ Interpreting nonverbal communication of adolescents
- 25 • Delivering treatment services to adolescents, including:
 - 26 ○ Tailoring therapies to the patient's developmental age and stage
 - 27 ○ Adjusting treatment plans based on patient and family progress as well as the
28 adolescent's development
- 29 • Monitoring treatment progress and challenges
- 30 • Working collaboratively with other systems of care (eg, schools, child welfare, juvenile
31 justice) to develop a comprehensive, integrated, and individualized treatment plan,
32 including coordinating treatment plan objectives in alignment with objectives of patient
33 individualized education programs (IEPs) and 504 plans
- 34 • Communicating effectively across disciplines
- 35 • Assisting patients and families in overcoming barriers to care

- 1 • Making effective referrals and supporting effective transitions in care (including
- 2 providing warm handoffs) as needed
- 3 • Managing the family’s involvement in care, including:
 - 4 ○ Assessing family dynamics and their impact on the patient’s SUD and mental
 - 5 health concerns
 - 6 ○ Reconciling conflicting information from patient, family, and collateral sources
 - 7 ○ Managing and using motivational enhancement strategies to address family
 - 8 ambivalence and other barriers to engagement
 - 9 ○ Negotiating confidentiality concerns between patients and their family members
 - 10 ○ Setting and managing appropriate boundaries with patients and their family
 - 11 members
 - 12 ○ Handling conflict between the patients and their family members
 - 13 ○ Ensuring that both the adolescent and family members are heard and given
 - 14 adequate time to express themselves in sessions
 - 15 ○ Appropriately balancing the needs and preferences of patients and their family
 - 16 members
 - 17 ○ Determining when it is or is not appropriate and beneficial to include family
 - 18 members
 - 19 ○ Building collaborative relationships with family members
 - 20 ○ Encouraging collaboration between patients and their family members
 - 21 ○ Providing psychoeducational services to families, including educating family
 - 22 members on how they can:
 - 23 ▪ Modify risk and protective factors
 - 24 ▪ Manage common stressors and fluctuations in SUD- and mental health-
 - 25 related signs and symptoms
 - 26 ○ Determining family members’ need for services and referrals, including parenting
 - 27 programs
 - 28 ○ Helping family members access services to address their own SUD and mental
 - 29 health treatment needs

30 **Medical Staff**

31 Medical staff include physicians, advanced practice providers, nurses, and other medical
32 support staff.

33 ***Physicians and Advanced Practice Providers***

34 All physicians and advanced practice providers should have an advanced understanding of *The*
35 *ASAM Criteria* that includes:

- 36 • Level of Care and Treatment Planning Assessments

- 1 • Dimensional Admission Criteria, including Risk Ratings
- 2 • Dimensional Drivers
- 3 • Medical capabilities at each level of care

4 All physicians and advanced practice providers should also have an advanced understanding of
5 the core medical knowledge about addiction, SUD, and related health conditions in adolescents,
6 including:

- 7 • The epidemiology and etiology of addiction
- 8 • The neurobiology and genetics of addiction
- 9 • Pharmacodynamics of commonly used substances
- 10 • Developmental considerations that interact with adolescent substance use
- 11 • The pathophysiology and neuropsychological effects of chronic substance use and SUDs
- 12 • Common comorbid medical and co-occurring psychiatric conditions associated with
- 13 SUDs
- 14 • Fetal and neonatal effects of commonly used substances and associated intoxication and
- 15 withdrawal

16 Physicians and advanced practice providers should be proficient in working with and leading an
17 interdisciplinary team comprised of both medical and nonmedical (ie, clinical and allied health)
18 staff and have knowledge of their duty to protect and mandated reporting requirements. In
19 support of provision of patient-centered, whole-person care, physicians and advanced practice
20 providers should understand the importance of families and support persons in addressing
21 addiction and communicate with them effectively as appropriate.

22 With respect to assessment and diagnosis, all physicians and advanced practice providers are
23 recommended to have the competency to:

- 24 • Conduct an accurate patient history that includes substance use history, trauma history,
25 and addiction and mental health treatment history, as well as the patient's ability to
26 function in home, school, and social environments
- 27 • Assess the patient's development and developmental history
- 28 • Perform an appropriate physical examination and detect physical signs of acute use
29 (ie, intoxication and withdrawal), chronic use, and complications of substance use
30 (eg, skin infections)
- 31 • Screen for and diagnose SUDs, intoxication, withdrawal, and common comorbid medical
32 and co-occurring psychiatric conditions
- 33 • Formulate a reasonable differential diagnosis based on:

- 1 ○ Signs and symptoms of acute substance use (ie, intoxication, withdrawal) and
- 2 chronic substance use
- 3 ○ Standard diagnostic criteria for addictive disorders
- 4 ○ Common biomedical (including obstetrical) and psychiatric comorbidities of
- 5 substance use
- 6 • Explain the patient’s diagnosis and rationale for their treatment to them and their family
- 7 and support persons (with appropriate patient consent) in developmentally and
- 8 cognitively appropriate language
- 9 • Order appropriate diagnostic tests (eg, routine laboratory tests, drug tests and
- 10 toxicology, diagnostic imaging) and be able to:
- 11 ○ Interpret laboratory findings
- 12 ○ Understand the appropriate use of drug testing and toxicology
- 13 ○ Understand the benefits and limitations of drug testing
- 14 ○ Collect, interpret, and monitor drug testing and toxicology data for patient
- 15 treatment needs
- 16 ○ Understand how drug testing and toxicology can support monitoring of
- 17 adherence to medications
- 18 ○ Use, interpret, and respond to drug testing results
- 19 • Determine the adolescent’s need for a neurocognitive assessment
- 20 • Use and evaluate ECG rhythm strips to rule out malignant arrhythmias, such as
- 21 prolonged QTc, previously undiagnosed atrial fibrillation, and sinus bradycardia and
- 22 tachycardia
- 23 • Use, interpret, and respond to prescription drug monitoring program (PDMP) reports
- 24 • Understand the role of PDMPs and the benefits and limitations of the data in local
- 25 PDMPs

26 With respect to treatment and treatment planning, all physicians and advanced practice
27 providers are recommended to have the competency to:

- 28 • Direct the pharmacological management of intoxication, withdrawal, SUDs, and
- 29 common psychiatric comorbidities tailored to adolescent patients with consideration of:
- 30 ○ Adolescent appropriate dosing
- 31 ○ Potential impacts on the developing brain
- 32 ○ Potential impacts on developmental trajectories
- 33 ○ Differential effectiveness in adults versus adolescents
- 34 • Direct the medical management of acute withdrawal and intoxication, SUDs, and
- 35 common medical and psychiatric comorbidities

- 1 • Understand the psychosocial interventions that are available to treat SUD and mental
2 health concerns in adolescents
- 3 • Provide medical management for common, low-complexity psychiatric conditions using
4 appropriate assessment instruments to guide treat-to-target decision-making
- 5 • Provide brief intervention, secure and appropriate consultations, and referral for
6 specialty treatment of addiction and other medical and psychiatric conditions
- 7 • Design a management plan to address nonadherence and treatment disengagement
- 8 • Determine the primary driver of the patient’s risks for biomedical and psychiatric issues
- 9 • Determine when biomedical and psychiatric issues necessitate transfer or referral to
10 other specialty systems
- 11 • Understand the unique clinical considerations related to:
 - 12 ○ IV drug use
 - 13 ○ Pre- and post-operative care
 - 14 ○ Nicotine/tobacco use
 - 15 ○ Co-occurring pain
 - 16 ○ Co-occurring cognitive impairment
 - 17 ○ Justice involvement
 - 18 ○ Child welfare involvement
 - 19 ○ Foster care involvement
 - 20 ○ Youth homelessness
 - 21 ○ Pregnancy, perinatal, and postpartum care (ie, parent-infant dyad)

22 With respect to care coordination, all physicians and advanced practice providers are
23 recommended to have the competency to:

- 24 • Lead interdisciplinary treatment teams in medically managed treatment programs
- 25 • Consult with other treatment resources as appropriate
- 26 • Coordinate care with specialty biomedical and psychiatric treatment providers to
27 support an integrated treatment plan

28 All physicians and advanced practice providers should have knowledge of the neurobiology of
29 pain and the ability to manage pain in patients with addiction, which includes the ability to:

- 30 • Conduct a pain-focused history and physical examination
- 31 • Use reliable standardized tools for measuring function in patients with pain
- 32 • Determine the difference between malignant and nonmalignant pain
- 33 • Determine whether pain significantly hinders participation in addiction treatment and
34 SUD recovery

- 1 • Design a treatment plan for patients with pain with attention to patient- and family-
- 2 centered goals
- 3 • Prescribe medications for patients with pain and SUDs, with management of initial
- 4 dosing, titrating, and maintaining medications as needed according to patient health
- 5 status and risk factors
- 6 • Prescribe nonpharmacological therapies to help manage pain
- 7 • Coordinate with other healthcare professionals, including when recommended treatment
- 8 options may pose risk for harms and alternative interventions may be needed
- 9 • Coordinate care with a pain specialist
- 10 • Know when to refer to an interventional pain specialist

11 *Addiction Specialist Physicians*

12 In addition to the competencies for physicians and advanced practice providers, addiction
13 specialist physicians are recommended to have the competency to:

- 14 • Supervise and teach other health care professionals
- 15 • Direct the medical management of:
 - 16 ○ Addiction at any level and intensity of treatment
 - 17 ○ Substance use-related psychiatric and biomedical emergencies.

18 *Psychiatric Specialist Physicians and Advanced Practice Providers*

19 In addition to the competencies for physicians and advanced practice providers, psychiatric
20 specialist physicians and advanced practice providers are recommended to have the competency
21 to:

- 22 • Supervise and teach other health care professionals
- 23 • Direct the medical management of psychiatric conditions at any level and intensity of
- 24 treatment
- 25 • Determine when a patient needs a physical examination and the urgency of the need
- 26 • Conduct a comprehensive assessment of the risk for harm to self or others
- 27 • Diagnose and treat severe and complicated adolescent psychiatric and developmental
- 28 disorders
- 29 • Formulate a multimodal treatment plan

30 *Nursing and Medical Support Staff*

31 Nursing and medical support staff—such as registered nurses (RNs), licensed practical nurses
32 (LPNs), and medical assistants (MAs)—should have a basic understanding of the core medical
33 knowledge about addiction, SUD, and related health conditions in adolescents that includes:

- 1 • The epidemiology of addiction
- 2 • The neurobiology and genetics of addiction
- 3 • The pathophysiological and neuropsychological effects of chronic substance use and
- 4 SUDs
- 5 • Common comorbid medical and co-occurring psychiatric conditions associated with
- 6 SUDs
- 7 • Fetal and neonatal effects of commonly used substances and associated intoxication and
- 8 withdrawal

9 With respect to the assessment process, nursing and medical support staff are recommended to
10 have the competency to:

- 11 • Conduct an accurate patient history that includes substance use history, trauma history,
12 and addiction and mental health treatment history
- 13 • Perform an appropriate physical assessment and detect physical signs of acute use
14 (ie, intoxication and withdrawal), including:
 - 15 ○ Assessing for serious harm due to patient impairment from substance use
 - 16 ○ Identifying overdose risks, treatment, and follow-up
 - 17 ○ Using standardized tools for assessing withdrawal severity (eg, Clinical Opioid
18 Withdrawal Scale [COWS], Clinical Institute Withdrawal Assessment for Alcohol,
19 revised [CIWA-Ar])
- 20 • Screen and assess patients for depression and anxiety and apply program protocols for
21 management of patients in need of urgent psychiatric support

22 Nursing and medical support staff should be trained in behavior management techniques and
23 psychotherapeutic and psychoeducational evidence-based interventions (EBIs) aligned with
24 their scopes of practice. Recommended competencies with respect to treatment include the
25 ability to:

- 26 • Implement physician-approved protocols for clinical management of intoxication and
27 withdrawal including:
 - 28 ○ Observation and supervision
 - 29 ○ Determination of appropriate level of care
 - 30 ○ Facilitation of the patient's transition to continuing care
- 31 • Identify indications for addiction medications and dose adjustments, and address
32 recurrent use
- 33 • Outline addiction medications and available formulations
- 34 • Implement recommended storage, handling, and administration of intramuscular and
35 subcutaneous medications for SUD

- 1 • Comprehend the importance of nursing standing orders for laboratory assessment,
2 medication refills, and interventions
- 3 • Understand the benefits and limitations of drug testing and toxicology, including how it
4 can support monitoring of adherence to medications
- 5 • Outline safety interventions required as a mandatory reporter if a patient is at risk for
6 harm to self or others
- 7 • Employ chart review and tools in health records to effectively document and monitor
8 patients engaged in addiction care
- 9 • Understand approaches to certain populations with addiction—such as patients with
10 chronic pain, patients who are pregnant, and homeless youth, among others—and
11 outline appropriate pain management strategies for patients with opioid use disorder

12 With respect to care coordination, nursing and medical support staff are recommended to have
13 the competency to:

- 14 • Coordinate care between local treatment levels (eg, transfer to acute treatment services,
15 transition to outpatient treatment programs)
- 16 • Identify local resources for RSS

17 **Clinical Staff**

18 Clinical staff include psychologists, clinical social workers, SUD and mental health counselors,
19 and others who assess and treat SUD and/or co-occurring mental health conditions. Clinical
20 staff should have a basic understanding of the core medical knowledge about addiction, SUD,
21 and related health conditions that includes:

- 22 • The epidemiology of addiction
- 23 • The neurobiology and genetics of addiction
- 24 • Developmental considerations that interact with adolescent substance use
- 25 • Common comorbid medical and co-occurring psychiatric conditions associated with
26 SUDs
- 27 • Familiarity with the efficacy and benefits of addiction and psychiatric medications,
28 including off-label use of evidence-based medications that have not been FDA-approved
29 for use in adolescents
- 30 • Crisis stabilization interventions tailored to adolescents
- 31 • Harm reduction approaches

32 With respect to the assessment process, clinical staff are recommended to have the competency
33 to:

- 1 • Conduct an accurate patient history that includes substance use history, trauma history,
2 and addiction and mental health treatment history, as well as the patient's ability to
3 function in home, school, and social environments
- 4 • Assess developmental age and stage and identify developmental delays
- 5 • Assess the patient's educational needs and coordinate with education systems to support
6 implementation of IEPs and 504 plans
- 7 • Assess safety risks and develop a safety plan in collaboration with the patient and family
- 8 • Screen, assess symptom severity, and monitor treatment progression for SUDs and co-
9 occurring psychiatric conditions using validated instruments
- 10 • Screen for signs and symptoms of intoxication and withdrawal
- 11 • Screen for risk of harm to self or others
- 12 • Perform crisis assessments
- 13 • Recognize the potential for SUDs to mimic a variety of biomedical and psychiatric
14 conditions

15 With respect to treatment and treatment planning, clinical staff should have knowledge of
16 psychosocial EBIs and are recommended to have the competency to:

- 17 • Develop treatment plans that are tailored to the developmental age and stage of the
18 patient
- 19 • Adjust psychosocial treatment modalities to the developmental age and stage of the
20 patient
- 21 • Engage in shared decision-making with both the patient and family, appropriately
22 balancing their needs and preferences to develop a family centered and youth-guided
23 treatment plan
- 24 • Describe and implement a variety of strategies for reducing the negative effects of SUDs
25 and addiction
- 26 • Support symptom management for patients with co-occurring mental health conditions
- 27 • Work with mental health treatment providers to deliver integrated care for patients with
28 co-occurring psychiatric conditions
- 29 • Deliver psychoeducation related to the interaction of substance use and common
30 biomedical and psychiatric comorbidities (eg, HIV, hepatitis C virus [HCV], depression,
31 anxiety)
- 32 • Manage the therapeutic milieu
- 33 • Understand how ACEs impact SUDs and co-occurring psychiatric disorders
- 34 • Recognize and address experiences of dating violence, domestic violence, IPV and sex
35 trafficking among patients, including:

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 ○ Performing trauma-sensitive assessments of current and past experiences of
- 2 dating violence, domestic violence, and IPV, including experiences of substance
- 3 use coercion
- 4 ○ Collaborating with patients in IPV-related treatment planning, including ongoing
- 5 safety and safety planning
- 6 ○ Referring to and coordinating with domestic violence agencies
- 7 • Recognize the importance of family, social networks including peers, and community
- 8 systems in the treatment and recovery process
- 9 • Describe the behavioral, psychological, biomedical, and social effects of substance use to
- 10 patients and their support networks

11 Every program should have clinical staff with the competency to:

- 12 • Triage mental health concerns
- 13 • Provide family services for co-occurring mental health concerns
- 14 • Provide mental health care in a trauma-informed, culturally humble and
- 15 developmentally appropriate context

16 With respect to the family, clinical staff are recommended to have the competency to:

- 17 • Assess the adolescent's attachment to their caregivers;
- 18 • Assess family dynamics and the impact on the adolescent's SUD and mental health
- 19 • Assess family strengths and leverage them to support the adolescent's recovery
- 20 • Guide families in how to:
 - 21 ○ Effectively support the adolescent's recovery from both SUD and mental health
 - 22 concerns
 - 23 ○ Support healthy development of the adolescent
 - 24 ○ Manage the stress related to the adolescent's SUD, mental health, and other
 - 25 health concerns

26 With respect to care coordination, clinical staff are recommended to have the competency to:

- 27 • Coordinate care with other providers involved in a patient's care
- 28 • Be familiar with local treatment resources, including RSS and social services for SUDs
- 29 and common comorbidities

30 ***Supervisory Clinical Staff***

31 In addition to the competencies for all clinical staff, clinical staff in supervisory roles should
32 have an advanced understanding of *The ASAM Criteria* that includes:

- 1 • Treatment modalities and placement considerations within the continuum of care
- 2 • Level of Care and Treatment Planning Assessments
- 3 • Dimensional Admission Criteria, including Risk Ratings
- 4 • Dimensional Drivers
- 5 • Medical capabilities at each level of care

6 Clinical staff in supervisory roles should also have the competency to:

- 7 • Understand the established diagnostic criteria for SUDs
- 8 • Understand and be able to provide psychosocial EBIs for SUDs and mental health
- 9 disorders
- 10 • Be familiar with medical and medication treatments for SUDs and common comorbid
- 11 biomedical and co-occurring psychiatric conditions
- 12 • Manage and supervise a clinical team
- 13 • Monitor the quality of care delivered by clinical staff

14 **Allied Health Staff**

15 Allied health staff include certified peer support specialists, patient and family navigators,
16 health educators, counselor aides, certified recovery coaches, and group living workers who
17 support ongoing engagement in addiction treatment, deliver recovery support services, and
18 provide warm handoffs to other levels of care. All allied health staff should have competencies
19 in:

- 20 • Building caring and collaborative relationships with adolescent patients and families
- 21 • Understanding appropriate roles and responsibilities
- 22 • Setting safe boundaries with patients and family members
- 23 • Recognizing and being aware of trauma
- 24 • Communicating with patients and their families and support persons (with appropriate
- 25 patient consent)
- 26 • Advocating for the needs, desires, and legal and human rights of people with SUD and
- 27 mental health conditions
- 28 • Providing information on community and other resources related to health, wellness,
- 29 and recovery services and supports
- 30 • Respecting diverse pathways to recovery, including treatment with evidence-based
- 31 addiction and psychiatric medications

32 In addition, certified peer support specialists should have further competencies in:

Public comments accepted until **November 15th, 2024** through the online form at https://bit.ly/adolescent_criteria

- 1 • Building supportive and collaborative long-term relationships
- 2 • Sharing personal recovery stories in a way that is inspiring and supportive
- 3 • Personalizing peer support services
- 4 • Supporting recovery planning
- 5 • Helping peers manage crises
- 6 • Protecting personal recovery while providing peer support services for others
- 7 • Recognizing countertransference and personal biases related to addiction and addiction
- 8 treatment
- 9 • All allied health staff should have a basic understanding of the pharmacological and
- 10 nonpharmacological interventions that are available to treat SUD and common mental
- 11 health conditions in adolescents.